@article {pmid34561208,
year = {2021},
author = {Sánchez-Álvarez, E and Quiroga, B and de Sequera, P and , },
title = {Position statement of the Spanish Society of Nephrology on the SARS-CoV-2 vaccines.},
journal = {Nefrologia},
volume = {41},
number = {4},
pages = {412-416},
pmid = {34561208},
issn = {2013-2514},
mesh = {*COVID-19/prevention & control ; COVID-19 Vaccines ; Humans ; *Nephrology ; RNA, Messenger ; SARS-CoV-2 ; *Vaccines ; },
abstract = {Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has spread worldwide over the last year causing more than one million deaths. Several treatments have tried to modify the natural history of the coronavirus disease 2019 (COVID-19) but only corticosteroids have demonstrated to be effective in moderate or severe affectation. In that situation, the development of vaccines for preventing the SARS-CoV-2 infection has focused the attention of the scientific community. At present, available messenger RNA-based technology vaccines have received the approval of local and international sanitary authorities. In this position statement, the Spanish Society of Nephrology wants to state that patients with chronic kidney disease and healthcare workers are at high-risk for contagion and complications of COVID-19 so they must have priority in the vaccine administration.},
}

*COVID-19/prevention & control
COVID-19 Vaccines
Humans
*Nephrology
RNA, Messenger
SARS-CoV-2
*Vaccines

@article {pmid34532923,
year = {2022},
author = {Testino, G and Vignoli, T and Patussi, V and Allosio, P and Amendola, MF and Aricò, S and Baselice, A and Balbinot, P and Campanile, V and Fanucchi, T and Macciò, L and Meneguzzi, C and Mioni, D and Parisi, M and Renzetti, D and Rossin, R and Gandin, C and Bottaro, LC and Caio, G and Lungaro, L and Zoli, G and Scafato, E and Caputo, F},
title = {Alcohol use disorder in the COVID-19 era: Position paper of the Italian Society on Alcohol (SIA).},
journal = {Addiction biology},
volume = {27},
number = {1},
pages = {e13090},
pmid = {34532923},
issn = {1369-1600},
mesh = {Alcoholics Anonymous ; Alcoholism/epidemiology/*therapy ; Ambulatory Care/organization & administration ; COVID-19/epidemiology/*prevention & control ; COVID-19 Vaccines/therapeutic use ; *Communicable Disease Control ; Delivery of Health Care/organization & administration ; Disease Susceptibility ; Drug Interactions ; Humans ; Immunosuppression Therapy/adverse effects ; Italy/epidemiology ; Liver Cirrhosis, Alcoholic/epidemiology/therapy ; Liver Transplantation ; Recurrence ; SARS-CoV-2 ; Societies, Medical ; Telemedicine ; COVID-19 Drug Treatment ; },
abstract = {Coronavirus disease 2019 (COVID-19) first emerged in China in November 2019. Most governments have responded to the COVID-19 pandemic by imposing a lockdown. Some evidence suggests that a period of isolation might have led to a spike in alcohol misuse, and in the case of patients with alcohol use disorder (AUD), social isolation can favour lapse and relapse. The aim of our position paper is to provide specialists in the alcohol addiction field, in psychopharmacology, gastroenterology and in internal medicine, with appropriate tools to better manage patients with AUD and COVID-19,considering some important topics: (a) the susceptibility of AUD patients to infection; (b) the pharmacological interaction between medications used to treat AUD and to treat COVID-19; (c) the reorganization of the Centre for Alcohol Addiction Treatment for the management of AUD patients in the COVID-19 era (group activities, telemedicine, outpatients treatment, alcohol-related liver disease and liver transplantation, collecting samples); (d) AUD and SARS-CoV-2 vaccination. Telemedicine/telehealth will undoubtedly be useful/practical tools even though it remains at an elementary level; the contribution of the family and of caregivers in the management of AUD patients will play a significant role; the multidisciplinary intervention involving experts in the treatment of AUD with specialists in the treatment of COVID-19 disease will need implementation. Thus, the COVID-19 pandemic is rapidly leading addiction specialists towards a new governance scenario of AUD, which necessarily needs an in-depth reconsideration, focusing attention on a safe approach in combination with the efficacy of treatment.},
}

Alcoholics Anonymous
Alcoholism/epidemiology/*therapy
Ambulatory Care/organization & administration
COVID-19/epidemiology/*prevention & control
COVID-19 Vaccines/therapeutic use
*Communicable Disease Control
Delivery of Health Care/organization & administration
Disease Susceptibility
Drug Interactions
Humans
Immunosuppression Therapy/adverse effects
Italy/epidemiology
Liver Cirrhosis, Alcoholic/epidemiology/therapy
Liver Transplantation
Recurrence
SARS-CoV-2
Societies, Medical
Telemedicine
COVID-19 Drug Treatment

@article {pmid34528075,
year = {2021},
author = {Cenko, E and Badimon, L and Bugiardini, R and Claeys, MJ and De Luca, G and de Wit, C and Derumeaux, G and Dorobantu, M and Duncker, DJ and Eringa, EC and Gorog, DA and Hassager, C and Heinzel, FR and Huber, K and Manfrini, O and Milicic, D and Oikonomou, E and Padro, T and Trifunovic-Zamaklar, D and Vasiljevic-Pokrajcic, Z and Vavlukis, M and Vilahur, G and Tousoulis, D},
title = {Cardiovascular disease and COVID-19: a consensus paper from the ESC Working Group on Coronary Pathophysiology & Microcirculation, ESC Working Group on Thrombosis and the Association for Acute CardioVascular Care (ACVC), in collaboration with the European Heart Rhythm Association (EHRA).},
journal = {Cardiovascular research},
volume = {117},
number = {14},
pages = {2705-2729},
pmid = {34528075},
issn = {1755-3245},
mesh = {Angiotensin-Converting Enzyme 2/metabolism ; COVID-19/*complications/enzymology/etiology/physiopathology/therapy ; Cardiometabolic Risk Factors ; Cardiovascular Diseases/enzymology/physiopathology/*virology ; Clinical Trials as Topic ; Humans ; Inflammation/complications/virology ; Microcirculation ; Sex Characteristics ; Post-Acute COVID-19 Syndrome ; },
abstract = {The cardiovascular system is significantly affected in coronavirus disease-19 (COVID-19). Microvascular injury, endothelial dysfunction, and thrombosis resulting from viral infection or indirectly related to the intense systemic inflammatory and immune responses are characteristic features of severe COVID-19. Pre-existing cardiovascular disease and viral load are linked to myocardial injury and worse outcomes. The vascular response to cytokine production and the interaction between severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) and angiotensin-converting enzyme 2 receptor may lead to a significant reduction in cardiac contractility and subsequent myocardial dysfunction. In addition, a considerable proportion of patients who have been infected with SARS-CoV-2 do not fully recover and continue to experience a large number of symptoms and post-acute complications in the absence of a detectable viral infection. This conditions often referred to as 'post-acute COVID-19' may have multiple causes. Viral reservoirs or lingering fragments of viral RNA or proteins contribute to the condition. Systemic inflammatory response to COVID-19 has the potential to increase myocardial fibrosis which in turn may impair cardiac remodelling. Here, we summarize the current knowledge of cardiovascular injury and post-acute sequelae of COVID-19. As the pandemic continues and new variants emerge, we can advance our knowledge of the underlying mechanisms only by integrating our understanding of the pathophysiology with the corresponding clinical findings. Identification of new biomarkers of cardiovascular complications, and development of effective treatments for COVID-19 infection are of crucial importance.},
}

Angiotensin-Converting Enzyme 2/metabolism
COVID-19/*complications/enzymology/etiology/physiopathology/therapy
Cardiometabolic Risk Factors
Cardiovascular Diseases/enzymology/physiopathology/*virology
Clinical Trials as Topic
Humans
Inflammation/complications/virology
Microcirculation
Sex Characteristics
Post-Acute COVID-19 Syndrome

@article {pmid34452470,
year = {2021},
author = {Botti-Lodovico, Y and Nair, P and Nosamiefan, D and Stremlau, M and Schaffner, S and Agignoae, SV and Aiyepada, JO and Ajogbasile, FV and Akpede, GO and Alhasan, F and Andersen, KG and Asogun, DA and Ayodeji, OO and Badiane, AS and Barnes, K and Bauer, MR and Bell-Kareem, A and Benard, ME and Benevolence, EO and Blessing, O and Boehm, CK and Boisen, ML and Bond, NG and Branco, LM and Butts, MJ and Carter, A and Colubri, A and Deme, AB and DeRuff, KC and Diédhiou, Y and Edamhande, AP and Elhamoumi, S and Engel, EJ and Eromon, P and Fallah, M and Folarin, OA and Fry, B and Garry, R and Gaye, A and Gbakie, M and Gevao, SM and Gionet, G and Gladden-Young, A and Goba, A and Gomis, JF and Happi, AN and Houghton, M and Ihekwuazu, C and Iruolagbe, CO and Jackson, J and Jalloh, S and Johnson, J and Kanneh, L and Kayode, A and Kemball, M and Kingsley, OC and Koroma, V and Kotliar, D and Mehta, S and Metsky, HC and Michael, A and Mirhashemi, ME and Modjarrad, K and Momoh, M and Myhrvold, CA and Naregose, OG and Ndiaye, T and Ndiaye, M and Ndiaye, A and Normandin, E and Odia, I and Oguzie, JU and Okogbenin, SA and Okokhere, PO and Okolie, J and Olawoye, IB and Olumade, TJ and Oluniyi, PE and Omoregie, O and Park, DJ and Paye, MF and Petros, B and Philippakis, AA and Priscilla, A and Ricks, A and Rimoin, A and Sandi, JD and Schieffelin, JS and Schreiber, M and Seck, MC and Siddiqui, S and Siddle, K and Smither, AR and Sy, M and Sy, N and Tomkins-Tinch, CH and Tomori, O and Ugwu, C and Uwanibe, JN and Uyigue, EA and Victoria, DI and Vinzé, A and Vodzak, ME and Welch, N and Wurie, HI and Zoumarou, D and Grant, DS and Ndiaye, D and MacInnis, B and Sabeti, PC and Happi, C},
title = {The Origins and Future of Sentinel: An Early-Warning System for Pandemic Preemption and Response.},
journal = {Viruses},
volume = {13},
number = {8},
pages = {},
pmid = {34452470},
issn = {1999-4915},
support = {T32 GM007753/GM/NIGMS NIH HHS/United States ; },
mesh = {Africa, Western/epidemiology ; *Disaster Planning/methods ; Humans ; Lassa Fever/*epidemiology/genetics/prevention & control/virology ; Lassa virus/genetics/*physiology ; N-Acetylglucosaminyltransferases/genetics/immunology ; Nigeria/epidemiology ; Pandemics ; Polymorphism, Genetic ; Receptors, Virus/genetics/immunology ; },
abstract = {While investigating a signal of adaptive evolution in humans at the gene LARGE, we encountered an intriguing finding by Dr. Stefan Kunz that the gene plays a critical role in Lassa virus binding and entry. This led us to pursue field work to test our hypothesis that natural selection acting on LARGE-detected in the Yoruba population of Nigeria-conferred resistance to Lassa Fever in some West African populations. As we delved further, we conjectured that the "emerging" nature of recently discovered diseases like Lassa fever is related to a newfound capacity for detection, rather than a novel viral presence, and that humans have in fact been exposed to the viruses that cause such diseases for much longer than previously suspected. Dr. Stefan Kunz's critical efforts not only laid the groundwork for this discovery, but also inspired and catalyzed a series of events that birthed Sentinel, an ambitious and large-scale pandemic prevention effort in West Africa. Sentinel aims to detect and characterize deadly pathogens before they spread across the globe, through implementation of its three fundamental pillars: Detect, Connect, and Empower. More specifically, Sentinel is designed to detect known and novel infections rapidly, connect and share information in real time to identify emerging threats, and empower the public health community to improve pandemic preparedness and response anywhere in the world. We are proud to dedicate this work to Stefan Kunz, and eagerly invite new collaborators, experts, and others to join us in our efforts.},
}

Africa, Western/epidemiology
*Disaster Planning/methods
Humans
Lassa Fever/*epidemiology/genetics/prevention & control/virology
Lassa virus/genetics/*physiology
N-Acetylglucosaminyltransferases/genetics/immunology
Nigeria/epidemiology
Pandemics
Polymorphism, Genetic
Receptors, Virus/genetics/immunology

@article {pmid34423546,
year = {2021},
author = {Hamad, N and Ananda-Rajah, M and Gilroy, N and MacIntyre, R and Gottlieb, D and Ritchie, D and Harrison, S and Kennedy, G and Watson, AM and Greenwood, M and Doocey, R and Perera, T and Spencer, A and Wong, E and O'Brien, T and Shaw, P and Conyers, R and Milliken, S and Bardy, P and Larsen, S and Ho, PJ and Lai, H and Bajel, A and Butler, J and Tiley, C and D'Rozario, J and Johnston, A and Cochrane, T and Mills, T and Irving, I and Pullon, H and Purtill, D},
title = {Australia and New Zealand Transplant and Cellular Therapies COVID-19 vaccination consensus position statement.},
journal = {Internal medicine journal},
volume = {51},
number = {8},
pages = {1321-1323},
pmid = {34423546},
issn = {1445-5994},
mesh = {Adult ; Australia/epidemiology ; *COVID-19/prevention & control ; *COVID-19 Vaccines ; Child ; Consensus ; Humans ; New Zealand/epidemiology ; Prospective Studies ; *Transplant Recipients ; Vaccination ; },
abstract = {Australia and New Zealand have achieved excellent community control of COVID-19 infection. In light of the imminent COVID-19 vaccination roll out in both countries, representatives of all adult and paediatric allogeneic bone marrow transplant and cellular therapy (TCT) centres as well as representatives from autologous transplant only centres in Australia and New Zealand collaborated with infectious diseases specialists with expertise in TCT on this consensus position statement regarding COVID-19 vaccination in TCT patients in Australia and New Zealand. It is our recommendation that TCT patients, should have expedited access to high-efficacy COVID-19 vaccines given that these patients are at high risk of morbidity and mortality from COVID-19 infection. We also recommend prioritising vaccination of TCT healthcare workers and household members of TCT patients. Vaccination should not replace other public health measures in TCT patients given the effectiveness of COVID-19 vaccination in TCT patients is unknown. Furthermore, given the limited available data, prospective collection of safety and efficacy data of COVID-19 vaccination in this patient group is a priority.},
}

Adult
Australia/epidemiology
*COVID-19/prevention & control
*COVID-19 Vaccines
Child
Consensus
Humans
New Zealand/epidemiology
Prospective Studies
*Transplant Recipients
Vaccination

@article {pmid34399446,
year = {2021},
author = {Ku, CR and Jung, KY and Ahn, CH and Moon, JS and Lee, JH and Kim, EH and Kwon, H and Kim, HK and Suh, S and Hong, S and Ha, J and Roh, E and Kim, JH and Kim, MK and , },
title = {COVID-19 Vaccination for Endocrine Patients: A Position Statement from the Korean Endocrine Society.},
journal = {Endocrinology and metabolism (Seoul, Korea)},
volume = {36},
number = {4},
pages = {757-765},
pmid = {34399446},
issn = {2093-5978},
mesh = {COVID-19/epidemiology/immunology/*prevention & control ; COVID-19 Vaccines/administration & dosage/adverse effects/*standards ; *Endocrine System Diseases/epidemiology/immunology ; Endocrinologists/*standards ; Humans ; Practice Guidelines as Topic/standards ; Republic of Korea/epidemiology ; Societies, Medical/*standards ; Vaccination/*standards ; },
abstract = {Since the first outbreak of coronavirus disease 2019 (COVID-19), ongoing efforts have been made to discover an efficacious vaccine against COVID-19 to combat the pandemic. In most countries, both mRNA and DNA vaccines have been administered, and their side effects have also been reported. The clinical course of COVID-19 and the effects of vaccination against COVID-19 are both influenced by patients' health status and involve a systemic physiological response. In view of the systemic function of endocrine hormones, endocrine disorders themselves and the therapeutics used to treat them can influence the outcomes of vaccination for COVID-19. However, there are very limited data to support the development of clinical guidelines for patients with specific medical backgrounds based on large clinical trials. In the current severe circumstances of the COVID-19 pandemic, position statements made by clinical specialists are essential to provide appropriate recommendations based on both medical evidence and clinical experiences. As endocrinologists, we would like to present the medical background of COVID-19 vaccination, as well as precautions to prevent the side effects of COVID-19 vaccination in patients with specific endocrine disorders, including adrenal insufficiency, diabetes mellitus, osteoporosis, autoimmune thyroid disease, hypogonadism, and pituitary disorders.},
}

COVID-19/epidemiology/immunology/*prevention & control
COVID-19 Vaccines/administration & dosage/adverse effects/*standards
*Endocrine System Diseases/epidemiology/immunology
Endocrinologists/*standards
Humans
Practice Guidelines as Topic/standards
Republic of Korea/epidemiology
Societies, Medical/*standards
Vaccination/*standards

@article {pmid34364845,
year = {2021},
author = {Roberts, DJ and Edlow, AG and Romero, RJ and Coyne, CB and Ting, DT and Hornick, JL and Zaki, SR and Das Adhikari, U and Serghides, L and Gaw, SL and Metz, TD and , },
title = {A standardized definition of placental infection by SARS-CoV-2, a consensus statement from the National Institutes of Health/Eunice Kennedy Shriver National Institute of Child Health and Human Development SARS-CoV-2 Placental Infection Workshop.},
journal = {American journal of obstetrics and gynecology},
volume = {225},
number = {6},
pages = {593.e1-593.e9},
pmid = {34364845},
issn = {1097-6868},
support = {HHSN275201300006C/HD/NICHD NIH HHS/United States ; U54 MH118919/MH/NIMH NIH HHS/United States ; },
mesh = {COVID-19/*diagnosis ; COVID-19 Nucleic Acid Testing ; COVID-19 Testing/*methods ; Consensus ; Female ; Guidelines as Topic ; Humans ; Immunohistochemistry ; In Situ Hybridization ; Microscopy, Electron ; National Institute of Child Health and Human Development (U.S.) ; Placenta Diseases/*diagnosis/*virology ; Pregnancy ; Pregnancy Complications, Infectious/*diagnosis/*virology ; *SARS-CoV-2 ; United States/epidemiology ; },
abstract = {Pregnant individuals infected with SARS-CoV-2 have higher rates of intensive care unit admission, oxygen requirement, need for mechanical ventilation, and death than nonpregnant individuals. Increased COVID-19 disease severity may be associated with an increased risk of viremia and placental infection. Maternal SARS-CoV-2 infection is also associated with pregnancy complications such as preeclampsia and preterm birth, which can be either placentally mediated or reflected in the placenta. Maternal viremia followed by placental infection may lead to maternal-fetal transmission (vertical), which affects 1% to 3% of exposed newborns. However, there is no agreed-upon or standard definition of placental infection. The National Institutes of Health/Eunice Kennedy Shriver National Institute of Child Health and Human Development convened a group of experts to propose a working definition of placental infection to inform ongoing studies of SARS-CoV-2 during pregnancy. Experts recommended that placental infection be defined using techniques that allow virus detection and localization in placental tissue by one or more of the following methods: in situ hybridization with antisense probe (detects replication) or a sense probe (detects viral messenger RNA) or immunohistochemistry to detect viral nucleocapsid or spike proteins. If the abovementioned methods are not possible, reverse transcription polymerase chain reaction detection or quantification of viral RNA in placental homogenates, or electron microscopy are alternative approaches. A graded classification for the likelihood of placental infection as definitive, probable, possible, and unlikely was proposed. Manuscripts reporting placental infection should describe the sampling method (location and number of samples collected), method of preservation of tissue, and detection technique. Recommendations were made for the handling of the placenta, examination, and sampling and the use of validated reagents and sample protocols (included as appendices).},
}

COVID-19/*diagnosis
COVID-19 Nucleic Acid Testing
COVID-19 Testing/*methods
Consensus
Female
Guidelines as Topic
Humans
Immunohistochemistry
In Situ Hybridization
Microscopy, Electron
National Institute of Child Health and Human Development (U.S.)
Placenta Diseases/*diagnosis/*virology
Pregnancy
Pregnancy Complications, Infectious/*diagnosis/*virology
*SARS-CoV-2
United States/epidemiology

@article {pmid34310563,
year = {2021},
author = {Caldarola, P and Murrone, A and Roncon, L and Di Pasquale, G and Tavazzi, L and Amodeo, V and Aspromonte, N and Cipriani, M and Di Lenarda, A and Domenicucci, S and Francese, GM and Imazio, M and Scotto di Uccio, F and Urbinati, S and Valente, S and Gulizia, MM and Colivicchi, F and Gabrielli, D},
title = {[ANMCO Position paper: Reorganization of cardiology in the era of the COVID-19 pandemic].},
journal = {Giornale italiano di cardiologia (2006)},
volume = {22},
number = {8},
pages = {610-619},
doi = {10.1714/3641.36216},
pmid = {34310563},
issn = {1972-6481},
mesh = {*COVID-19 ; Cardiology/*organization & administration ; Cardiovascular Diseases/therapy ; Delivery of Health Care/*organization & administration ; Health Personnel/organization & administration ; Humans ; Italy ; National Health Programs/organization & administration ; },
abstract = {The COVID-19 pandemic represents an unprecedented event that has brought deep changes in hospital facilities with reshaping of the health system organization, revealing inadequacies of current hospital and local health systems. When the COVID-19 emergency will end, further evaluation of the national health system, new organization of acute wards, and a further evolution of the entire health system will be needed to improve care during the chronic phase of disease. Therefore, new standards for healthcare personnel, more efficient organization of hospital facilities for patients with acute illnesses, improvement of technological approaches, and better integration between hospital and territorial services should be pursued. With experience derived from the COVID-19 pandemic, new models, paradigms, interventional approaches, values and priorities should be suggested and implemented.},
}

*COVID-19
Cardiology/*organization & administration
Cardiovascular Diseases/therapy
Delivery of Health Care/*organization & administration
Health Personnel/organization & administration
Humans
Italy
National Health Programs/organization & administration

@article {pmid34307071,
year = {2021},
author = {McNabb, SJN and Magowe, M and Shaw, N and Berrian, AM and Wilkes, M and Shaikh, A and Gachuno, O and Perrone, LA and Murray, BL and Berman, E and Hansoti, B},
title = {Delivering Modern Global Health Learning Requires New Obligations and Approaches.},
journal = {Annals of global health},
volume = {87},
number = {1},
pages = {68},
pmid = {34307071},
issn = {2214-9996},
mesh = {Education, Distance/*methods ; Educational Measurement/methods ; Global Health/*education ; Humans ; International Cooperation ; *Learning ; Mentoring/*methods ; Problem-Based Learning/*methods ; },
abstract = {INTRODUCTION: The COVID-19 pandemic has forced a new look (or modernization) for both the obligations and approaches to achieve best-practices in global health learning. These best-practices have moved beyond traditional, face-to-face (F2F), classroom-based didactics to the use of innovative online, asynchronous and synchronous instructional design and the information and communication technology (ICT) tools to support it. But moving to this higher level of online in-service and pre-service training, key obligations (e.g., stopping neocolonialization, cultural humility, reversing brain drain, gender equity) must guide the modernization of instructional design and the supporting ICT. To positively impact global health training, educators must meet the needs of learners where they are.

PURPOSE: We describe a set of multi-communication methods, e-Learning principles, strategies, and ICT approaches for educators to pivot content delivery from traditional, F2F classroom didactics into the modern era. These best-practices in both the obligations and approaches utilize thoughtful, modern strategies of instructional design and ICT.

APPROACH: We harnessed our collective experiences in global health training to present thoughtful insights on the guiding principles, strategies, and ICT environment central to develop learning curricula that meet trainee needs and how they can be actualized. Specifically, we describe five strategies: 1. Individualized learning; 2. Provide experiential learning; 3. Mentor … Mentor … Mentor; 4. Reinforce learning through assessment; and 5. Information and communication technology and tools to support learning.

DISCUSSION: We offer a vision, set of guiding principles, and five strategies for successful curricula delivery in the modern era so that global health training can be made available to a wider audience more efficiently and effectively.},
}

Education, Distance/*methods
Educational Measurement/methods
Global Health/*education
Humans
International Cooperation
*Learning
Mentoring/*methods
Problem-Based Learning/*methods

@article {pmid34266813,
year = {2021},
author = {Beniczky, S and Husain, A and Ikeda, A and Alabri, H and Cross, JH and Wilmshurst, J and Seeck, M and Focke, N and Braga, P and Wiebe, S and Schuele, S and Trinka, E},
title = {Importance of access to epilepsy monitoring units during the COVID-19 pandemic: consensus statement of the International League Against Epilepsy and the International Federation of Clinical Neurophysiology.},
journal = {Epileptic disorders : international epilepsy journal with videotape},
volume = {23},
number = {4},
pages = {533-536},
pmid = {34266813},
issn = {1950-6945},
mesh = {*COVID-19/diagnosis/prevention & control ; *Consensus ; *Electroencephalography/standards ; *Epilepsy/diagnosis/therapy ; *Health Services Accessibility/organization & administration/standards ; Humans ; *Neurophysiological Monitoring/standards ; *Outpatient Clinics, Hospital/organization & administration/standards ; Societies, Medical/standards ; },
abstract = {Restructuring of healthcare services during the COVID-19 pandemic has led to lockdown of epilepsy monitoring units (EMUs) in many hospitals. The ad-hoc taskforce of the International League Against Epilepsy (ILAE) and the International Federation of Clinical Neurophysiology (IFCN) highlights the detrimental effect of postponing video-EEG monitoring of patients with epilepsy and other paroxysmal events. The taskforce calls for action for continued functioning of EMUs during emergency situations, such as the COVID-19 pandemic. Long-term video-EEG monitoring is an essential diagnostic service. Access to video-EEG monitoring of the patients in the EMUs must be given high priority. Patients should be screened for COVID-19, before admission, according to the local regulations. Local policies for COVID-19 infection control should be adhered to during the video-EEG monitoring. In cases of differential diagnosis in which reduction of antiseizure medication is not required, home video-EEG monitoring should be considered as an alternative in selected patients.},
}

*COVID-19/diagnosis/prevention & control
*Consensus
*Electroencephalography/standards
*Epilepsy/diagnosis/therapy
*Health Services Accessibility/organization & administration/standards
Humans
*Neurophysiological Monitoring/standards
*Outpatient Clinics, Hospital/organization & administration/standards
Societies, Medical/standards

@article {pmid34253266,
year = {2022},
author = {Weber, DJ and Al-Tawfiq, JA and Babcock, HM and Bryant, K and Drees, M and Elshaboury, R and Essick, K and Fakih, M and Henderson, DK and Javaid, W and Juffras, D and Jump, RLP and Lee, F and Malani, AN and Mathew, TA and Murthy, RK and Nace, D and O'Shea, T and Pettigrew, E and Pettis, AM and Schaffzin, JK and Shenoy, ES and Vaishampayan, J and Wiley, Z and Wright, SB and Yokoe, D and Young, H},
title = {Multisociety statement on coronavirus disease 2019 (COVID-19) vaccination as a condition of employment for healthcare personnel.},
journal = {Infection control and hospital epidemiology},
volume = {43},
number = {1},
pages = {3-11},
pmid = {34253266},
issn = {1559-6834},
mesh = {*COVID-19 ; COVID-19 Vaccines ; Child ; Delivery of Health Care ; Employment ; Humans ; SARS-CoV-2 ; United States/epidemiology ; Vaccination ; },
abstract = {This consensus statement by the Society for Healthcare Epidemiology of America (SHEA) and the Society for Post-Acute and Long-Term Care Medicine (AMDA), the Association for Professionals in Epidemiology and Infection Control (APIC), the HIV Medicine Association (HIVMA), the Infectious Diseases Society of America (IDSA), the Pediatric Infectious Diseases Society (PIDS), and the Society of Infectious Diseases Pharmacists (SIDP) recommends that coronavirus disease 2019 (COVID-19) vaccination should be a condition of employment for all healthcare personnel in facilities in the United States. Exemptions from this policy apply to those with medical contraindications to all COVID-19 vaccines available in the United States and other exemptions as specified by federal or state law. The consensus statement also supports COVID-19 vaccination of nonemployees functioning at a healthcare facility (eg, students, contract workers, volunteers, etc).},
}

*COVID-19
COVID-19 Vaccines
Child
Delivery of Health Care
Employment
Humans
SARS-CoV-2
United States/epidemiology
Vaccination

@article {pmid34236416,
year = {2021},
author = {Geerts, JM and Kinnair, D and Taheri, P and Abraham, A and Ahn, J and Atun, R and Barberia, L and Best, NJ and Dandona, R and Dhahri, AA and Emilsson, L and Free, JR and Gardam, M and Geerts, WH and Ihekweazu, C and Johnson, S and Kooijman, A and Lafontaine, AT and Leshem, E and Lidstone-Jones, C and Loh, E and Lyons, O and Neel, KAF and Nyasulu, PS and Razum, O and Sabourin, H and Schleifer Taylor, J and Sharifi, H and Stergiopoulos, V and Sutton, B and Wu, Z and Bilodeau, M},
title = {Guidance for Health Care Leaders During the Recovery Stage of the COVID-19 Pandemic: A Consensus Statement.},
journal = {JAMA network open},
volume = {4},
number = {7},
pages = {e2120295},
doi = {10.1001/jamanetworkopen.2021.20295},
pmid = {34236416},
issn = {2574-3805},
support = {001/WHO_/World Health Organization/International ; },
mesh = {*COVID-19 ; Consensus ; Disaster Planning ; *Health Personnel/legislation & jurisprudence/organization & administration ; Humans ; *Leadership ; Models, Organizational ; *Pandemics ; SARS-CoV-2 ; },
abstract = {IMPORTANCE: The COVID-19 pandemic is the greatest global test of health leadership of our generation. There is an urgent need to provide guidance for leaders at all levels during the unprecedented preresolution recovery stage.

OBJECTIVE: To create an evidence- and expertise-informed framework of leadership imperatives to serve as a resource to guide health and public health leaders during the postemergency stage of the pandemic.

EVIDENCE REVIEW: A literature search in PubMed, MEDLINE, and Embase revealed 10 910 articles published between 2000 and 2021 that included the terms leadership and variations of emergency, crisis, disaster, pandemic, COVID-19, or public health. Using the Standards for Quality Improvement Reporting Excellence reporting guideline for consensus statement development, this assessment adopted a 6-round modified Delphi approach involving 32 expert coauthors from 17 countries who participated in creating and validating a framework outlining essential leadership imperatives.

FINDINGS: The 10 imperatives in the framework are: (1) acknowledge staff and celebrate successes; (2) provide support for staff well-being; (3) develop a clear understanding of the current local and global context, along with informed projections; (4) prepare for future emergencies (personnel, resources, protocols, contingency plans, coalitions, and training); (5) reassess priorities explicitly and regularly and provide purpose, meaning, and direction; (6) maximize team, organizational, and system performance and discuss enhancements; (7) manage the backlog of paused services and consider improvements while avoiding burnout and moral distress; (8) sustain learning, innovations, and collaborations, and imagine future possibilities; (9) provide regular communication and engender trust; and (10) in consultation with public health and fellow leaders, provide safety information and recommendations to government, other organizations, staff, and the community to improve equitable and integrated care and emergency preparedness systemwide.

CONCLUSIONS AND RELEVANCE: Leaders who most effectively implement these imperatives are ideally positioned to address urgent needs and inequalities in health systems and to cocreate with their organizations a future that best serves stakeholders and communities.},
}

*COVID-19
Consensus
Disaster Planning
*Health Personnel/legislation & jurisprudence/organization & administration
Humans
*Leadership
Models, Organizational
*Pandemics
SARS-CoV-2

@article {pmid34227785,
year = {2021},
author = {Gnanaraj, JP and Anne, PS and Majella, CM and Durairaj, P and Edwin, R and Kannan, K and Ramachandran, V and Jeyabalan, N and Mohanan, N and Krishnan, S and Somasundaram, S},
title = {Antithrombotic Therapy in COVID-19 - A Scientific Position Statement by Heart Disease Management Program, National Health Mission, Government of Tamil Nadu.},
journal = {The Journal of the Association of Physicians of India},
volume = {69},
number = {1},
pages = {82-87},
pmid = {34227785},
issn = {0004-5772},
mesh = {*COVID-19 ; Disease Management ; *Fibrinolytic Agents ; Government ; Humans ; India ; National Health Programs ; SARS-CoV-2 ; },
}

*COVID-19
Disease Management
*Fibrinolytic Agents
Government
Humans
India
National Health Programs
SARS-CoV-2

@article {pmid34212511,
year = {2021},
author = {Butsch, WS and Hajduk, A and Cardel, MI and Donahoo, WT and Kyle, TK and Stanford, FC and Zeltser, LM and Kotz, CM and Jastreboff, AM},
title = {COVID-19 vaccines are effective in people with obesity: A position statement from The Obesity Society.},
journal = {Obesity (Silver Spring, Md.)},
volume = {29},
number = {10},
pages = {1575-1579},
pmid = {34212511},
issn = {1930-739X},
support = {P30 DK040561/DK/NIDDK NIH HHS/United States ; UL1 TR001863/TR/NCATS NIH HHS/United States ; I01 BX003004/BX/BLRD VA/United States ; P30 DK045735/DK/NIDDK NIH HHS/United States ; I01 BX003687/BX/BLRD VA/United States ; },
mesh = {Adolescent ; Adult ; Aged ; COVID-19/*immunology/*prevention & control/virology ; COVID-19 Vaccines/*immunology ; Clinical Trials as Topic ; Humans ; Middle Aged ; Obesity/*immunology ; SARS-CoV-2/*immunology ; *Societies, Medical ; Young Adult ; },
abstract = {The position statement is issued by The Obesity Society in response to published literature, as well as inquiries made to the Society by patients, providers, Society members, policy makers, and others regarding the efficacy of vaccines in persons with obesity against SARS-CoV-2, the virus that causes COVID-19. The Obesity Society has critically evaluated data from published peer-reviewed literature and briefing documents from Emergency Use Authorization applications submitted by Pfizer-BioNTech, Moderna, and Johnson & Johnson. We conclude that these vaccines are highly efficacious, and their efficacy is not significantly different in people with and without obesity, based on scientific evidence available at the time of publication. The Obesity Society believes there is no definitive way to determine which of these three COVID-19 vaccines is "best" for any weight subpopulation (because of differences in the trial design and outcome measures in the phase 3 trials, elapsed time between doses, and regional differences in the presence of SARS-CoV-2 variants [e.g., South Africa B.1.351 in Johnson & Johnson trial]). All three trials have demonstrated high efficacy against COVID-19-associated hospitalization and death. Therefore, The Obesity Society encourages adults with obesity ≥18 years (≥16 years for Pfizer-BioNTech) to undergo vaccination with any one of the currently available vaccines authorized for emergency use by the US Food and Drug Administration as soon as they are able.},
}

Adolescent
Adult
Aged
COVID-19/*immunology/*prevention & control/virology
COVID-19 Vaccines/*immunology
Clinical Trials as Topic
Humans
Middle Aged
Obesity/*immunology
SARS-CoV-2/*immunology
*Societies, Medical
Young Adult

@article {pmid34187457,
year = {2021},
author = {Corby, S and Whittaker, K and Ash, JS and Mohan, V and Becton, J and Solberg, N and Bergstrom, R and Orwoll, B and Hoekstra, C and Gold, JA},
title = {The future of medical scribes documenting in the electronic health record: results of an expert consensus conference.},
journal = {BMC medical informatics and decision making},
volume = {21},
number = {1},
pages = {204},
pmid = {34187457},
issn = {1472-6947},
support = {R01 HS025141/HS/AHRQ HHS/United States ; T15 LM007088/LM/NLM NIH HHS/United States ; },
mesh = {*COVID-19 ; Documentation ; *Electronic Health Records ; Humans ; SARS-CoV-2 ; Workflow ; },
abstract = {BACKGROUND: With the use of electronic health records (EHRs) increasing and causing unintended negative consequences, the medical scribe profession has burgeoned, but it has yet to be regulated. The purpose of this study was to describe scribe workflow as well as identify the threats and opportunities for the future of the scribe industry.

METHODS: The first phase of the study used ethnographic methods consisting of interviews and observations by a multi-disciplinary team of researchers at five United States sites. In April 2019, a two-day conference of experts representing different stakeholder perspectives was held to discuss the results from site visits and to predict the future of medical scribing. An interpretive content analysis approach was used to discover threats and opportunities for the future of medical scribes.

RESULTS: Threats facing the medical scribe industry were related to changes in the documentation model, EHR usability, different payment structures, the need to acquire disparate data during clinical encounters, and workforce-related changes relevant to the scribing model. Simultaneously, opportunities for medical scribing in the future included extension of their role to include workflow analysis, acting as EHR-related subject-matter-experts, and becoming integrated more effectively into the clinical care delivery team. Experts thought that if EHR usability increases, the need for medical scribes might decrease. Additionally, the scribe role could be expanded to allow scribes to document more or take on more informatics-related tasks. The experts also anticipated an increased use of alternative models of scribing, like tele-scribing.

CONCLUSION: Threats and opportunities for medical scribing were identified. Many experts thought that if the scribe role could be expanded to allow scribes to document more or take on more informatics activities, it would be beneficial. With COVID-19 continuing to change workflows, it is critical that medical scribes receive standardized training as tele-scribing continues to grow in popularity and new roles for scribes as medical team members are identified.},
}

*COVID-19
Documentation
*Electronic Health Records
Humans
SARS-CoV-2
Workflow

@article {pmid34180546,
year = {2022},
author = {Korath, ADJ and Janda, J and Untersmayr, E and Sokolowska, M and Feleszko, W and Agache, I and Adel Seida, A and Hartmann, K and Jensen-Jarolim, E and Pali-Schöll, I},
title = {One Health: EAACI Position Paper on coronaviruses at the human-animal interface, with a specific focus on comparative and zoonotic aspects of SARS-CoV-2.},
journal = {Allergy},
volume = {77},
number = {1},
pages = {55-71},
pmid = {34180546},
issn = {1398-9995},
support = {//European Academy of Allergy and Clinical Immunology (EAACI)/ ; },
mesh = {Animals ; *COVID-19 ; Humans ; *One Health ; Pandemics ; Quality of Life ; SARS-CoV-2 ; },
abstract = {The latest outbreak of a coronavirus disease in 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), evolved into a worldwide pandemic with massive effects on health, quality of life, and economy. Given the short period of time since the outbreak, there are several knowledge gaps on the comparative and zoonotic aspects of this new virus. Within the One Health concept, the current EAACI position paper dwells into the current knowledge on SARS-CoV-2's receptors, symptoms, transmission routes for human and animals living in close vicinity to each other, usefulness of animal models to study this disease and management options to avoid intra- and interspecies transmission. Similar pandemics might appear unexpectedly and more frequently in the near future due to climate change, consumption of exotic foods and drinks, globe-trotter travel possibilities, the growing world population, the decreasing production space, declining room for wildlife and free-ranging animals, and the changed lifestyle including living very close to animals. Therefore, both the society and the health authorities need to be aware and well prepared for similar future situations, and research needs to focus on prevention and fast development of treatment options (medications, vaccines).},
}

Animals
*COVID-19
Humans
*One Health
Pandemics
Quality of Life
SARS-CoV-2

@article {pmid34170086,
year = {2021},
author = {Richter, D and Guasti, L and Koehler, F and Squizzato, A and Nistri, S and Christodorescu, R and Dievart, F and Gaudio, G and Asteggiano, R and Ferrini, M},
title = {Late phase of COVID-19 pandemic in General Cardiology. A position paper of the ESC Council for Cardiology Practice.},
journal = {ESC heart failure},
volume = {8},
number = {5},
pages = {3483-3494},
pmid = {34170086},
issn = {2055-5822},
mesh = {*COVID-19/complications ; *Cardiology ; Humans ; Pandemics ; SARS-CoV-2 ; Post-Acute COVID-19 Syndrome ; },
abstract = {Cardiovascular (CV) engagement in coronavirus disease 2019 (COVID-19) is a huge determinant of prognosis during the acute phase of the disease. However, little is known about the potential chronic implications of the late phase of COVID-19 and about the appropriate approach to these patients. Heart failure, type 1 and type 2 myocardial infarction, arrhythmias, myocarditis, pulmonary fibrosis, and thrombosis have been shown to be related to severe acute respiratory syndrome coronavirus 2 infection, and a 'long COVID-19' illness has been recognized with fatigue, chest pain, and dyspnoea among the most frequent symptoms reported after discharge from hospital. This paper focuses on some open questions that cardiologists are going to face during the next months in a general cardiology outpatient clinic, in particular how to evaluate a 'post-COVID' patient during follow-up of CV complications of the acute phase and how to manage new CV symptoms that could be the consequence, at least in part, of heart/vessels and/or lung involvement of the previous virus infection. Present symptoms and signs, history of previous CV disease (both preceding COVID-19 and occurring during viral infection), and specific laboratory and imaging measurements during the acute phase may be of interest in focusing on how to approach the clinical evaluation of a post-COVID patient and how to integrate in our standard of care the new information on COVID-19, possibly in a multidisciplinary view. Dealing with the increased COVID-associated CV risk burden and becoming acquainted with potential new e-cardiology approaches aimed at integrating the cardiology practice are relevant new challenges brought by severe acute respiratory syndrome coronavirus 2 infection and its sequelae.},
}

*COVID-19/complications
*Cardiology
Humans
Pandemics
SARS-CoV-2
Post-Acute COVID-19 Syndrome

@article {pmid34169495,
year = {2021},
author = {Gerotziafas, GT and Catalano, M and Theodorou, Y and Dreden, PV and Marechal, V and Spyropoulos, AC and Carter, C and Jabeen, N and Harenberg, J and Elalamy, I and Falanga, A and Fareed, J and Agathaggelou, P and Antic, D and Antignani, PL and Bosch, MM and Brenner, B and Chekhonin, V and Colgan, MP and Dimopoulos, MA and Douketis, J and Elnazar, EA and Farkas, K and Fazeli, B and Fowkes, G and Gu, Y and Gligorov, J and Ligocki, MA and Indran, T and Kannan, M and Kantarcioglu, B and Kasse, AA and Konstantinidis, K and Leivano, F and Lewis, J and Makatsariya, A and Mbaye, PM and Mahé, I and Panovska-Stavridis, I and Olinic, DM and Papageorgiou, C and Pecsvarady, Z and Pillon, S and Ramacciotti, E and Abdel-Razeq, H and Sabbah, M and Sassi, M and Schernthaner, G and Siddiqui, F and Shiomura, J and Slama-Schwok, A and Wautrecht, JC and Tafur, A and Taher, A and Klein-Wegel, P and Zhai, Z and Zoubida, TM and , },
title = {The COVID-19 Pandemic and the Need for an Integrated and Equitable Approach: An International Expert Consensus Paper.},
journal = {Thrombosis and haemostasis},
volume = {121},
number = {8},
pages = {992-1007},
pmid = {34169495},
issn = {2567-689X},
mesh = {COVID-19/diagnosis/*epidemiology/*prevention & control ; COVID-19 Testing/methods ; COVID-19 Vaccines/therapeutic use ; Disease Management ; Humans ; Immunization Programs/methods ; Pandemics/prevention & control ; *Public Health/methods ; Risk Assessment ; SARS-CoV-2/isolation & purification ; },
abstract = {BACKGROUND: One year after the declaration of the coronavirus disease 2019 (COVID-19) pandemic by the World Health Organization (WHO) and despite the implementation of mandatory physical barriers and social distancing, humanity remains challenged by a long-lasting and devastating public health crisis.

MANAGEMENT: Non-pharmacological interventions (NPIs) are efficient mitigation strategies. The success of these NPIs is dependent on the approval and commitment of the population. The launch of a mass vaccination program in many countries in late December 2020 with mRNA vaccines, adenovirus-based vaccines, and inactivated virus vaccines has generated hope for the end of the pandemic.

CURRENT ISSUES: The continuous appearance of new pathogenic viral strains and the ability of vaccines to prevent infection and transmission raise important concerns as we try to achieve community immunity against severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) and its variants. The need of a second and even third generation of vaccines has already been acknowledged by the WHO and governments.

PERSPECTIVES: There is a critical and urgent need for a balanced and integrated strategy for the management of the COVID-19 outbreaks organized on three axes: (1) Prevention of the SARS-CoV-2 infection, (2) Detection and early diagnosis of patients at risk of disease worsening, and (3) Anticipation of medical care (PDA).

CONCLUSION: The "PDA strategy" integrated into state policy for the support and expansion of health systems and introduction of digital organizations (i.e., telemedicine, e-Health, artificial intelligence, and machine-learning technology) is of major importance for the preservation of citizens' health and life world-wide.},
}

COVID-19/diagnosis/*epidemiology/*prevention & control
COVID-19 Testing/methods
COVID-19 Vaccines/therapeutic use
Disease Management
Humans
Immunization Programs/methods
Pandemics/prevention & control
*Public Health/methods
Risk Assessment
SARS-CoV-2/isolation & purification

@article {pmid34155756,
year = {2021},
author = {Kanjanapan, Y and Blinman, P and Underhill, C and Karikios, D and Segelov, E and Yip, D},
title = {Medical Oncology Group of Australia position statement: COVID-19 vaccination in patients with solid tumours.},
journal = {Internal medicine journal},
volume = {51},
number = {6},
pages = {955-959},
pmid = {34155756},
issn = {1445-5994},
mesh = {Australia/epidemiology ; *COVID-19 ; COVID-19 Vaccines ; Humans ; Medical Oncology ; *Neoplasms/epidemiology/therapy ; SARS-CoV-2 ; Vaccination ; },
abstract = {People with cancer are vulnerable to increased morbidity and mortality from the coronavirus disease 2019 (COVID-19). COVID-19 vaccination is key to protecting the population of people with cancer from adverse outcomes of SARS-CoV-2 infection. The Medical Oncology Group of Australia aimed to address the considerations around COVID-19 vaccination in people with cancer, in particular, safety and efficacy of vaccination. The assessment of patients with generalised allergic reaction to anti-cancer therapy containing vaccine components and practical implementation of vaccination of people on active anti-cancer therapy are also discussed.},
}

Australia/epidemiology
*COVID-19
COVID-19 Vaccines
Humans
Medical Oncology
*Neoplasms/epidemiology/therapy
SARS-CoV-2
Vaccination

@article {pmid34152382,
year = {2021},
author = {Orkin, AM and Gill, PJ and Ghersi, D and Campbell, L and Sugarman, J and Emsley, R and Steg, PG and Weijer, C and Simes, J and Rombey, T and Williams, HC and Wittes, J and Moher, D and Richards, DP and Kasamon, Y and Getz, K and Hopewell, S and Dickersin, K and Wu, T and Ayala, AP and Schulz, KF and Calleja, S and Boutron, I and Ross, JS and Golub, RM and Khan, KM and Mulrow, C and Siegfried, N and Heber, J and Lee, N and Kearney, PR and Wanyenze, RK and Hróbjartsson, A and Williams, R and Bhandari, N and Jüni, P and Chan, AW and , },
title = {Guidelines for Reporting Trial Protocols and Completed Trials Modified Due to the COVID-19 Pandemic and Other Extenuating Circumstances: The CONSERVE 2021 Statement.},
journal = {JAMA},
volume = {326},
number = {3},
pages = {257-265},
doi = {10.1001/jama.2021.9941},
pmid = {34152382},
issn = {1538-3598},
mesh = {*COVID-19 ; Clinical Protocols ; Delphi Technique ; *Guidelines as Topic ; Humans ; Publishing/standards ; Randomized Controlled Trials as Topic/*standards ; Research Report/*standards ; Surveys and Questionnaires ; },
abstract = {IMPORTANCE: Extenuating circumstances can trigger unplanned changes to randomized trials and introduce methodological, ethical, feasibility, and analytical challenges that can potentially compromise the validity of findings. Numerous randomized trials have required changes in response to the COVID-19 pandemic, but guidance for reporting such modifications is incomplete.

OBJECTIVE: As a joint extension for the CONSORT and SPIRIT reporting guidelines, CONSERVE (CONSORT and SPIRIT Extension for RCTs Revised in Extenuating Circumstances) aims to improve reporting of trial protocols and completed trials that undergo important modifications in response to extenuating circumstances.

EVIDENCE: A panel of 37 international trial investigators, patient representatives, methodologists and statisticians, ethicists, funders, regulators, and journal editors convened to develop the guideline. The panel developed CONSERVE following an accelerated, iterative process between June 2020 and February 2021 involving (1) a rapid literature review of multiple databases (OVID Medline, OVID EMBASE, and EBSCO CINAHL) and gray literature sources from 2003 to March 2021; (2) consensus-based panelist meetings using a modified Delphi process and surveys; and (3) a global survey of trial stakeholders.

FINDINGS: The rapid review yielded 41 673 citations, of which 38 titles were relevant, including emerging guidance from regulatory and funding agencies for managing the effects of the COVID-19 pandemic on trials. However, no generalizable guidance for all circumstances in which trials and trial protocols might face unanticipated modifications were identified. The CONSERVE panel used these findings to develop a consensus reporting guidelines following 4 rounds of meetings and surveys. Responses were received from 198 professionals from 34 countries, of whom 90% (n = 178) indicated that they understood the concept definitions and 85.4% (n = 169) indicated that they understood and could use the implementation tool. Feedback from survey respondents was used to finalize the guideline and confirm that the guideline's core concepts were applicable and had utility for the trial community. CONSERVE incorporates an implementation tool and checklists tailored to trial reports and trial protocols for which extenuating circumstances have resulted in important modifications to the intended study procedures. The checklists include 4 sections capturing extenuating circumstances, important modifications, responsible parties, and interim data analyses.

CONCLUSIONS AND RELEVANCE: CONSERVE offers an extension to CONSORT and SPIRIT that could improve the transparency, quality, and completeness of reporting important modifications to trials in extenuating circumstances such as COVID-19.},
}

*COVID-19
Clinical Protocols
Delphi Technique
*Guidelines as Topic
Humans
Publishing/standards
Randomized Controlled Trials as Topic/*standards
Research Report/*standards
Surveys and Questionnaires

@article {pmid34142284,
year = {2022},
author = {Testino, G and Vignoli, T and Patussi, V and Allosio, P and Amendola, MF and Aricò, S and Baselice, A and Balbinot, P and Campanile, V and Fanucchi, T and Greco, G and Macciò, L and Meneguzzi, C and Mioni, D and Palmieri, VO and Parisi, M and Renzetti, D and Rossin, R and Gandin, C and Bottaro, LC and Bernardi, M and Addolorato, G and Lungaro, L and Zoli, G and Scafato, E and Caputo, F},
title = {Alcohol-Related Liver Disease in the Covid-19 Era: Position Paper of the Italian Society on Alcohol (SIA).},
journal = {Digestive diseases and sciences},
volume = {67},
number = {6},
pages = {1975-1986},
pmid = {34142284},
issn = {1573-2568},
mesh = {*Alcoholism/complications/epidemiology/therapy ; *COVID-19 ; Communicable Disease Control ; Humans ; *Liver Diseases, Alcoholic/epidemiology/therapy ; Pandemics ; },
abstract = {BACKGROUND: Coronavirus Disease 2019 (COVID-19), firstly reported in China last November 2019, became a global pandemic. It has been shown that periods of isolation may induce a spike in alcohol use disorder (AUD). In addition, alcohol-related liver disease (ALD) is the most common consequence of excessive alcohol consumption worldwide. Moreover, liver impairment has also been reported as a common manifestation of COVID-19.

AIMS: The aim of our position paper was to consider some critical issues regarding the management of ALD in patients with AUD in the era of COVID-19.

METHODS: A panel of experts of the Italian Society of Alcohology (SIA) met via "conference calls" during the lockdown period to draft the SIA's criteria for the management of ALD in patients with COVID-19 as follows: (a) liver injury in patients with ALD and COVID-19 infection; (b) toxicity to the liver of the drugs currently tested to treat COVID-19 and the pharmacological interaction between medications used to treat AUD and to treat COVID-19; (c) reorganization of the management of compensated and decompensated ALD and liver transplantation in the COVID-19 era.

RESULTS AND CONCLUSIONS: The COVID-19 pandemic has rapidly carried us toward a new governance scenario of AUD and ALD which necessarily requires an in-depth review of the management of these diseases with a new safe approach (management of out-patients and in-patients following new rules of safety, telemedicine, telehealth, call meetings with clinicians, nurses, patients, and caregivers) without losing the therapeutic efficacy of multidisciplinary treatment.},
}

*Alcoholism/complications/epidemiology/therapy
*COVID-19
Communicable Disease Control
Humans
*Liver Diseases, Alcoholic/epidemiology/therapy
Pandemics

@article {pmid34133609,
year = {2021},
author = {Colombo, CSSS and Leitão, MB and Avanza Junior, AC and Borges, SF and Silveira, ADD and Braga, F and Camarozano, AC and Kopiler, DA and Lazzoli, JK and Freitas, OGA and Grossman, GB and Milani, M and Nunes, MB and Ritt, LEF and Sellera, CAC and Ghorayeb, N},
title = {Position Statement on Post-COVID-19 Cardiovascular Preparticipation Screening: Guidance for Returning to Physical Exercise and Sports - 2020.},
journal = {Arquivos brasileiros de cardiologia},
volume = {116},
number = {6},
pages = {1213-1226},
pmid = {34133609},
issn = {1678-4170},
mesh = {*COVID-19 ; *Cardiovascular Diseases/diagnosis/prevention & control ; Death, Sudden, Cardiac/prevention & control ; Exercise ; Humans ; Mass Screening ; Physical Examination ; SARS-CoV-2 ; *Sports ; *Sports Medicine ; },
}

*COVID-19
*Cardiovascular Diseases/diagnosis/prevention & control
Death, Sudden, Cardiac/prevention & control
Exercise
Humans
Mass Screening
Physical Examination
SARS-CoV-2
*Sports
*Sports Medicine

@article {pmid34100388,
year = {2021},
author = {Alqahtani, SA and Barry, M and Memish, Z and Hashim, A and Alfares, MA and Alghamdi, SA and Al-Hamoudi, WK and Al-Judaibi, B and Alhazzani, W and Al-Tawfiq, JA and Abaalkhail, F},
title = {Use of COVID-19 vaccines in patients with liver disease and post-liver transplantation: Position statement of the Saudi association for the study of liver diseases and transplantation.},
journal = {Saudi journal of gastroenterology : official journal of the Saudi Gastroenterology Association},
volume = {27},
number = {4},
pages = {201-207},
pmid = {34100388},
issn = {1998-4049},
mesh = {BNT162 Vaccine ; *COVID-19 ; COVID-19 Vaccines ; ChAdOx1 nCoV-19 ; Humans ; *Liver Diseases ; *Liver Transplantation ; SARS-CoV-2 ; Saudi Arabia ; },
abstract = {Patients with chronic liver disease (CLD) and liver transplant recipients are at increased risk of morbidity and mortality from coronavirus disease 2019 (COVID-19). Although several studies demonstrated the safety and efficacy of COVID-19 vaccines in the general population, data in CLD patients and liver transplant recipients are lacking. Two COVID-19 vaccines were approved by the Saudi Food and Drug Authority and rolled out to several million recipients in Saudi Arabia. These vaccines are mRNA-based vaccine BNT162b2 from Pfizer/BioNTech and adenovirus-based AZD1222 from Oxford/AstraZeneca from three manufacturing sites (EU Nodes, Serum Institute of India, and South Korea Bio). The Saudi Association for the Study of Liver diseases and Transplantation (SASLT) has reviewed the available evidence and issued interim recommendations for COVID-19 vaccination in CLD and liver transplant recipients. Since there is no evidence contradicting the safety and immunogenicity of the currently approved COVID-19 vaccines in patients with CLD and hepatobiliary cancer and liver transplant recipients, the SASLT recommends vaccination in those patient populations. CLD and hepatobiliary cancer patients and liver transplant recipients should be prioritized depending on the risk factors for severe COVID-19. In transplant recipients, the optimal timing of vaccination remains unknown; however, immunization is recommended after the initial immunosuppression phase. Patients with CLD and liver transplant candidates or recipients should be closely monitored after COVID-19 vaccination. These patient populations should be included in future clinical trials to provide further evidence on the efficacy and safety of COVID-19 vaccines.},
}

BNT162 Vaccine
*COVID-19
COVID-19 Vaccines
ChAdOx1 nCoV-19
Humans
*Liver Diseases
*Liver Transplantation
SARS-CoV-2
Saudi Arabia

@article {pmid34085330,
year = {2021},
author = {Giamarellos-Bourboulis, EJ and Bettoli, V and Jemec, GBE and Del Marmol, V and Marzano, AV and Prens, EP and Tzellos, T and Zouboulis, CC},
title = {Anti-COVID-19 measurements for hidradenitis suppurativa patients.},
journal = {Experimental dermatology},
volume = {30 Suppl 1},
number = {Suppl 1},
pages = {18-22},
pmid = {34085330},
issn = {1600-0625},
mesh = {Adalimumab/therapeutic use ; COVID-19/*complications/epidemiology/prevention & control ; COVID-19 Vaccines/immunology/pharmacology ; Cohort Studies ; Disease Susceptibility ; Europe ; Foundations ; Hidradenitis Suppurativa/*complications/*drug therapy/immunology ; Humans ; Incidence ; Interleukin 1 Receptor Antagonist Protein/therapeutic use ; Metabolic Syndrome/complications/immunology ; Pandemics ; *SARS-CoV-2 ; Severity of Illness Index ; },
abstract = {The reported incidence of COVID-19 among cohorts of patients with inflammatory bowel and skin diseases under treatment with biologicals is low. Treatment may further modify disease severity as some biological modifiers, such as anakinra, are also proposed for the management of COVID-19 patients potentially providing HS patients with an advantage. The above preliminary evidence suggests that hidradenitis suppurativa (HS) does probably not provide an increased susceptibility for COVID-19 and that any susceptibility is unlikely to be modified negatively by treatment with biologicals. On the occasion of its 10th International Conference, experts of the European Hidradenitis Suppurativa Foundation e.V. have prepared a consensus statement regarding anti-COVID-19 measurements for HS patients. Based on the available knowledge, patients with HS may be vaccinated against SARS-CoV2 and patients affected by metabolic syndrome constitute a high-risk group for COVID-19 and should be vaccinated at the earliest convenient point in time. HS patients on treatment with adalimumab can be vaccinated with non-living virus anti-SARS-CoV2 vaccines. A possible suboptimal effect of the vaccine may be suspected but might not be expected universally. The management of the biological treatment in HS patients is at the discretion of the dermatologist / responsible physician.},
}

Adalimumab/therapeutic use
COVID-19/*complications/epidemiology/prevention & control
COVID-19 Vaccines/immunology/pharmacology
Cohort Studies
Disease Susceptibility
Europe
Foundations
Hidradenitis Suppurativa/*complications/*drug therapy/immunology
Humans
Incidence
Interleukin 1 Receptor Antagonist Protein/therapeutic use
Metabolic Syndrome/complications/immunology
Pandemics
*SARS-CoV-2
Severity of Illness Index

@article {pmid34059190,
year = {2021},
author = {Prati, D and Fiorin, F and Berti, P and De Silvestro, G and Accorsi, P and Ostuni, A and , },
title = {Position paper on the use of COVID-19 convalescent plasma: an update.},
journal = {Blood transfusion = Trasfusione del sangue},
volume = {19},
number = {4},
pages = {277-280},
pmid = {34059190},
issn = {2385-2070},
mesh = {COVID-19/blood/*therapy ; *Consensus ; Humans ; Immunization, Passive/standards ; Inpatients ; Italy ; Meta-Analysis as Topic ; Randomized Controlled Trials as Topic ; Treatment Outcome ; COVID-19 Serotherapy ; },
}

COVID-19/blood/*therapy
*Consensus
Humans
Immunization, Passive/standards
Inpatients
Italy
Meta-Analysis as Topic
Randomized Controlled Trials as Topic
Treatment Outcome
COVID-19 Serotherapy

@article {pmid34052501,
year = {2021},
author = {Al-Motlaq, M and Neill, S and Foster, MJ and Coyne, I and Houghton, D and Angelhoff, C and Rising-Holmström, M and Majamanda, M},
title = {Position Statement of the International Network for Child and Family Centered Care: Child and Family Centred Care during the COVID19 Pandemic.},
journal = {Journal of pediatric nursing},
volume = {61},
number = {},
pages = {140-143},
pmid = {34052501},
issn = {1532-8449},
mesh = {*COVID-19 ; Child ; Family ; Humans ; Pandemics ; Patient-Centered Care ; SARS-CoV-2 ; },
abstract = {It is the position of the International Network for Child and Family Centered Care (INCFCC) that COVID19 restrictions pose tremendous challenges for the health care team in their efforts to provide child and family centered care (CFCC). COVID-19 restrictions impact on the family's right to be presernt with their ill child and to contribute to the caring process. A limited number of articles have discussed challenges about the successful delivery of CFCC during the COVID-19 pandemic. Based on current literature, the INCFCC stresses the need for continuous facilitation implementation of child and family centred care as, it is essential for children's physical and psychological wellbeing. Furthermore we believe that the families' presence and participation holds more benefits than risks to the health of children, their families, and the health care team.},
}

*COVID-19
Child
Family
Humans
Pandemics
Patient-Centered Care
SARS-CoV-2

@article {pmid34048585,
year = {2021},
author = {Bean, MK and Adams, EL and Buscemi, J and Ford, S and Wischenka, D and Behrman, P and Wilson, DK and Gladstone, TRG and Fitzgibbon, ML},
title = {Society of Behavioral Medicine (SBM) Position Statement: increase access to mental health services due to COVID-19-related parent and family stress.},
journal = {Translational behavioral medicine},
volume = {11},
number = {8},
pages = {1635-1637},
pmid = {34048585},
issn = {1613-9860},
support = {T32 CA093423/CA/NCI NIH HHS/United States ; 2T32CA093423//National Cancer Institute at the National Institutes of Health/ ; 2T32 CA093423/NH/NIH HHS/United States ; },
mesh = {*Behavioral Medicine ; *COVID-19 ; Child ; Humans ; *Mental Health Services ; Parents ; SARS-CoV-2 ; United States/epidemiology ; },
abstract = {COVID-19 has caused drastic increases in family stress contributing to deleterious social and emotional ramifications. Before COVID-19, millions of Americans lacked access to mental health resources, and now in the midst of a global pandemic, resources are more limited in times of greater need. In March 2020, the Coronavirus Aid, Relief, and Economic Security (CARES) Act provided funding for mental health reforms; yet many barriers remained to receiving sufficient care. In February 2021, the Society of Behavioral Medicine recommended federal legislators expand Community Behavioral Healthcare Centers, increase funding for Federally Qualified Healthcare Centers and School Based Health Centers, incentivize providers to accept Medicaid, and institute more statewide licensing flexibilities to expand the reach of mental health care. In March 2021, the American Rescue Plan was signed into law and provided an additional ~$4 billion in funding for community mental health services, implementing substance abuse prevention and treatment programs, increasing the behavioral health workforce, promoting behavioral telehealth within primary care, increasing school-based mental health services, implementing suicide prevention programs, and improving services for traumatized families. This significant investment in parents and children's mental health is a tremendous step in the right direction and provides reassurance that relief is underway. Ongoing surveillance of the programmatic and clinical outcomes that result from these new policy reforms will be important for identifying areas that may need continual support as our nation recovers from COVID-19.},
}

*Behavioral Medicine
*COVID-19
Child
Humans
*Mental Health Services
Parents
SARS-CoV-2
United States/epidemiology

@article {pmid34047035,
year = {2021},
author = {McCaughan, G and Di Ciaccio, P and Ananda-Rajah, M and Gilroy, N and MacIntyre, R and Teh, B and Weinkove, R and Curnow, J and Szer, J and Enjeti, AK and Ross, DM and Mulligan, S and Trotman, J and Dickinson, M and Quach, H and Choi, P and Polizzotto, MN and Tam, CS and Ho, PJ and Ku, M and Gregory, G and Gangatharan, S and Hapgood, G and Cochrane, T and Cheah, C and Gibbs, S and Wei, A and Johnston, A and Greenwood, M and Prince, HM and Latimer, M and Berkahn, L and Wight, J and Armytage, T and Hamad, N},
title = {COVID-19 vaccination in haematology patients: an Australian and New Zealand consensus position statement.},
journal = {Internal medicine journal},
volume = {51},
number = {5},
pages = {763-768},
pmid = {34047035},
issn = {1445-5994},
mesh = {Australia/epidemiology ; *COVID-19 ; COVID-19 Vaccines ; Consensus ; *Hematology ; Humans ; New Zealand/epidemiology ; Prospective Studies ; SARS-CoV-2 ; Vaccination ; },
abstract = {Australia and New Zealand have achieved excellent community control of COVID-19 infection. In light of the imminent COVID-19 vaccination roll out in both countries, representatives from the Haematology Society of Australia and New Zealand and infectious diseases specialists have collaborated on this consensus position statement regarding COVID-19 vaccination in patients with haematological disorders. It is our recommendation that patients with haematological malignancies, and some benign haematological disorders, should have expedited access to high-efficacy COVID-19 vaccines, given that these patients are at high risk of morbidity and mortality from COVID-19 infection. Vaccination should not replace other public health measures in these patients, given that the effectiveness of COVID-19 vaccination, specifically in patients with haematological malignancies, is not known. Given the limited available data, prospective collection of safety and efficacy data of COVID-19 vaccination in this patient group is a priority.},
}

Australia/epidemiology
*COVID-19
COVID-19 Vaccines
Consensus
*Hematology
Humans
New Zealand/epidemiology
Prospective Studies
SARS-CoV-2
Vaccination

@article {pmid34030157,
year = {2021},
author = {Exten, C and Pinto, CN and Gaynor, AM and Meyerson, B and Griner, SB and Van Der Pol, B and , },
title = {Direct-to-Consumer Sexually Transmitted Infection Testing Services: A Position Statement from the American Sexually Transmitted Diseases Association.},
journal = {Sexually transmitted diseases},
volume = {48},
number = {11},
pages = {e155-e159},
pmid = {34030157},
issn = {1537-4521},
mesh = {*COVID-19 ; Humans ; Pandemics ; SARS-CoV-2 ; *Sexually Transmitted Diseases/diagnosis/epidemiology ; Specimen Handling ; United States/epidemiology ; },
abstract = {Direct-to-consumer test services have gained popularity for sexually transmitted infections in recent years, with substantially increased use as a result of the SARS-CoV-2 (CoVID-19) global pandemic. This method of access has been variously known as "self-testing," "home testing," and "direct access testing." Although these online services may be offered through different mechanisms, here we focus on those that are consumer-driven and require self-collected samples, and sample shipment to a centralized laboratory without involvement of health care providers and/or local health departments. We provide the American Sexually Transmitted Diseases Association's position on utilization of these services and recommendations for both consumers and health care providers.},
}

*COVID-19
Humans
Pandemics
SARS-CoV-2
*Sexually Transmitted Diseases/diagnosis/epidemiology
Specimen Handling
United States/epidemiology

@article {pmid34013968,
year = {2021},
author = {Al-Riyami, AZ and Burnouf, T and Yazer, M and Triulzi, D and Kumaş, LT and Sağdur, L and Pelit, NB and Bazin, R and Hindawi, SI and Badawi, MA and Patidar, GK and Pandey, HC and Chaurasia, R and Fachini, RM and Scuracchio, P and Wendel, S and Ang, AL and Ong, KH and Young, P and Ihalainen, J and Vierikko, A and Qiu, Y and Yang, R and Xu, H and Rahimi-Levene, N and Shinar, E and Izak, M and Gonzalez, CA and Ferrari, DM and Cini, PV and Aditya, RN and Sharma, RR and Sachdev, S and Hans, R and Lamba, DS and Nissen-Meyer, LSH and Devine, DV and Lee, CK and Leung, JN and Hung, IFN and Tiberghien, P and Gallian, P and Morel, P and Al Maamari, K and Al-Hinai, Z and Vrielink, H and So-Osman, C and De Angelis, V and Berti, P and Ostuni, A and Marano, G and Nevessignsky, MT and El Ekiaby, M and Daly, J and Hoad, V and Kim, S and van den Berg, K and Vermeulen, M and Glatt, TN and Schäfer, R and Reik, R and Gammon, R and Lopez, M and Estcourt, L and MacLennan, S and Roberts, D and Louw, V and Dunbar, N and , },
title = {International Forum on the Collection and Use of COVID-19 Convalescent Plasma: Protocols, Challenges and Lessons Learned: Summary.},
journal = {Vox sanguinis},
volume = {116},
number = {10},
pages = {1117-1135},
pmid = {34013968},
issn = {1423-0410},
support = {D43 TW010345/TW/FIC NIH HHS/United States ; },
mesh = {*COVID-19/therapy ; *Coronavirus Infections ; Humans ; Immunization, Passive ; SARS-CoV-2 ; COVID-19 Serotherapy ; },
}

*COVID-19/therapy
*Coronavirus Infections
Humans
Immunization, Passive
SARS-CoV-2
COVID-19 Serotherapy

@article {pmid33976449,
year = {2020},
author = {Awuku, YA and Jibril, AT and Bockarie, AS and Duah, A and Tachi, K and Agyei-Nkansah, A and Afihene, MY},
title = {Gastroenterology practice in the COVID-19 era: Ghana Association for the Study of Liver and Digestive Diseases (GASLIDD) position statement.},
journal = {Ghana medical journal},
volume = {54},
number = {4 Suppl},
pages = {104-106},
pmid = {33976449},
issn = {2616-163X},
mesh = {COVID-19/*prevention & control ; Endoscopy, Gastrointestinal/*standards ; Gastroenterology/*standards ; Ghana ; Humans ; Infection Control/*standards ; *Practice Guidelines as Topic ; SARS-CoV-2 ; Societies, Medical ; },
abstract = {UNLABELLED: The COVID-19 pandemic has impacted healthcare negatively across the globe. The practice of gastroenterology has been affected especially gastrointestinal (GI) endoscopy which is considered high risk for transmission of the virus. As a community of practitioners there is the need to share information and make evidence-based statements to guide GI practice in Ghana. This GASLIDD position statement based on the growing and rapidly evolving body of knowledge is to provide up to date information on the COVID-19 disease and guidance for the practice of gastroenterology in Ghana and beyond. It is to help the GI community of practice to maintain the highest level of health delivery and safety for our patients, staff, community and GI practitioners.

FUNDING: Self-funded.},
}

COVID-19/*prevention & control
Endoscopy, Gastrointestinal/*standards
Gastroenterology/*standards
Ghana
Humans
Infection Control/*standards
*Practice Guidelines as Topic
SARS-CoV-2
Societies, Medical

@article {pmid33972142,
year = {2021},
author = {De Luca, A and Frusone, F and Buzzacchino, F and Amabile, MI and Taffurelli, M and Del Mastro, L and Rutgers, EJT and Sacchini, V and Caruso, F and Minelli, M and Fortunato, L},
title = {First Surgical National Consensus Conference of the Italian Breast Surgeons association (ANISC) on breast cancer management in neoadjuvant setting: Results and summary.},
journal = {European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology},
volume = {47},
number = {8},
pages = {1913-1919},
doi = {10.1016/j.ejso.2021.04.037},
pmid = {33972142},
issn = {1532-2157},
mesh = {Antineoplastic Agents/*therapeutic use ; Clinical Trials as Topic ; Female ; Humans ; Italy ; Lymph Node Excision ; Lymphatic Metastasis ; Margins of Excision ; Mastectomy ; *Neoadjuvant Therapy ; Neoplasm Grading ; Neoplasm Micrometastasis/therapy ; Neoplasm Staging ; Patient Selection ; Erb-b2 Receptor Tyrosine Kinases/metabolism ; Triple Negative Breast Neoplasms/diagnostic imaging/metabolism/*pathology/*therapy ; Tumor Burden ; },
abstract = {RATIONALE: On October 15th, 2020, the first Surgical National Consensus Conference on neoadjuvant chemotherapy (NACT) was promoted by the Italian Association of Breast Surgeons (ANISC).

METHOD: The Consensus Conference was entirely held online due to anti-Covid-19 restrictions and after an introductory four lectures held by national and international experts in the field, a total of nine questions were presented and a digital "real-time" voting system was obtained. A consensus was reached if 75% or more of all panelists agreed on a given question.

RESULTS: A total of 202 physicians, from 76 different Italian Breast Centers homogeneously distributed throughout the Italian country, participated to the Conference. Most participants were surgeons (75%). Consensus was reached for seven out of the nine considered topics, including management of margins and lymph nodes at surgery, and there was good correspondence between the 32 "Expert Panelists" and the "Participants" to the Conference. Consensus was not achieved regarding the indications to NACT for high-grade luminal-like breast tumors, and the need to perform an axillary lymph node dissection in case of micrometastases in the sentinel lymph node after NACT.

CONCLUSIONS: NACT is a topic of major interest among surgeons, and there is need to develop shared guidelines. While a Consensus was obtained for most issues presented at this Conference, controversies still exist regarding indications to NACT in luminal B-like tumors and management of lymph node micrometastases. There is need for clinical studies and analysis of large databases to improve our knowledge on this subject.},
}

Antineoplastic Agents/*therapeutic use
Clinical Trials as Topic
Female
Humans
Italy
Lymph Node Excision
Lymphatic Metastasis
Margins of Excision
Mastectomy
*Neoadjuvant Therapy
Neoplasm Grading
Neoplasm Micrometastasis/therapy
Neoplasm Staging
Patient Selection
Erb-b2 Receptor Tyrosine Kinases/metabolism
Triple Negative Breast Neoplasms/diagnostic imaging/metabolism/*pathology/*therapy
Tumor Burden

@article {pmid33970888,
year = {2021},
author = {Vicari, AS and Olson, D and Vilajeliu, A and Andrus, JK and Ropero, AM and Morens, DM and Santos, IJ and Azziz-Baumgartner, E and Berman, S},
title = {Seasonal Influenza Prevention and Control Progress in Latin America and the Caribbean in the Context of the Global Influenza Strategy and the COVID-19 Pandemic.},
journal = {The American journal of tropical medicine and hygiene},
volume = {105},
number = {1},
pages = {93-101},
pmid = {33970888},
issn = {1476-1645},
mesh = {COVID-19/complications/*prevention & control ; Caribbean Region ; Global Health ; Humans ; Influenza Vaccines/administration & dosage/*supply & distribution ; Influenza, Human/complications/*prevention & control ; Latin America ; Seasons ; },
abstract = {Each year in Latin America and the Caribbean, seasonal influenza is associated with an estimated 36,500 respiratory deaths and 400,000 hospitalizations. Since the 2009 influenza A(H1N1) pandemic, the Region has made significant advances in the prevention and control of seasonal influenza, including improved surveillance systems, burden estimates, and vaccination of at-risk groups. The Global Influenza Strategy 2019-2030 provides a framework to strengthen these advances. Against the backdrop of this new framework, the University of Colorado convened in October 2020 its Immunization Advisory Group of Experts to review and discuss current surveillance, prevention, and control strategies for seasonal influenza in Latin America and the Caribbean, also in the context of the COVID-19 pandemic. This review identified five areas for action and made recommendations specific to each area. The Region should continue its efforts to strengthen surveillance and impact evaluations. Existing data on disease burden, seasonality patterns, and vaccination effectiveness should be used to inform decision-making at the country level as well as advocacy efforts for programmatic resources. Regional and country strategic plans should be prepared and include specific targets for 2030. Existing investments in influenza prevention and control, including for immunization programs, should be optimized. Finally, regional partnerships, such as the regional networks for syndromic surveillance and vaccine effectiveness evaluation (SARInet and REVELAC-i), should continue to play a critical role in continuous learning and standardization by sharing experiences and best practices among countries.},
}

COVID-19/complications/*prevention & control
Caribbean Region
Global Health
Humans
Influenza Vaccines/administration & dosage/*supply & distribution
Influenza, Human/complications/*prevention & control
Latin America
Seasons

@article {pmid33960979,
year = {2021},
author = {Indolfi, C and Barillà, F and Basso, C and Ciccone, MM and Curcio, A and Mancone, M and Mercuro, G and Muscoli, S and Nodari, S and Pedrinelli, R and Romeo, F and Sinagra, G and Filardi, PP},
title = {[Position paper of the Italian Society of Cardiology (SIC) on COVID-19 vaccine priority in patients with cardiovascular diseases].},
journal = {Giornale italiano di cardiologia (2006)},
volume = {22},
number = {5},
pages = {363-375},
doi = {10.1714/3592.35745},
pmid = {33960979},
issn = {1972-6481},
mesh = {Age Factors ; Animals ; COVID-19/epidemiology/mortality/*prevention & control ; COVID-19 Vaccines/*administration & dosage ; Cardiology ; Cardiovascular Diseases/*complications ; *Consensus ; Coronary Disease/complications ; Disease Vectors ; Heart Failure/complications ; Heart Transplantation ; Heart Valve Diseases/complications ; Humans ; Hypertension, Pulmonary/complications ; Italy/epidemiology ; Prognosis ; Renal Insufficiency/complications ; SARS-CoV-2/immunology ; Societies, Medical ; Vaccines, Synthetic/administration & dosage ; mRNA Vaccines ; },
abstract = {In over a year, the COVID-19 pandemic caused 2.69 million deaths and 122 million infections. Social isolation and distancing measures have been the only prevention available for months. Scientific research has done a great deal of work, developing in a few months safe and effective vaccines against COVID-19. In the European Union, nowadays, four vaccines have been authorized for use: Pfizer-BioNTech, Moderna, ChAdOx1 (AstraZeneca/Oxford), Janssen (Johnson & Johnson), and three others are currently under rolling review.Vaccine allocation policy is crucial to optimize the advantage of treatment preferring people with the highest risk of contagion. These days the priority in the vaccination program is of particular importance since it has become clear that the number of vaccines is not sufficient for the entire Italian population in the short term. Cardiovascular diseases are frequently associated with severe COVID-19 infections, leading to the worst prognosis. The elderly population suffering from cardiovascular diseases is, therefore, to be considered a particularly vulnerable population. However, age cannot be considered the only discriminating factor because in the young-adult population suffering from severe forms of heart disease, the prognosis, if affected by COVID-19, is particularly ominous and these patients should have priority access to the vaccination program. The aim of this position paper is to establish a consensus on a priority in the vaccination of COVID-19 among subjects suffering from different cardiovascular diseases.},
}

Age Factors
Animals
COVID-19/epidemiology/mortality/*prevention & control
COVID-19 Vaccines/*administration & dosage
Cardiology
Cardiovascular Diseases/*complications
*Consensus
Coronary Disease/complications
Disease Vectors
Heart Failure/complications
Heart Transplantation
Heart Valve Diseases/complications
Humans
Hypertension, Pulmonary/complications
Italy/epidemiology
Prognosis
Renal Insufficiency/complications
SARS-CoV-2/immunology
Societies, Medical
Vaccines, Synthetic/administration & dosage
mRNA Vaccines

@article {pmid33946120,
year = {2021},
author = {Elalamy, I and Gerotziafas, G and Alamowitch, S and Laroche, JP and Van Dreden, P and Ageno, W and Beyer-Westendorf, J and Cohen, AT and Jimenez, D and Brenner, B and Middeldorp, S and Cacoub, P and , },
title = {SARS-CoV-2 Vaccine and Thrombosis: An Expert Consensus on Vaccine-Induced Immune Thrombotic Thrombocytopenia.},
journal = {Thrombosis and haemostasis},
volume = {121},
number = {8},
pages = {982-991},
pmid = {33946120},
issn = {2567-689X},
mesh = {COVID-19/*prevention & control ; COVID-19 Vaccines/*adverse effects/therapeutic use ; Clinical Decision-Making ; Hemorrhage/etiology ; Humans ; Purpura, Thrombocytopenic, Idiopathic/*etiology ; Risk Factors ; Thrombocytopenia/etiology ; Thrombosis/*etiology ; Vaccination/adverse effects/methods ; },
abstract = {Historically, the vaccination strategies developed in the second half of the 20th century have facilitated the eradication of infectious diseases. From the onset of COVID-19 pandemic to the end of April 2021, more than 150 million cases and 3 million deaths were documented worldwide with disruption of the economic and social activity, and with devastating material, physical, and psychological consequences. Reports of unusual and severe thrombotic events, including cerebral and splanchnic venous thrombosis and other autoimmune adverse reactions, such as immune thrombocytopenia or thrombotic microangiopathies in connection with some of the SARS-CoV-2 vaccines, have caused a great deal of concern within the population and the medical community. This report is intended to provide practical answers following an overview of our knowledge on these thrombotic events that are extremely rare but have serious consequences. Vaccine hesitancy threatens to reverse the progress made in controlling vaccine-preventable diseases. These adverse events must be put into perspective with an objective analysis of the facts and the issues of the vaccination strategy during this SARS-CoV-2 pandemic. Health care professionals remain the most pertinent advisors and influencers regarding vaccination decisions; they have to be supported to provide reliable and credible information on vaccines. We need to inform, reassure, and support our patients when the prescription is made. Facing these challenges and observations, a panel of experts express their insights and propose a tracking algorithm for vaccinated patients based on a 10-point guideline for decision-making on what to do and not to do.},
}

COVID-19/*prevention & control
COVID-19 Vaccines/*adverse effects/therapeutic use
Clinical Decision-Making
Hemorrhage/etiology
Humans
Purpura, Thrombocytopenic, Idiopathic/*etiology
Risk Factors
Thrombocytopenia/etiology
Thrombosis/*etiology
Vaccination/adverse effects/methods

@article {pmid33941488,
year = {2021},
author = {Russo, FP and Piano, S and Bruno, R and Burra, P and Puoti, M and Masarone, M and Montagnese, S and Ponziani, FR and Petta, S and Aghemo, A and , },
title = {Italian association for the study of the liver position statement on SARS-CoV2 vaccination.},
journal = {Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver},
volume = {53},
number = {6},
pages = {677-681},
pmid = {33941488},
issn = {1878-3562},
mesh = {*COVID-19/epidemiology/prevention & control ; *COVID-19 Vaccines/classification/pharmacology ; Humans ; *Immunization Programs/methods/organization & administration ; Immunosuppressive Agents/therapeutic use ; Italy/epidemiology ; *Liver Diseases/immunology/therapy ; Liver Transplantation ; Patient Safety ; Patient Selection ; Risk Adjustment/*methods ; Risk Assessment ; SARS-CoV-2/immunology ; Transplant Recipients ; Treatment Outcome ; },
abstract = {The vaccination campaign against Sars-CoV-2 commenced in Italy at the end of December 2020. The first ones to receive the immunization against the virus were the health workers and the residents of nursing homes, following which the vaccine would be available for the entire population, beginning with the most vulnerable individuals. SARS-CoV2 vaccines have been demonstrated to be safe for the general population, although no data for patients with liver diseases or those having undergone liver transplantation are available so far. The present position statement AISF is an attempt to suggest, based on the published data on the impact of Sars-Cov-2 infection in patients with chronic liver disease, a possible priority for vaccination for this category of patients.},
}

*COVID-19/epidemiology/prevention & control
*COVID-19 Vaccines/classification/pharmacology
Humans
*Immunization Programs/methods/organization & administration
Immunosuppressive Agents/therapeutic use
Italy/epidemiology
*Liver Diseases/immunology/therapy
Liver Transplantation
Patient Safety
Patient Selection
Risk Adjustment/*methods
Risk Assessment
SARS-CoV-2/immunology
Transplant Recipients
Treatment Outcome

@article {pmid33909805,
year = {2021},
author = {Queiroz, NSF and Teixeira, FV and Freire, CCF and Motta, MP and Vasconcellos, MAM and Chebli, LA and Saad-Hossne, R and , },
title = {BRAZILIAN IBD STUDY GROUP POSITION STATEMENT ON SARS-COV2 VACCINATION.},
journal = {Arquivos de gastroenterologia},
volume = {58},
number = {1},
pages = {1-4},
doi = {10.1590/S0004-2803.202100000-02},
pmid = {33909805},
issn = {1678-4219},
mesh = {Brazil ; *COVID-19 ; COVID-19 Vaccines ; Humans ; *Inflammatory Bowel Diseases ; Pandemics ; RNA, Viral ; SARS-CoV-2 ; Vaccination ; },
abstract = {Mass vaccination offers the best strategy to fight against COVID-19 pandemic, and SARS-CoV2 vaccines are being approved in several countries for emergency use. In Brazil, vaccine approval is expected in the next few days, however potential concerns exist regarding vaccine recommendations for specific populations, such as patients with inflammatory bowel disease (IBD). To address these questions, the Brazilian IBD Study Group (GEDIIB) provides this practical advice with key recommendations about the COVID-19 vaccines in IBD population.},
}

Brazil
*COVID-19
COVID-19 Vaccines
Humans
*Inflammatory Bowel Diseases
Pandemics
RNA, Viral
SARS-CoV-2
Vaccination

@article {pmid33909785,
year = {2021},
author = {Beck, ALS and Barberato, SH and Almeida, ALC and Grau, CRPC and Lopes, MMU and Lima, RSL and Cerci, RJ and Albricker, ACL and Barros, FS and Oliveira, AJ and Lira Filho, EB and Miglioranza, MH and Vieira, MLC and Pena, JLB and Strabelli, TMV and Bihan, DCSL and Tsutsui, JM and Rochitte, CE},
title = {Position Statement on Indications and the Safe Reintroduction of Cardiovascular Imaging Methods in the COVID-19 Scenario - 2021.},
journal = {Arquivos brasileiros de cardiologia},
volume = {116},
number = {3},
pages = {659-678},
pmid = {33909785},
issn = {1678-4170},
mesh = {Humans ; *Cardiovascular System ; *COVID-19 ; SARS-CoV-2 ; Societies, Medical ; },
}

Humans
*Cardiovascular System
*COVID-19
SARS-CoV-2
Societies, Medical

@article {pmid33887076,
year = {2021},
author = {Hegde, MN and Parmar, G and Logani, A and Hegde, ND and Ballal, S and Krithikadatta, J and Nawal, R and Amalavathy, K and Devadiga, D and Bhat, R},
title = {Dental practice management during COVID-19 times-Now and beyond.},
journal = {International journal of clinical practice},
volume = {75},
number = {9},
pages = {e14251},
pmid = {33887076},
issn = {1742-1241},
mesh = {*COVID-19 ; Humans ; Pandemics ; *Practice Management, Dental ; Public Health ; SARS-CoV-2 ; },
abstract = {AIM: Coronavirus disease 2019 (COVID-19) being declared a global public health emergency has become a significant challenge for all healthcare workers, including dentistry, recognised as a high-risk profession during these times. This consensus statement aims to highlight and provide guidelines necessary to be implemented for a clinical dental practice.

MATERIALS AND METHODS: A total of nine conservative Dentists and Endodontists and one Oral and Maxillofacial Surgeon; with four panelists from government dental colleges, one each from the North, South, East and West India and six resource persons from private colleges in South India, all of them being clinicians and administrators practicing dentistry since the inception of the pandemic, collaborated in this consensus statement. The consensus statement was developed through a symposium conducted on the topics; general dental practice during COVID-19 times, the importance of aerosols in clinical dental practice in the spread of COVID-19, effective standard operating protocols for clinical dental practice and Institutional settings with scientific evidence-based justifications, followed by a panel discussion with to devise mandatory protocols to be followed in clinical and institutional settings. The symposium was attended by 46 practitioners who participated in the deliberation.

RESULTS: This consensus statement provides clinicians and researchers with protocols for the dental practice, agreed upon by experts in the field. The Consensus Statement has been formulated according to the AGREE Reporting checklist for the formulation of guidelines.

CONCLUSION: The experts and panelists reached a Consensus on the protocols and guidelines for the safe clinical and institutional dental practice.},
}

*COVID-19
Humans
Pandemics
*Practice Management, Dental
Public Health
SARS-CoV-2

@article {pmid33861837,
year = {2020},
author = {Álvarez Z, P and Larios G, G and Toro R, L and Acevedo A, V and Arancibia G, F and Cárdenas M, L and Fernández C, C},
title = {[Recommendation for the recognition, management and follow up of cardiovascular compromise in patients with Pediatric Multisystemic Inflammatory Syndrome associated with COVID-19 (PIMS-CT). Position statement of Chilean Scientific Societies].},
journal = {Revista chilena de pediatria},
volume = {91},
number = {6},
pages = {982-990},
doi = {10.32641/rchped.vi91i6.3215},
pmid = {33861837},
issn = {0717-6228},
mesh = {Biomarkers/metabolism ; COVID-19/diagnosis/physiopathology/*therapy/complications ; Cardiovascular Diseases/diagnosis/therapy/*virology ; Child ; Chile ; Humans ; Mucocutaneous Lymph Node Syndrome/therapy/virology ; Patient Care Team/organization & administration ; Shock/therapy/virology ; Systemic Inflammatory Response Syndrome/diagnosis/physiopathology/*therapy ; },
abstract = {Since the onset of the SARS-CoV-2 pandemic, the pediatric population has been less affected by the disease both in frequency and severity. However, since April cases of variable presentation and severity characterized by inflammatory phenomena that affect multiple organs have been reported, a condition called Multisystem Inflammatory Syndrome in Children (MIS-C). The literature has reported frequent cardiac involvement, up to 80%. This is characterized by myocardial injury with a significant increase of biomarkers such as serum troponins I and T, BNP, or NT-ProBNP coupled with varying degrees of ventricular dysfunction, pericarditis, valvulitis, and arrhythmias. Coronary compromise has also been described, which can occur in up to 23% of cases, and ranges from dila tations to aneurysms. Inpatient and outpatient cardiology follow-up has been systematized based on the clinical phenotypes such as myocardial injury (myocarditis, valvulitis, pericarditis), shock (usua lly vasoplegic), Kawasaki disease-type manifestations, and those MIS-C that do not comply with the clinic of the previous three. This last group represents the main challenge in the short-, medium- and long-term follow-up, therefore, it is necessary a multidisciplinary team for managing these patients. Considering the high frequency of cardiac compromise in MIS-C, and the importance of reaching a consensus regarding its management and follow-up, we present these recommendations according to the current state of knowledge regarding this recently described pathology.},
}

Biomarkers/metabolism
COVID-19/diagnosis/physiopathology/*therapy/complications
Cardiovascular Diseases/diagnosis/therapy/*virology
Child
Chile
Humans
Mucocutaneous Lymph Node Syndrome/therapy/virology
Patient Care Team/organization & administration
Shock/therapy/virology
Systemic Inflammatory Response Syndrome/diagnosis/physiopathology/*therapy

@article {pmid33857654,
year = {2021},
author = {Ng, YS and Ong, PH and Mah, SM and Koh, CWC and Loh, YJ and Chew, E},
title = {Rehabilitation prioritization: Development of expert consensus on essential rehabilitation during pandemics.},
journal = {Annals of physical and rehabilitation medicine},
volume = {64},
number = {6},
pages = {101512},
pmid = {33857654},
issn = {1877-0665},
mesh = {Consensus ; Humans ; *Pandemics ; },
}

Consensus
Humans
*Pandemics

@article {pmid33855628,
year = {2021},
author = {Saibene, AM and Allevi, F and Ayad, T and Baudoin, T and Bernal-Sprekelsen, M and Briganti, G and Carrie, S and Cayé-Thomasen, P and Dahman Saidi, S and Dauby, N and Fenton, J and Golusiński, W and Klimek, L and Leclerc, AA and Longtin, Y and Mannelli, G and Mayo-Yáñez, M and Meço, C and Metwaly, O and Mouawad, F and Niemczyk, K and Pedersen, U and Piersiala, K and Plzak, J and Remacle, M and Rommel, N and Saleh, H and Szpecht, D and Tedla, M and Tincati, C and Tucciarone, M and Zelenik, K and Lechien, JR},
title = {Appropriateness for SARS-CoV-2 vaccination for otolaryngologist and head and neck surgeons in case of pregnancy, breastfeeding, or childbearing potential: Yo-IFOS and CEORL-HNS joint clinical consensus statement.},
journal = {European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery},
volume = {278},
number = {10},
pages = {4091-4099},
pmid = {33855628},
issn = {1434-4726},
mesh = {Breast Feeding ; *COVID-19 ; *COVID-19 Vaccines ; Consensus ; Female ; Humans ; Male ; *Otolaryngologists ; Pregnancy ; SARS-CoV-2 ; *Surgeons ; Vaccination ; },
abstract = {PURPOSE: SARS-CoV-2 vaccines are a key step in fighting the pandemic. Nevertheless, their rapid development did not allow for testing among specific population subgroups such as pregnant and breastfeeding women, or elaborating specific guidelines for healthcare personnel working in high infection risk specialties, such as otolaryngology (ORL). This clinical consensus statement (CCS) aims to offer guidance for SARS-CoV-2 vaccination to this high-risk population based on the best evidence available.

METHODS: A multidisciplinary international panel of 33 specialists judged statements through a two-round modified Delphi method survey. Statements were designed to encompass the following topics: risk of SARS-Cov-2 infection and use of protective equipment in ORL; SARS-Cov-2 infection and vaccines and respective risks for the mother/child dyad; and counseling for SARS-CoV-2 vaccination in pregnant, breastfeeding, or fertile healthcare workers (PBFHW). All ORL PBFHW were considered as the target audience.

RESULTS: Of the 13 statements, 7 reached consensus or strong consensus, 2 reached no consensus, and 2 reached near-consensus. According to the statements with strong consensus otorhinolaryngologists-head and neck surgeons who are pregnant, breastfeeding, or with childbearing potential should have the opportunity to receive SARS-Cov-2 vaccination. Moreover, personal protective equipment (PPE) should still be used even after the vaccination.

CONCLUSION: Until prospective evaluations on these topics are available, ORL-HNS must be considered a high infection risk specialty. While the use of PPE remains pivotal, ORL PBFHW should be allowed access to SARS-CoV-2 vaccination provided they receive up-to-date information.},
}

Breast Feeding
*COVID-19
*COVID-19 Vaccines
Consensus
Female
Humans
Male
*Otolaryngologists
Pregnancy
SARS-CoV-2
*Surgeons
Vaccination

@article {pmid33844898,
year = {2021},
author = {Martins, JRM and Villagelin, DGP and Carvalho, GA and Vaisman, F and Teixeira, PFS and Scheffel, RS and Sgarbi, JA},
title = {Management of thyroid disorders during the COVID-19 outbreak: a position statement from the Thyroid Department of the Brazilian Society of Endocrinology and Metabolism (SBEM).},
journal = {Archives of endocrinology and metabolism},
volume = {65},
number = {3},
pages = {368-375},
pmid = {33844898},
issn = {2359-4292},
mesh = {Brazil ; *COVID-19 ; Graves Ophthalmopathy/therapy ; Humans ; Hyperthyroidism/therapy ; Iodine Radioisotopes ; Pandemics ; Thyroid Diseases/*therapy ; Thyroid Gland ; },
abstract = {This position statement was prepared to guide endocrinologists on the best approach to managing thyroid disorders during the coronavirus disease (COVID-19) pandemic. The most frequent thyroid hormonal findings in patients with COVID-19, particularly in individuals with severe disease, are similar to those present in the non-thyroidal illness syndrome and require no intervention. Subacute thyroiditis has also been reported during COVID-19 infection. Diagnosis and treatment of hypothyroidism during the COVID-19 pandemic may follow usual practice; however, should avoid frequent laboratory tests in patients with previous controlled disease. Well-controlled hypo and hyperthyroidism are not associated with an increased risk of COVID-19 infection or severity. Newly diagnosed hyperthyroidism during the pandemic should be preferably treated with antithyroid drugs (ATDs), bearing in mind the possibility of rare side effects with these medications, particularly agranulocytosis, which requires immediate intervention. Definitive treatment of hyperthyroidism (radioiodine therapy or surgery) may be considered in those cases that protective protocols can be followed to avoid COVID-19 contamination or once the pandemic is over. In patients with moderate Graves' ophthalmopathy (GO) not at risk of visual loss, glucocorticoids at immunosuppressive doses should be avoided, while in those with severe GO without COVID-19 and at risk of vision loss, intravenous glucocorticoid is the therapeutic choice. Considering that most of the thyroid cancer cases are low risk and associated with an excellent prognosis, surgical procedures could and should be postponed safely during the pandemic period. Additionally, when indicated, radioiodine therapy could also be safely postponed as long as it is possible.},
}

Brazil
*COVID-19
Graves Ophthalmopathy/therapy
Humans
Hyperthyroidism/therapy
Iodine Radioisotopes
Pandemics
Thyroid Diseases/*therapy
Thyroid Gland

@article {pmid33844056,
year = {2021},
author = {Centonze, D and Rocca, MA and Gasperini, C and Kappos, L and Hartung, HP and Magyari, M and Oreja-Guevara, C and Trojano, M and Wiendl, H and Filippi, M},
title = {Disease-modifying therapies and SARS-CoV-2 vaccination in multiple sclerosis: an expert consensus.},
journal = {Journal of neurology},
volume = {268},
number = {11},
pages = {3961-3968},
pmid = {33844056},
issn = {1432-1459},
mesh = {*COVID-19 ; COVID-19 Vaccines ; Consensus ; Humans ; *Multiple Sclerosis/drug therapy ; SARS-CoV-2 ; Vaccination ; },
abstract = {Coronavirus disease (COVID-19) appeared in December 2019 in the Chinese city of Wuhan and has quickly become a global pandemic. The disease is caused by the severe acute respiratory syndrome coronavirus type-2 (SARS-CoV-2), an RNA beta coronavirus phylogenetically similar to SARS coronavirus. To date, more than 132 million cases of COVID19 have been recorded in the world, of which over 2.8 million were fatal (https://coronavirus.jhu.edu/map.html). A huge vaccination campaign has started around the world since the end of 2020. The availability of vaccines has raised some concerns among neurologists regarding the safety and efficacy of vaccination in patients with multiple sclerosis (MS) taking immunomodulatory or immunosuppressive therapies.},
}

*COVID-19
COVID-19 Vaccines
Consensus
Humans
*Multiple Sclerosis/drug therapy
SARS-CoV-2
Vaccination

@article {pmid33839767,
year = {2021},
author = {Badimon, L and Robinson, EL and Jusic, A and Carpusca, I and deWindt, LJ and Emanueli, C and Ferdinandy, P and Gu, W and Gyöngyösi, M and Hackl, M and Karaduzovic-Hadziabdic, K and Lustrek, M and Martelli, F and Nham, E and Potočnjak, I and Satagopam, V and Schneider, R and Thum, T and Devaux, Y},
title = {Cardiovascular RNA markers and artificial intelligence may improve COVID-19 outcome: a position paper from the EU-CardioRNA COST Action CA17129.},
journal = {Cardiovascular research},
volume = {117},
number = {8},
pages = {1823-1840},
pmid = {33839767},
issn = {1755-3245},
support = {CH/15/1/31199/BHF_/British Heart Foundation/United Kingdom ; RG/20/9/35101/BHF_/British Heart Foundation/United Kingdom ; },
mesh = {Artificial Intelligence/*economics ; Biomarkers/*analysis ; COVID-19/*diagnosis ; Cardiovascular Diseases/diagnosis/genetics ; Cardiovascular System/virology ; Humans ; Quality of Life ; RNA/*genetics ; SARS-CoV-2/pathogenicity ; },
abstract = {The coronavirus disease 2019 (COVID-19) pandemic has been as unprecedented as unexpected, affecting more than 105 million people worldwide as of 8 February 2020 and causing more than 2.3 million deaths according to the World Health Organization (WHO). Not only affecting the lungs but also provoking acute respiratory distress, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is able to infect multiple cell types including cardiac and vascular cells. Hence a significant proportion of infected patients develop cardiac events, such as arrhythmias and heart failure. Patients with cardiovascular comorbidities are at highest risk of cardiac death. To face the pandemic and limit its burden, health authorities have launched several fast-track calls for research projects aiming to develop rapid strategies to combat the disease, as well as longer-term projects to prepare for the future. Biomarkers have the possibility to aid in clinical decision-making and tailoring healthcare in order to improve patient quality of life. The biomarker potential of circulating RNAs has been recognized in several disease conditions, including cardiovascular disease. RNA biomarkers may be useful in the current COVID-19 situation. The discovery, validation, and marketing of novel biomarkers, including RNA biomarkers, require multi-centre studies by large and interdisciplinary collaborative networks, involving both the academia and the industry. Here, members of the EU-CardioRNA COST Action CA17129 summarize the current knowledge about the strain that COVID-19 places on the cardiovascular system and discuss how RNA biomarkers can aid to limit this burden. They present the benefits and challenges of the discovery of novel RNA biomarkers, the need for networking efforts, and the added value of artificial intelligence to achieve reliable advances.},
}

Artificial Intelligence/*economics
Biomarkers/*analysis
COVID-19/*diagnosis
Cardiovascular Diseases/diagnosis/genetics
Cardiovascular System/virology
Humans
Quality of Life
RNA/*genetics
SARS-CoV-2/pathogenicity

@article {pmid33837003,
year = {2021},
author = {Weiler, R and Blauwet, C and Clarke, D and Dalton, K and Derman, W and Fagher, K and Gouttebarge, V and Kissick, J and Lee, K and Lexell, J and Van de Vliet, P and Verhagen, E and Webborn, N and Ahmed, OH},
title = {Concussion in para sport: the first position statement of the Concussion in Para Sport (CIPS) Group.},
journal = {British journal of sports medicine},
volume = {55},
number = {21},
pages = {1187-1195},
pmid = {33837003},
issn = {1473-0480},
mesh = {*Athletes ; Athletic Injuries/*complications ; *Brain Concussion ; Persons with Disabilities ; Humans ; *Sports for Persons with Disabilities ; },
abstract = {Concussion is a frequent injury in many sports and is also common in para athletes. However, there is a paucity of concussion research related to para sport, and prior International Concussion in Sport (CIS) consensus papers have not substantively addressed this population. To remedy this and to improve concussion care provided to para athletes, the concussion in para sport (CIPS) multidisciplinary expert group was created. This group analysed and discussed in-depth para athlete-specific issues within the established key clinical domains of the current (2017) consensus statement on CIS. Due to the onset of the COVID-19 pandemic, the group held all meetings by video conferencing. The existing Sport Concussion Assessment Tool 5 (SCAT5) for the immediate on-field and office-based off-field assessment of concussion was evaluated as part of this process, to identify any para athlete-specific concerns. Regular preparticipation and periodic health examinations are essential to determine a baseline reference point for concussion symptoms but pose additional challenges for the interpreting clinician. Further considerations for concussion management for the para athlete are required within the remove, rest, reconsider and refer consensus statement framework. Considering return to sport (RTS), the 2017 CIS consensus statement has limitations when considering the RTS of the para athlete. Case-by-case decision making related to RTS following concussion is imperative for para athletes. Additional challenges exist for the evaluation and management of concussion in para athletes. There is a need for greater understanding of existing knowledge gaps and attitudes towards concussion among athlete medical staff, coaches and para athletes. Future research should investigate the use and performance of common assessment tools in the para athlete population to better guide their clinical application and inform potential modifications. Concussion prevention strategies and sport-specific rule changes, such as in Para Alpine Skiing and Cerebral Palsy Football, also should be carefully considered to reduce the occurrence of concussion in para athletes.},
}

*Athletes
Athletic Injuries/*complications
*Brain Concussion
Persons with Disabilities
Humans
*Sports for Persons with Disabilities

@article {pmid33820898,
year = {2021},
author = {Rodrigues, AM and Romeu, JC and Canas da Silva, J and Tavares-Costa, J and Faustino, A and Vaz, C and Pereira da Silva, JA and Canhão, H},
title = {Osteoporosis management during the COVID-19 pandemic - Position paper.},
journal = {Acta reumatologica portuguesa},
volume = {46},
number = {1},
pages = {55-57},
pmid = {33820898},
issn = {2184-8777},
mesh = {*COVID-19 ; Humans ; Osteoporosis/*therapy ; },
abstract = {COVID-19 pandemic significantly increased the already large number of victims of osteoporosis in Portugal. Osteoporosis outpatient clinics were either closed or had limited presential appointments. Many hospitals reduced orthopaedic services to make space for patients with COVID-19. In addition, the volunteer or forced sedentarism, as imposed by the pandemic, increased the risk of falls and fractures drastically. It urges to intensify the current efforts to improve the management of bone health and to prioritize fragility fracture care and prevention. This paper addresses the challenges in osteoporosis management during the COVID-19 pandemic and provides guidance on osteoporosis management. This position paper is a joint initiative of several health professionals and patients dedicated to osteoporosis.},
}

*COVID-19
Humans
Osteoporosis/*therapy

@article {pmid33797444,
year = {2021},
author = {Silva, CF and Alegria, J and Ramos, C and Verdugo, J and Diaz, JC and Varela, C and Barbe, M},
title = {RSNA-STR-ACR Consensus Statement for COVID-19 CT Patterns: Interreader Agreement in 240 Consecutive Patients and Association With RT-PCR Status.},
journal = {Journal of computer assisted tomography},
volume = {45},
number = {3},
pages = {485-489},
doi = {10.1097/RCT.0000000000001162},
pmid = {33797444},
issn = {1532-3145},
mesh = {Adult ; Aged ; Aged, 80 and over ; COVID-19/*diagnosis ; Consensus ; Female ; Humans ; Male ; Middle Aged ; Observer Variation ; Radiographic Image Interpretation, Computer-Assisted/*standards ; Retrospective Studies ; Reverse Transcriptase Polymerase Chain Reaction/*standards ; Severity of Illness Index ; Tomography, X-Ray Computed/*standards ; Young Adult ; },
abstract = {PURPOSE: The aim of this study was to study interreader agreement of the RSNA-STR-ACR (Radiological Society of North America/Society of Thoracic Radiology/American College of Radiology) consensus statement on reporting chest computed tomography (CT) findings related to COVID-19 on a sample of consecutive patients confirmed with reverse transcriptase-polymerase chain reaction (RT-PCR) for severe acute respiratory syndrome coronavirus 2.

MATERIALS AND METHODS: This institutional review board-approved retrospective study included 240 cases with a mean age of 47.6 ± 15.9 years, ranging from 20 to 90 years, who had a chest CT and RT-PCR performed. Computed tomography images were independently analyzed by 2 thoracic radiologists to identify patterns defined by the RSNA-STR-ACR consensus statement, and concordance was determined with weighted κ tests. Also, CT findings and CT severity scores were tabulated and compared.

RESULTS: Of the 240 cases, 118 had findings on CT. The most frequent on the RT-PCR-positive group were areas of ground-glass opacities (80.5%), crazy-paving pattern (32.2%), and rounded pseudonodular ground-glass opacities (22.9%). Regarding the CT patterns, the most frequent in the RT-PCR-positive group was typical in 75.9%, followed by negative in 17.1%. The interreader agreement was 0.90 (95% confidence interval, 0.80-0.96) in this group. The CT severity score had a mean difference of -0.07 (95% confidence interval, -0.48 to 0.34) among the readers, showing no significant differences regarding visual estimation.

CONCLUSIONS: The RSNA-STR-ACR consensus statement on reporting chest CT patterns for COVID-19 presents a high interreader agreement, with the typical pattern being more frequently associated with RT-PCR-positive examinations.},
}

Adult
Aged
Aged, 80 and over
COVID-19/*diagnosis
Consensus
Female
Humans
Male
Middle Aged
Observer Variation
Radiographic Image Interpretation, Computer-Assisted/*standards
Retrospective Studies
Reverse Transcriptase Polymerase Chain Reaction/*standards
Severity of Illness Index
Tomography, X-Ray Computed/*standards
Young Adult

@article {pmid33795490,
year = {2021},
author = {Alharbi, AS and Alzahrani, M and Alodayani, AN and Alhindi, MY and Alharbi, S and Alnemri, A},
title = {Saudi experts' recommendation for RSV prophylaxis in the era of COVID-19: Consensus from the Saudi Pediatric Pulmonology Association.},
journal = {Saudi medical journal},
volume = {42},
number = {4},
pages = {355-362},
pmid = {33795490},
issn = {1658-3175},
mesh = {Advisory Committees ; Antiviral Agents/*therapeutic use ; Bronchiolitis, Viral/*prevention & control ; COVID-19/epidemiology/prevention & control ; Delivery of Health Care/*methods ; Home Care Services ; Humans ; Immunization Programs/*methods ; Infant ; Infant, Newborn ; Injections ; Palivizumab/*therapeutic use ; Pulmonary Medicine ; Respiratory Syncytial Virus Infections/*prevention & control ; SARS-CoV-2 ; Saudi Arabia ; Societies, Medical ; },
abstract = {Respiratory syncytial virus (RSV) is the most common cause of bronchiolitis and viral pneumonia in pediatrics worldwide. In the Kingdom of Saudi Arabia (KSA), the prevalence of RSV is 23.5% in pediatric patients with acute lower respiratory tract illness. Coronavirus disease (COVID-19) poses critical public health and socioeconomic challenges in KSA. The Saudi Pediatric Pulmonology Association (SPPA), a subsidiary of the Saudi Thoracic Society (STS), developed a task force to determine the potential challenges and barriers to the RSV immunoprophylaxis program during the era of COVID-19 and to compose a practical, nationwide, and multidisciplinary approach to address these challenges. Some of the recommendations to manage these challenges include increasing the number of RSV immunoprophylaxis clinics, drive-thru visits, home-care services, and swift referrals to the RSV immunoprophylaxis program specialists. Additional training is required for healthcare personnel to add RSV immunoprophylaxis to the regular immunization schedule.},
}

Advisory Committees
Antiviral Agents/*therapeutic use
Bronchiolitis, Viral/*prevention & control
COVID-19/epidemiology/prevention & control
Delivery of Health Care/*methods
Home Care Services
Humans
Immunization Programs/*methods
Infant
Infant, Newborn
Injections
Palivizumab/*therapeutic use
Pulmonary Medicine
Respiratory Syncytial Virus Infections/*prevention & control
SARS-CoV-2
Saudi Arabia
Societies, Medical

@article {pmid33780557,
year = {2021},
author = {Arenbergerova, M and Lallas, A and Nagore, E and Rudnicka, L and Forsea, AM and Pasek, M and Meier, F and Peris, K and Olah, J and Posch, C},
title = {Position statement of the EADV Melanoma Task Force on recommendations for the management of cutaneous melanoma patients during COVID-19.},
journal = {Journal of the European Academy of Dermatology and Venereology : JEADV},
volume = {35},
number = {7},
pages = {e427-e428},
pmid = {33780557},
issn = {1468-3083},
support = {PROGRES Q28//Charles University, Prague, Czech Republic/ ; },
mesh = {*COVID-19 ; Humans ; *Melanoma/therapy ; SARS-CoV-2 ; *Skin Neoplasms/therapy ; },
}

*COVID-19
Humans
*Melanoma/therapy
SARS-CoV-2
*Skin Neoplasms/therapy

@article {pmid33766471,
year = {2021},
author = {Guarracino, F and Shernan, SK and Tahan, ME and Bertini, P and Stone, ME and Kachulis, B and Paternoster, G and Mukherjee, C and Wouters, P and Rex, S},
title = {EACTA/SCA Recommendations for the Cardiac Anesthesia Management of Patients With Suspected or Confirmed COVID-19 Infection: An Expert Consensus From the European Association of Cardiothoracic Anesthesiology and Society of Cardiovascular Anesthesiologists With Endorsement From the Chinese Society of Cardiothoracic and Vascular Anesthesiology.},
journal = {Journal of cardiothoracic and vascular anesthesia},
volume = {35},
number = {7},
pages = {1953-1963},
pmid = {33766471},
issn = {1532-8422},
mesh = {*Anesthesia, Cardiac Procedures ; Anesthesiologists ; *Anesthesiology ; *COVID-19 ; China ; Consensus ; Humans ; Pandemics ; SARS-CoV-2 ; },
abstract = {The European Association of Cardiothoracic Anaesthesiology (EACTA) and the Society of Cardiovascular Anesthesiologists (SCA) aimed to create joint recommendations for the perioperative management of patients with suspected or proven severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection undergoing cardiac surgery or invasive cardiac procedures. To produce appropriate recommendations, the authors combined the evidence from the literature review, reevaluating the clinical experience of routine cardiac surgery in similar cases during the Middle East Respiratory Syndrome (MERS-CoV) outbreak and the current pandemic with suspected coronavirus disease 2019 (COVID-19) patients, and the expert opinions through broad discussions within the EACTA and SCA. The authors took into consideration the balance between established procedures and the feasibility during the present outbreak. The authors present an agreement between the European and US practices in managing patients during the COVID-19 pandemic. The recommendations take into consideration a broad spectrum of issues, with a focus on preoperative testing, safety concerns, overall approaches to general and specific aspects of preparation for anesthesia, airway management, transesophageal echocardiography, perioperative ventilation, coagulation, hemodynamic control, and postoperative care. As the COVID-19 pandemic is spreading, it will continue to present a challenge for the worldwide anesthesiology community. To allow these recommendations to be updated as long as possible, the authors provided weblinks to international public and academic sources providing timely updated data. This document should be the basis of future task forces to develop a more comprehensive consensus considering new evidence uncovered during the COVID-19 pandemic.},
}

*Anesthesia, Cardiac Procedures
Anesthesiologists
*Anesthesiology
*COVID-19
China
Consensus
Humans
Pandemics
SARS-CoV-2

@article {pmid33766426,
year = {2021},
author = {Gallo, G and Grossi, U and Sturiale, A and Di Tanna, GL and Picciariello, A and Pillon, S and Mascagni, D and Altomare, DF and Naldini, G and Perinotti, R and , },
title = {E-consensus on telemedicine in proctology: A RAND/UCLA-modified study.},
journal = {Surgery},
volume = {170},
number = {2},
pages = {405-411},
doi = {10.1016/j.surg.2021.01.049},
pmid = {33766426},
issn = {1532-7361},
mesh = {Colorectal Surgery/*standards ; Female ; Humans ; Male ; Middle Aged ; Telemedicine/*standards ; },
abstract = {BACKGROUND: Coronavirus disease 2019 is revolutionizing healthcare delivery. The aim of this study was to reach a consensus among experts as to the possible applications of telemedicine in the proctologic field.

METHODS: A group of 55 clinical practice recommendations was developed by a clinical guidance group based on coalescence of evidence and expert opinion. The Telemedicine in Proctology Italian Working Group included 47 Italian Society of Colorectal Surgery nominated experts evaluating the appropriateness of each clinical practice recommendations based on published RAND/UCLA methodology in 2 rounds.

RESULTS: Stakeholder median age was 53 years (interquartile range limits 40-60), and 38 (81%) were men. Nine (19%) panelists reported no experience with telemedicine before the pandemic. Agreement was obtained on a minimum of 3 to 5 years of practice in the proctologic field before starting teleconsultations, which should be regularly paid, with advice and prescriptions incorporated into a formal report sent to the patient by e-mail along with a receipt. Of the panelists, 35 of 47 (74%) agreed that teleconsultation carries the risk of misdiagnosis of cancer, thus recommending an in-person assessment before scheduling any surgery. Fifteen additional clinical practice recommendations were re-elaborated in the second round and assessed by 44 of 47 (93.6%) panelists. The application of telemedicine for the diagnosis of common proctologic conditions (eg, hemorrhoidal disease, anal abscess and fistula, anal condylomas, and anal fissure) and functional pelvic floor disorders was generally considered inappropriate. Teleconsultation was instead deemed appropriate for the diagnosis and management of pilonidal disease.

CONCLUSION: This e-consensus revealed the boundaries of telemedicine in Italy. Standardization of infrastructures, logistics, and legality remain to be better elucidated.},
}

Colorectal Surgery/*standards
Female
Humans
Male
Middle Aged
Telemedicine/*standards

@article {pmid33752263,
year = {2021},
author = {Ring, J and Worm, M and Wollenberg, A and Thyssen, JP and Jakob, T and Klimek, L and Bangert, C and Barbarot, S and Bieber, T and de Bruin-Weller, MS and Chernyshov, PV and Christen-Zaech, S and Cork, M and Darsow, U and Flohr, C and Fölster-Holst, R and Gelmetti, C and Gieler, U and Gutermuth, J and Heratizadeh, A and Hijnen, DJ and von Kobyletzki, LB and Kunz, B and Paul, C and De Raeve, L and Seneschal, J and Simon, D and Spuls, PI and Stalder, JF and Svensson, A and Szalai, Z and Taieb, A and Torrelo, A and Trzeciak, M and Vestergaard, C and Werfel, T and Weidinger, S and Deleuran, M},
title = {Risk of severe allergic reactions to COVID-19 vaccines among patients with allergic skin diseases - practical recommendations. A position statement of ETFAD with external experts.},
journal = {Journal of the European Academy of Dermatology and Venereology : JEADV},
volume = {35},
number = {6},
pages = {e362-e365},
pmid = {33752263},
issn = {1468-3083},
mesh = {*Anaphylaxis ; *COVID-19 ; COVID-19 Vaccines ; *Dermatitis, Atopic/prevention & control ; Humans ; SARS-CoV-2 ; *Vaccines ; },
}

*Anaphylaxis
*COVID-19
COVID-19 Vaccines
*Dermatitis, Atopic/prevention & control
Humans
SARS-CoV-2
*Vaccines

@article {pmid33726819,
year = {2021},
author = {Nasa, P and Azoulay, E and Khanna, AK and Jain, R and Gupta, S and Javeri, Y and Juneja, D and Rangappa, P and Sundararajan, K and Alhazzani, W and Antonelli, M and Arabi, YM and Bakker, J and Brochard, LJ and Deane, AM and Du, B and Einav, S and Esteban, A and Gajic, O and Galvagno, SM and Guérin, C and Jaber, S and Khilnani, GC and Koh, Y and Lascarrou, JB and Machado, FR and Malbrain, MLNG and Mancebo, J and McCurdy, MT and McGrath, BA and Mehta, S and Mekontso-Dessap, A and Mer, M and Nurok, M and Park, PK and Pelosi, P and Peter, JV and Phua, J and Pilcher, DV and Piquilloud, L and Schellongowski, P and Schultz, MJ and Shankar-Hari, M and Singh, S and Sorbello, M and Tiruvoipati, R and Udy, AA and Welte, T and Myatra, SN},
title = {Expert consensus statements for the management of COVID-19-related acute respiratory failure using a Delphi method.},
journal = {Critical care (London, England)},
volume = {25},
number = {1},
pages = {106},
pmid = {33726819},
issn = {1466-609X},
mesh = {COVID-19/*complications ; *Consensus ; *Delphi Technique ; Humans ; Respiratory Insufficiency/*therapy/*virology ; },
abstract = {BACKGROUND: Coronavirus disease 2019 (COVID-19) pandemic has caused unprecedented pressure on healthcare system globally. Lack of high-quality evidence on the respiratory management of COVID-19-related acute respiratory failure (C-ARF) has resulted in wide variation in clinical practice.

METHODS: Using a Delphi process, an international panel of 39 experts developed clinical practice statements on the respiratory management of C-ARF in areas where evidence is absent or limited. Agreement was defined as achieved when > 70% experts voted for a given option on the Likert scale statement or > 80% voted for a particular option in multiple-choice questions. Stability was assessed between the two concluding rounds for each statement, using the non-parametric Chi-square (χ[2]) test (p < 0·05 was considered as unstable).

RESULTS: Agreement was achieved for 27 (73%) management strategies which were then used to develop expert clinical practice statements. Experts agreed that COVID-19-related acute respiratory distress syndrome (ARDS) is clinically similar to other forms of ARDS. The Delphi process yielded strong suggestions for use of systemic corticosteroids for critical COVID-19; awake self-proning to improve oxygenation and high flow nasal oxygen to potentially reduce tracheal intubation; non-invasive ventilation for patients with mixed hypoxemic-hypercapnic respiratory failure; tracheal intubation for poor mentation, hemodynamic instability or severe hypoxemia; closed suction systems; lung protective ventilation; prone ventilation (for 16-24 h per day) to improve oxygenation; neuromuscular blocking agents for patient-ventilator dyssynchrony; avoiding delay in extubation for the risk of reintubation; and similar timing of tracheostomy as in non-COVID-19 patients. There was no agreement on positive end expiratory pressure titration or the choice of personal protective equipment.

CONCLUSION: Using a Delphi method, an agreement among experts was reached for 27 statements from which 20 expert clinical practice statements were derived on the respiratory management of C-ARF, addressing important decisions for patient management in areas where evidence is either absent or limited.

TRIAL REGISTRATION: The study was registered with Clinical trials.gov Identifier: NCT04534569.},
}

COVID-19/*complications
*Consensus
*Delphi Technique
Humans
Respiratory Insufficiency/*therapy/*virology

@article {pmid33685875,
year = {2021},
author = {Dambha-Miller, H and Griffin, SJ and Young, D and Watkinson, P and Tan, PS and Clift, AK and Payne, RA and Coupland, C and Hopewell, JC and Mant, J and Martin, RM and Hippisley-Cox, J},
title = {The Use of Primary Care Big Data in Understanding the Pharmacoepidemiology of COVID-19: A Consensus Statement From the COVID-19 Primary Care Database Consortium.},
journal = {Annals of family medicine},
volume = {19},
number = {2},
pages = {135-140},
pmid = {33685875},
issn = {1544-1717},
support = {29019/CRUK_/Cancer Research UK/United Kingdom ; MC_UU_00006/6/MRC_/Medical Research Council/United Kingdom ; MC_UU_12015/4/MRC_/Medical Research Council/United Kingdom ; MR/V027778/1/MRC_/Medical Research Council/United Kingdom ; },
mesh = {Big Data ; COVID-19/diagnosis/*epidemiology ; *Consensus ; Databases, Factual/*standards ; Humans ; Medical Records Systems, Computerized/*standards ; Pharmacoepidemiology ; Primary Health Care/*organization & administration ; Public Health ; *Public Health Surveillance ; United Kingdom/epidemiology ; },
abstract = {The use of big data containing millions of primary care medical records provides an opportunity for rapid research to help inform patient care and policy decisions during the first and subsequent waves of the coronavirus disease 2019 (COVID-19) pandemic. Routinely collected primary care data have previously been used for national pandemic surveillance, quantifying associations between exposures and outcomes, identifying high risk populations, and examining the effects of interventions at scale, but there is no consensus on how to effectively conduct or report these data for COVID-19 research. A COVID-19 primary care database consortium was established in April 2020 and its researchers have ongoing COVID-19 projects in overlapping data sets with over 40 million primary care records in the United Kingdom that are variously linked to public health, secondary care, and vital status records. This consensus agreement is aimed at facilitating transparency and rigor in methodological approaches, and consistency in defining and reporting cases, exposures, confounders, stratification variables, and outcomes in relation to the pharmacoepidemiology of COVID-19. This will facilitate comparison, validation, and meta-analyses of research during and after the pandemic.},
}

Big Data
COVID-19/diagnosis/*epidemiology
*Consensus
Databases, Factual/*standards
Humans
Medical Records Systems, Computerized/*standards
Pharmacoepidemiology
Primary Health Care/*organization & administration
Public Health
*Public Health Surveillance
United Kingdom/epidemiology

@article {pmid33642133,
year = {2021},
author = {Tarazona-Santabalbina, FJ and Cuadra, L and Cancio, JM and Carbonell, FR and Garrote, JMP and Casas-Herrero, Á and Martínez-Velilla, N and Serra-Rexach, JA and Formiga, F},
title = {VitaminD supplementation for the prevention and treatment of COVID-19: a position statement from the Spanish Society of Geriatrics and Gerontology.},
journal = {Revista espanola de geriatria y gerontologia},
volume = {56},
number = {3},
pages = {177-182},
pmid = {33642133},
issn = {1578-1747},
mesh = {Aged ; COVID-19/complications/immunology/prevention & control/*therapy ; *Cytokine Release Syndrome/prevention & control ; *Dietary Supplements ; *Geriatrics ; Humans ; Receptors, Calcitriol/metabolism ; Societies, Medical ; Spain ; Vitamin D/*administration & dosage/immunology ; Vitamin D Deficiency/complications/*therapy ; Vitamins/*administration & dosage/immunology ; },
abstract = {The coronavirus disease 2019 (COVID-19) produces severe respiratory symptoms such as bilateral pneumonia associated to a high morbidity and mortality, especially in patients of advanced age. Vitamin D deficiency has been reported in several chronic conditions associated with increased inflammation and dysregulation of the immune system. Vitamin D in modulates immune function too. Vitamin D receptor (VDR) is expressed by most immune cells, including B and T lymphocytes, monocytes, macrophages, and dendritic cells and the signalling of vitamin D and VDR together has an anti-inflammatory effect. Some studies have reported that vitamin D treatment could be useful for the prevention and treatment of COVID-19 because vitamin D plays an important role as a modulator of immunocompetence. Over the last few months, some studies have hypothesized the possible beneficial effect of vitamin D supplementation in patients with COVID-19 in order to improve the immune balance and prevent the hyperinflammatory cytokine storm. Some preliminary studies have already shown promising results with vitamin D supplementation in hospitalized COVID-19 patients. Vitamin D should be administered daily until adequate levels are achieved due to vitamin D behaves as a negative acute phase reactant (APR). Despite the lack of evidence on specific doses of vitamin D to treat COVID-19 in older adults, authors consider it is necessary to standardize the use in clinical practice. These recommendations advice supplement vitamin D in a protocoled fashion based on expert opinions, level of evidence 5.},
}

Aged
COVID-19/complications/immunology/prevention & control/*therapy
*Cytokine Release Syndrome/prevention & control
*Dietary Supplements
*Geriatrics
Humans
Receptors, Calcitriol/metabolism
Societies, Medical
Spain
Vitamin D/*administration & dosage/immunology
Vitamin D Deficiency/complications/*therapy
Vitamins/*administration & dosage/immunology

@article {pmid33641834,
year = {2021},
author = {Jain, M and Rajpal, S and Arora, VK and Bhargav, S and Chopra, KK},
title = {White paper on challenges and opportunities for TB elimination with focus on COVID & Post-COVID era developed through scientific roundtable resolutions at NATCON 2020.},
journal = {The Indian journal of tuberculosis},
volume = {68},
number = {1},
pages = {134-138},
pmid = {33641834},
issn = {0019-5707},
mesh = {*COVID-19 ; Congresses as Topic ; *Epidemics ; Global Health ; Humans ; National Health Programs ; *SARS-CoV-2 ; Tuberculosis, Pulmonary/*prevention & control ; },
abstract = {A group of TB experts with vast clinical and epidemiological experience were drawn from a pool of doctors, epidemiologists and scientists participating in NATCON 2020 Conference in a closed-door session to discuss, highlight, and prioritize key resolutions that are most pertinent at present to eliminate TB from India and other developing countries in the Covid and post-COVID era. These Scientific experts were non-industry persons who met on 17th December, 2020 and used the prevailing scientific literature along with 2019 Joint Monitoring Mission document as a starting point of the discussion on this specific topic to build an agreement upon the resolutions. After the meeting on the virtual platform, all the attending doctors gave a set of recommendations on rebuilding TB Elimination programme in the Covid and Post-Covid era. Focused scientific roundtable discussion on rebuilding TB Elimination Post-Covid. Develop actionable recommendations for the scientific community and the government leadership to consider in moving forward. To prioritize the recommendations in the categories of Build-Prevent-Detect-Treat.},
}

*COVID-19
Congresses as Topic
*Epidemics
Global Health
Humans
National Health Programs
*SARS-CoV-2
Tuberculosis, Pulmonary/*prevention & control

@article {pmid33639998,
year = {2021},
author = {Davanzo, R and Agosti, M and Cetin, I and Chiantera, A and Corsello, G and Ramenghi, LA and Staiano, A and Tavio, M and Villani, A and Viora, E and Mosca, F},
title = {Breastfeeding and COVID-19 vaccination: position statement of the Italian scientific societies.},
journal = {Italian journal of pediatrics},
volume = {47},
number = {1},
pages = {45},
pmid = {33639998},
issn = {1824-7288},
mesh = {*Breast Feeding ; COVID-19/*prevention & control ; *COVID-19 Vaccines ; Consensus ; Female ; Humans ; Italy ; Societies, Medical ; },
abstract = {The availability of a COVID-19 vaccine has raised the issue of its compatibility with breastfeeding. Consequently, the Italian Society of Neonatology (SIN), the Italian Society of Pediatrics (SIP), the Italian Society of Perinatal Medicine (SIMP), the Italian Society of Obstetrics and Gynecology (SIGO), the Italian Association of Hospital Obstetricians-Gynecologists (AOGOI) and the Italian Society of Infectious and Tropical Diseases (SIMIT) have made an ad hoc consensus statement. Currently, knowledge regarding the administration of COVID-19 vaccine to the breastfeeding mother is limited. Nevertheless, as health benefits of breastfeeding are well demonstrated and since biological plausibility suggests that the health risk for the nursed infant is unlikely, Italian scientific societies conclude that COVID-19 vaccination is compatible with breastfeeding.},
}

*Breast Feeding
COVID-19/*prevention & control
*COVID-19 Vaccines
Consensus
Female
Humans
Italy
Societies, Medical

@article {pmid33630471,
year = {2021},
author = {Asbun, HJ and Abu Hilal, M and Kunzler, F and Asbun, D and Bonjer, J and Conlon, K and Demartines, N and Feldman, LS and Morales-Conde, S and Pietrabissa, A and Pryor, AD and Schlachta, CM and Sylla, P and Targarona, EM and Agra, Y and Besselink, MG and Callery, M and Cleary, SP and De La Cruz, L and Eckert, P and Evans, C and Han, HS and Jones, DB and Gan, TJ and Koch, D and Lillemoe, KD and Lomanto, D and Marks, J and Matthews, B and Mellinger, J and Melvin, WS and Moreno-Paquentin, E and Navarrete, C and Pawlik, TM and Pessaux, P and Ricciardi, W and Schwaitzberg, S and Shah, P and Szokol, J and Talamini, M and Torres, R and Triboldi, A and Udomsawaengsup, S and Valsecchi, F and Vauthey, JN and Wallace, M and Wexner, SD and Zinner, M and Francis, N},
title = {International Delphi Expert Consensus on Safe Return to Surgical and Endoscopic Practice: From the Coronavirus Global Surgical Collaborative.},
journal = {Annals of surgery},
volume = {274},
number = {1},
pages = {50-56},
pmid = {33630471},
issn = {1528-1140},
mesh = {COVID-19/epidemiology/*prevention & control/transmission ; Consensus ; Delphi Technique ; *Elective Surgical Procedures ; *Endoscopy ; Humans ; Infection Control/*organization & administration ; Internationality ; Intersectoral Collaboration ; Triage ; },
abstract = {OBJECTIVE: The aim of this work is to formulate recommendations based on global expert consensus to guide the surgical community on the safe resumption of surgical and endoscopic activities.

BACKGROUND: The COVID-19 pandemic has caused marked disruptions in the delivery of surgical care worldwide. A thoughtful, structured approach to resuming surgical services is necessary as the impact of COVID-19 becomes better controlled. The Coronavirus Global Surgical Collaborative sought to formulate, through rigorous scientific methodology, consensus-based recommendations in collaboration with a multidisciplinary group of international experts and policymakers.

METHODS: Recommendations were developed following a Delphi process. Domain topics were formulated and subsequently subdivided into questions pertinent to different aspects of surgical care in the COVID-19 crisis. Forty-four experts from 15 countries across 4 continents drafted statements based on the specific questions. Anonymous Delphi voting on the statements was performed in 2 rounds, as well as in a telepresence meeting.

RESULTS: One hundred statements were formulated across 10 domains. The statements addressed terminology, impact on procedural services, patient/staff safety, managing a backlog of surgeries, methods to restart and sustain surgical services, education, and research. Eighty-three of the statements were approved during the first round of Delphi voting, and 11 during the second round. A final telepresence meeting and discussion yielded acceptance of 5 other statements.

CONCLUSIONS: The Delphi process resulted in 99 recommendations. These consensus statements provide expert guidance, based on scientific methodology, for the safe resumption of surgical activities during the COVID-19 pandemic.},
}

COVID-19/epidemiology/*prevention & control/transmission
Consensus
Delphi Technique
*Elective Surgical Procedures
*Endoscopy
Humans
Infection Control/*organization & administration
Internationality
Intersectoral Collaboration
Triage

@article {pmid33586006,
year = {2021},
author = {Kaplan, AG and Correia-de-Sousa, J and McIvor, A and , },
title = {Global Quality Statements on Reliever Use in Asthma in Adults and Children Older than 5 Years of Age.},
journal = {Advances in therapy},
volume = {38},
number = {3},
pages = {1382-1396},
pmid = {33586006},
issn = {1865-8652},
mesh = {Adrenergic beta-Agonists/*pharmacology ; Adult ; Anti-Asthmatic Agents/pharmacology ; *Asthma/diagnosis/drug therapy ; *COVID-19/epidemiology/prevention & control ; Child ; Drug Misuse/*prevention & control ; Female ; Global Health/standards ; Guideline Adherence ; Humans ; Male ; Medication Therapy Management/*standards ; Metered Dose Inhalers ; Practice Guidelines as Topic ; Quality Improvement/*organization & administration ; SARS-CoV-2 ; },
abstract = {INTRODUCTION: Widespread misuse of short-acting beta-agonists (SABAs) may contribute to asthma-related morbidity and mortality. Recognizing this, the Global Initiative for Asthma neither recommends SABA monotherapy nor regards this formulation as a preferred reliever. Many health systems and healthcare professionals (HCPs) experience practical issues in implementing guidelines. Clear quality standards can drive improvements in asthma care and encourage implementation of global and national medical guidelines.

METHODS: A steering group of global asthma experts came together between May and September 2019 to develop quality statements codifying the minimum elements of good quality asthma care. These statements were either evidence based (when robust evidence was available) or reflected a consensus based on clinical expertise and experience of the group.

RESULTS: The quality statements (and associated essential criteria) developed emphasize key elements concerning (1) objective diagnosis specific to individual symptoms, (2) treatment appropriate to the long-term management of asthma as an inflammatory disease, consistent with evidence-based recommendations, (3) controlled dispensing of SABA canisters and monitoring to prevent overuse, (4) regular review of patients after treatment initiation or change, and (5) follow-up of patients in primary care after treatment for an exacerbation in a hospital or an emergency department.

CONCLUSIONS: The steering group proposes quality statements that national and local clinical groups can implement as quantitative quality standards that are appropriate to their local circumstances, including during the coronavirus disease 2019 (Covid-19) pandemic. By translating these statements into locally relevant quality standards, primary care physicians and HCPs can encourage optimal management and reduce preventable healthcare interactions. The evidence-based evolution of care encapsulated in these statements will further engender high-quality, patient-centered holistic management that addresses asthma as an inflammatory disease. In particular, the statements empower self-management by patients and encourage health-promoting behaviors, which are essential to reduce exacerbations, the primary goal of asthma management.},
}

Adrenergic beta-Agonists/*pharmacology
Adult
Anti-Asthmatic Agents/pharmacology
*Asthma/diagnosis/drug therapy
*COVID-19/epidemiology/prevention & control
Child
Drug Misuse/*prevention & control
Female
Global Health/standards
Guideline Adherence
Humans
Male
Medication Therapy Management/*standards
Metered Dose Inhalers
Practice Guidelines as Topic
Quality Improvement/*organization & administration
SARS-CoV-2

@article {pmid33577086,
year = {2021},
author = {Fix, OK and Blumberg, EA and Chang, KM and Chu, J and Chung, RT and Goacher, EK and Hameed, B and Kaul, DR and Kulik, LM and Kwok, RM and McGuire, BM and Mulligan, DC and Price, JC and Reau, NS and Reddy, KR and Reynolds, A and Rosen, HR and Russo, MW and Schilsky, ML and Verna, EC and Ward, JW and Fontana, RJ and , },
title = {American Association for the Study of Liver Diseases Expert Panel Consensus Statement: Vaccines to Prevent Coronavirus Disease 2019 Infection in Patients With Liver Disease.},
journal = {Hepatology (Baltimore, Md.)},
volume = {74},
number = {2},
pages = {1049-1064},
pmid = {33577086},
issn = {1527-3350},
support = {UL1 TR001863/TR/NCATS NIH HHS/United States ; },
mesh = {Adult ; COVID-19/*prevention & control ; COVID-19 Vaccines/administration & dosage/*standards ; Consensus ; Humans ; *Liver Diseases ; *Liver Transplantation ; Practice Guidelines as Topic ; SARS-CoV-2/immunology ; United States ; },
abstract = {The aim of this document is to provide a concise scientific review of the currently available COVID-19 vaccines and those in development, including mRNA, adenoviral vectors, and recombinant protein approaches. The anticipated use of COVID-19 vaccines in patients with chronic liver disease (CLD) and liver transplant (LT) recipients is reviewed and practical guidance is provided for health care providers involved in the care of patients with liver disease and LT about vaccine prioritization and administration. The Pfizer and Moderna mRNA COVID-19 vaccines are associated with a 94%-95% vaccine efficacy compared to placebo against COVID-19. Local site reactions of pain and tenderness were reported in 70%-90% of clinical trial participants, and systemic reactions of fever and fatigue were reported in 40%-70% of participants, but these reactions were generally mild and self-limited and occurred more frequently in younger persons. Severe hypersensitivity reactions related to the mRNA COVID-19 vaccines are rare and more commonly observed in women and persons with a history of previous drug reactions for unclear reasons. Because patients with advanced liver disease and immunosuppressed patients were excluded from the vaccine licensing trials, additional data regarding the safety and efficacy of COVID-19 vaccines are eagerly awaited in these and other subgroups. Remarkably safe and highly effective mRNA COVID-19 vaccines are now available for widespread use and should be given to all adult patients with CLD and LT recipients. The online companion document located at https://www.aasld.org/about-aasld/covid-19-resources will be updated as additional data become available regarding the safety and efficacy of other COVID-19 vaccines in development.},
}

Adult
COVID-19/*prevention & control
COVID-19 Vaccines/administration & dosage/*standards
Consensus
Humans
*Liver Diseases
*Liver Transplantation
Practice Guidelines as Topic
SARS-CoV-2/immunology
United States

@article {pmid33533553,
year = {2021},
author = {Beecker, J and Papp, KA and Dutz, J and Vender, RB and Gniadecki, R and Cooper, C and Gisondi, P and Gooderham, M and Hong, CH and Kirchhof, MG and Lynde, CW and Maari, C and Poulin, Y and Puig, L},
title = {Position statement for a pragmatic approach to immunotherapeutics in patients with inflammatory skin diseases during the coronavirus disease 2019 pandemic and beyond.},
journal = {Journal of the European Academy of Dermatology and Venereology : JEADV},
volume = {35},
number = {4},
pages = {797-806},
pmid = {33533553},
issn = {1468-3083},
mesh = {COVID-19/complications/*epidemiology/therapy ; Dermatitis/*therapy ; Humans ; *Immunotherapy ; Practice Patterns, Physicians' ; Risk Assessment ; },
abstract = {Coronavirus disease 2019 (COVID-19) is caused by SARS-CoV-2, a novel RNA virus that was declared a global pandemic on 11 March 2020. The efficiency of infection with SARS-CoV-2 is reflected by its rapid global spread. The SARS-CoV-2 pandemic has implications for patients with inflammatory skin diseases on systemic immunotherapy who may be at increased risk of infection or more severe infection. This position paper is a focused examination of current evidence considering the mechanisms of action of immunotherapeutic drugs in relation to immune response to SARS-CoV-2. We aim to provide practical guidance for dermatologists managing patients with inflammatory skin conditions on systemic therapies during the current pandemic and beyond. Considering the limited and rapidly evolving evidence, mechanisms of action of therapies, and current knowledge of SARS-CoV-2 infection, we propose that systemic immunotherapy can be continued, with special considerations for at risk patients or those presenting with symptoms.},
}

COVID-19/complications/*epidemiology/therapy
Dermatitis/*therapy
Humans
*Immunotherapy
Practice Patterns, Physicians'
Risk Assessment

@article {pmid33518409,
year = {2021},
author = {Zimmerman, E and Martins, NN and Verheijen, RHM and Mahmood, T},
title = {EBCOG position statement - Simulation-based training for obstetrics and gynaecology during the COVID-19 pandemic.},
journal = {European journal of obstetrics, gynecology, and reproductive biology},
volume = {258},
number = {},
pages = {457-458},
pmid = {33518409},
issn = {1872-7654},
mesh = {COVID-19/epidemiology ; Curriculum ; Female ; Gynecology/*education ; Humans ; Obstetrics/*education ; Pandemics ; Pregnancy ; SARS-CoV-2 ; Simulation Training/*standards ; },
abstract = {The specialty of Obstetrics and Gynaecology has been on the forefront of introducing simulation in post graduate education for the past two decades. Simulation training is known to enhance psychomotor skills and is considered an important step in the transition from classroom learning to clinical practice. Training on simulators allows trainees to acquire basic skills before getting involved in day to day care in real life situations. Clinical circumstances around the COVID 19 pandemic have highlighted the key importance of simulation training in delivering post graduate curriculum.},
}

COVID-19/epidemiology
Curriculum
Female
Gynecology/*education
Humans
Obstetrics/*education
Pandemics
Pregnancy
SARS-CoV-2
Simulation Training/*standards

@article {pmid33495916,
year = {2021},
author = {Torres-Naranjo, F and De la Peña-Rodríguez, P and López-Cervantes, RE and Morales-Torres, J and Morales-Vargas, J and Gutiérrez-Hermosillo, H and Guzmán-Rico, AC and González-Mendoza, RG and Rueda Plata, PN and Flores Castro, M and Celis Gonzalez, C and Espinosa Morales, R and Quintero Hernández, S and López-Taylor, JR},
title = {Joint position statement on management of patient with osteoporosis during COVID-19 contingency from the AMMOM, CONAMEGER, FELAEN, FEMECOG, FEMECOT, and ICAAFYD.},
journal = {Archives of osteoporosis},
volume = {16},
number = {1},
pages = {18},
pmid = {33495916},
issn = {1862-3514},
mesh = {Aged ; *COVID-19 ; Humans ; *Medicine ; *Orthopedics ; *Osteoporosis/epidemiology/therapy ; Pandemics ; SARS-CoV-2 ; *Traumatology ; },
abstract = {UNLABELLED: Infection by SARS-Cov-2 (COVID-19) has affected practically all the world. This joint position statement of Latin American Medical Societies provides an updated guide for the prevention, diagnosis, and treatment of osteoporotic patients in the face of possible clinical scenarios posed by the COVID-19 health crisis.

BACKGROUND: Infection by SARS-Cov-2 (COVID-19) has affected practically all the world. Characterized by high contagiousness, significative morbidity, and mortality in a segment of those infected, it has overwhelmed health services and forced to redirect resources to the emergency while impacting the attention of acute non-COVID-19 and many chronic conditions.

OBJECTIVE: The objective of this study is to provide an updated guide for the prevention, diagnosis, and treatment of osteoporotic patients in the face of possible clinical scenarios posed by the COVID-19 health crisis.

METHODS: A task force, of bone specialists with a wide range of disciplines in the field of osteoporosis and fragility fracture, was convened with the representation of several professional associations, namely, the Mexican Association of Bone and Mineral Metabolism (AMMOM), the National College of Geriatric Medicine (CONAMEGER), the Latin American Federation of Endocrinology (FELAEN), the Mexican Federation of Colleges of Obstetrics and Gynecology (FEMECOG), the Mexican Federation of Colleges of Orthopedics and Traumatology (FEMECOT), and the Institute of Applied Sciences for Physical Activity and Sports of the University of Guadalajara (ICAAFYD). Clinical evidence was collated, and an evidence report was rapidly generated and disseminated. After finding the gaps in the available evidence, a consensus opinion of experts was made. The resulting draft was reviewed and modified accordingly, in 4 rounds, by the participants.

RESULTS: The task force approved the initial guidance statements, with moderate and high consensus. These were combined, resulting in the final guidance statements on the (1) evaluation of fracture risk; (2) stratification of risk priorities; (3) indications of bone density scans and lab tests; (4) initiation and continuation of pharmacologic therapy; (5) interruptions of therapy; (6) treatment of patients with incident fracture; (7) physical therapy and fall prevention; and (8) nutritional interventions.

CONCLUSION: These guidance statements are provided to promote optimal care to patients at risk for osteoporosis and fracture, during the current COVID-19 pandemic. However, given the low level of available evidence and the rapidly evolving literature, this guidance is presented as a "living document" and future updates are anticipated.},
}

Aged
*COVID-19
Humans
*Medicine
*Orthopedics
*Osteoporosis/epidemiology/therapy
Pandemics
SARS-CoV-2
*Traumatology

@article {pmid33484264,
year = {2021},
author = {Ma, B and Fan, X and Kong, W and Xiao, S and Zhu, S and Yao, M and Liu, Y and Zhu, W and Wang, J and Zeng, Y and Zhao, Y and Su, B and Xu, S and Dong, Z and Gu, H and Li, W and Jiang, Y and Gu, D and Xia, Z},
title = {Expert Consensus on Clinical Practice of Burn Units in Shanghai During the COVID-19 Epidemic.},
journal = {Journal of burn care & research : official publication of the American Burn Association},
volume = {42},
number = {4},
pages = {642-645},
doi = {10.1093/jbcr/irab010},
pmid = {33484264},
issn = {1559-0488},
support = {81930057//National Natural Science Foundation of China/ ; 2019-I2M-5-076//CAMS Innovation Fund for Medical Sciences/ ; },
mesh = {Burn Units/*organization & administration ; Burns/epidemiology/*therapy ; COVID-19/*epidemiology/therapy ; China/epidemiology ; *Consensus ; Critical Care/*organization & administration ; Humans ; Infection Control/organization & administration ; },
abstract = {In response to coronavirus disease 2019 (COVID-19), the Shanghai Burn Clinical Quality Control Center organized experts to formulate and implement a set of rapid, simple, and effective prevention and control measures, and there have not been any cases of health care professionals or inpatients in burn units suspected or confirmed with COVID-19. This article elaborates on the specific measures in burn units in response to the epidemic, including the implementation of standardized procedures, remote consultations, strengthened follow-up, exchange of experience, and popular science, among others. We share experience from Shanghai to benefit related disciplines in other countries and regions.},
}

Burn Units/*organization & administration
Burns/epidemiology/*therapy
COVID-19/*epidemiology/therapy
China/epidemiology
*Consensus
Critical Care/*organization & administration
Humans
Infection Control/organization & administration

@article {pmid33472895,
year = {2021},
author = {Siegel, CA and Melmed, GY and McGovern, DP and Rai, V and Krammer, F and Rubin, DT and Abreu, MT and Dubinsky, MC and , and , },
title = {SARS-CoV-2 vaccination for patients with inflammatory bowel diseases: recommendations from an international consensus meeting.},
journal = {Gut},
volume = {70},
number = {4},
pages = {635-640},
pmid = {33472895},
issn = {1468-3288},
support = {P30 DK042086/DK/NIDDK NIH HHS/United States ; },
mesh = {Anti-Inflammatory Agents/immunology/pharmacology ; *COVID-19/epidemiology/immunology/prevention & control ; *COVID-19 Vaccines/classification/immunology/therapeutic use ; Consensus ; Gastroenterology/methods/standards ; Humans ; Immunogenicity, Vaccine/drug effects/immunology ; Immunomodulation/drug effects/immunology ; *Inflammatory Bowel Diseases/drug therapy/immunology ; International Cooperation ; SARS-CoV-2 ; *Vaccination/methods/standards ; },
}

Anti-Inflammatory Agents/immunology/pharmacology
*COVID-19/epidemiology/immunology/prevention & control
*COVID-19 Vaccines/classification/immunology/therapeutic use
Consensus
Gastroenterology/methods/standards
Humans
Immunogenicity, Vaccine/drug effects/immunology
Immunomodulation/drug effects/immunology
*Inflammatory Bowel Diseases/drug therapy/immunology
International Cooperation
SARS-CoV-2
*Vaccination/methods/standards

@article {pmid33419600,
year = {2021},
author = {White, SJ and Barello, S and Cao di San Marco, E and Colombo, C and Eeckman, E and Gilligan, C and Graffigna, G and Jirasevijinda, T and Mosconi, P and Mullan, J and Rehman, SU and Rubinelli, S and Vegni, E and Krystallidou, D},
title = {Critical observations on and suggested ways forward for healthcare communication during COVID-19: pEACH position paper.},
journal = {Patient education and counseling},
volume = {104},
number = {2},
pages = {217-222},
pmid = {33419600},
issn = {1873-5134},
mesh = {*COVID-19 ; *Health Communication ; Health Literacy ; Health Personnel/*psychology ; Health Promotion/*methods ; Humans ; Pandemics ; *Public Health Practice ; *SARS-CoV-2 ; *Telemedicine ; Uncertainty ; },
abstract = {OBJECTIVE: Communication in healthcare has influenced and been influenced by the COVID-19 pandemic. In this position paper, we share observations based on the latest available evidence and experiential knowledge that have emerged during the pandemic, with a specific focus on policy and practice.

METHODS: This is a position paper that presents observations relating to policy and practice in communication in healthcare related to COVID-19.

RESULTS: Through our critical observations as experts in the field of healthcare communication, we share our stance how healthcare communication has occured during the pandemic and suggest possible ways of improving policy and professional practice. We make recommendations for policy makers, healthcare providers, and communication experts while also highlighting areas that merit further investigation regarding healthcare communication in times of healthcare crises.

CONCLUSION: We have witnessed an upheaval of healthcare practice and the development of policy on-the-run. To ensure that policy and practice are evidence-based, person-centred, more inclusive and equitable, we advocate for critical reflection on this symbiotic relationship between COVID-19 and the central role of communication in healthcare.

PRACTICE IMPLICATIONS: This paper provides a summary of the key areas for development in communication in healthcare during COVID-19. It offers recommendations for improvement and a call to review policies and practice to build resilience and inclusive and equitable responsiveness in communication in healthcare.},
}

*COVID-19
*Health Communication
Health Literacy
Health Personnel/*psychology
Health Promotion/*methods
Humans
Pandemics
*Public Health Practice
*SARS-CoV-2
*Telemedicine
Uncertainty

@article {pmid33416050,
year = {2021},
author = {Chieffo, A and Tarantini, G and Naber, CK and Barbato, E and Roffi, M and Stefanini, GG and Buchanan, GL and Buszman, P and Moreno, R and Zawiślak, B and Cayla, G and Danenberg, H and Da Silveira, JAB and Nef, H and James, SK and Mauri Ferre, J and Voskuil, M and Witt, N and Windecker, S and Baumbach, A and Dudek, D},
title = {Performing elective cardiac invasive procedures during the COVID-19 outbreak: a position statement from the European Association of Percutaneous Cardiovascular Interventions (EAPCI).},
journal = {EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology},
volume = {16},
number = {14},
pages = {1177-1186},
pmid = {33416050},
issn = {1969-6213},
mesh = {*COVID-19 ; *Cardiovascular Surgical Procedures ; *Elective Surgical Procedures ; Humans ; Masks ; *Pandemics ; Personal Protective Equipment ; SARS-CoV-2 ; },
abstract = {The rearrangement of healthcare services required to face the coronavirus disease 2019 (COVID-19) pandemic led to a drastic reduction in elective cardiac invasive procedures. We are already facing a "second wave" of infections and we might be dealing during the next months with a "third wave" and subsequently new waves. Therefore, during the different waves of the COVID-19 pandemic we have to face the problems of how to perform elective cardiac invasive procedures in non-COVID patients and which patients/procedures should be prioritised. In this context, the interplay between the pandemic stage, the availability of healthcare resources and the priority of specific cardiac disorders is crucial. Clear pathways for "hot" or presumed "hot" patients and "cold" patients are mandatory in each hospital. Depending on the local testing capacity and intensity of transmission in the area, healthcare facilities may test patients for SARS-CoV-2 infection before the interventional procedure, regardless of risk assessment for COVID-19. Pre-hospital testing should always be conducted in the presence of symptoms suggestive of SARS-CoV-2 infection. In cases of confirmed or suspected COVID-19 positive patients, full personal protective equipment using FFP 2/N95 masks, eye protection, gowning and gloves is indicated during cardiac interventions for healthcare workers. When patients have tested negative for COVID-19, medical masks may be sufficient. Indeed, individual patients should themselves wear medical masks during cardiac interventions and outpatient visits.},
}

*COVID-19
*Cardiovascular Surgical Procedures
*Elective Surgical Procedures
Humans
Masks
*Pandemics
Personal Protective Equipment
SARS-CoV-2

@article {pmid33414261,
year = {2021},
author = {Wu, F and Burt, J and Chowdhury, T and Fitzpatrick, R and Martin, G and van der Scheer, JW and Hurst, JR},
title = {Specialty COPD care during COVID-19: patient and clinician perspectives on remote delivery.},
journal = {BMJ open respiratory research},
volume = {8},
number = {1},
pages = {},
pmid = {33414261},
issn = {2052-4439},
mesh = {Adult ; Aged ; *Attitude of Health Personnel ; Attitude to Health ; COVID-19 ; Delivery of Health Care/methods ; Female ; Humans ; Male ; Middle Aged ; Nurses ; Patient Acceptance of Health Care ; *Patient Education as Topic ; Physical Therapists ; Physicians ; Practice Patterns, Nurses' ; *Practice Patterns, Physicians' ; Pulmonary Disease, Chronic Obstructive/physiopathology/*therapy ; SARS-CoV-2 ; *Self-Management ; Severity of Illness Index ; *Smoking Cessation ; Surveys and Questionnaires ; Telemedicine/*methods ; United Kingdom ; },
abstract = {INTRODUCTION: The COVID-19 pandemic has impacted specialty chronic obstructive pulmonary disease (COPD) care. We examined the degree to which care has moved to remote approaches, eliciting clinician and patient perspectives on what is appropriate for ongoing remote delivery.

METHODS: Using an online research platform, we conducted a survey and consensus-building process involving clinicians and patients with COPD.

RESULTS: Fifty-five clinicians and 19 patients responded. The majority of clinicians felt able to assess symptom severity (n=52, 95%), reinforce smoking cessation (n=46, 84%) and signpost to other healthcare resources (n=44, 80%). Patients reported that assessing COPD severity and starting new medications were being addressed through remote care. Forty-three and 31 respondents participated in the first and second consensus-building rounds, respectively. When asked to rate the appropriateness of using remote delivery for specific care activities, respondents reached consensus on 5 of 14 items: collecting information about COPD and overall health status (77%), providing COPD education and developing a self-management plan (74%), reinforcing smoking cessation (81%), deciding whether patients should seek in-person care (72%) and initiating a rescue pack (76%).

CONCLUSION: Adoption of remote care delivery appears high, with many care activities partially or completely delivered remotely. Our work identifies strengths and limitations of remote care delivery.},
}

Adult
Aged
*Attitude of Health Personnel
Attitude to Health
COVID-19
Delivery of Health Care/methods
Female
Humans
Male
Middle Aged
Nurses
Patient Acceptance of Health Care
*Patient Education as Topic
Physical Therapists
Physicians
Practice Patterns, Nurses'
*Practice Patterns, Physicians'
Pulmonary Disease, Chronic Obstructive/physiopathology/*therapy
SARS-CoV-2
*Self-Management
Severity of Illness Index
*Smoking Cessation
Surveys and Questionnaires
Telemedicine/*methods
United Kingdom

@article {pmid33412794,
year = {2020},
author = {Ciccone, G and Deandrea, S and Clavenna, A and Kirchmayer, U and Simeon, V and Acampora, A and Agabiti, N and Angelici, L and Banzi, R and Cadum, E and Castiglione, A and Chiodini, P and Colombo, C and Ferroni, E and Migliore, E and Nisticò, L and Pagano, E and Sabelli, AM and Sacerdote, C and Silvestri, C and Soldati, S and Stranges, S and Tirani, M and Davoli, M and Galassi, C and Forastiere, F},
title = {[Covid-19 and clinical-epidemiological research in Italy: proposal of a research agenda on priority topics by the Italian association of epidemiology].},
journal = {Epidemiologia e prevenzione},
volume = {44},
number = {5-6 Suppl 2},
pages = {51-59},
doi = {10.19191/EP20.5-6.S2.103},
pmid = {33412794},
issn = {1120-9763},
mesh = {Adult ; Aged ; COVID-19/*epidemiology/therapy ; Child ; *Epidemiologic Research Design ; Epidemiology/organization & administration ; Female ; Humans ; Italy/epidemiology ; Male ; Middle Aged ; *Pandemics ; Pregnancy ; Pregnancy Complications, Infectious/epidemiology ; Prognosis ; *Research ; *SARS-CoV-2 ; Societies, Scientific ; Therapeutic Equipoise ; COVID-19 Drug Treatment ; },
abstract = {BACKGROUND: the Covid-19 pandemic has provoked a huge of clinical and epidemiological research initiatives, especially in the most involved countries. However, this very large effort was characterized by several methodological weaknesses, both in the field of discovering effective treatments (with too many small and uncontrolled trials) and in the field of identifying preventable risks and prognostic factors (with too few large, representative and well-designed cohorts or case-control studies).

OBJECTIVES: in response to the fragmented and uncoordinated research production on Covid-19, the   italian Association of Epidemiology (AIE) stimulated the formation of a working group (WG) with the aims of identifying the most important gaps in knowledge and to propose a structured research agenda of clinical and epidemiological studies considered at high priority on Covid-19, including recommendations on the preferable methodology.

METHODS: the WG was composed by 25 subjects, mainly epidemiologists, statisticians, and other experts in specific fields, who have voluntarily agreed to the proposal. The agreement on a list of main research questions and on the structure of the specific documents to be produced were defined through few meetings and cycles of document exchanges.

RESULTS: twelve main research questions on Covid-19 were identified, covering aetiology, prognosis, interventions, follow-up and impact on general and specific populations (children, pregnant women). For each of them, a two-page form was developed, structured in: background, main topics, methods (with recommendations on preferred study design and warnings for bias prevention) and an essential bibliography.

CONCLUSIONS: this research agenda represents an initial contribution to direct clinical and epidemiological research efforts on high priority topics with a focus on methodological aspects. Further development and refinements of this agenda by Public Health Authorities are encouraged.},
}

Adult
Aged
COVID-19/*epidemiology/therapy
Child
*Epidemiologic Research Design
Epidemiology/organization & administration
Female
Humans
Italy/epidemiology
Male
Middle Aged
*Pandemics
Pregnancy
Pregnancy Complications, Infectious/epidemiology
Prognosis
*Research
*SARS-CoV-2
Societies, Scientific
Therapeutic Equipoise
COVID-19 Drug Treatment

@article {pmid33394078,
year = {2021},
author = {Lan, X and Long, Y and Shao, F and Song, Y},
title = {Expert consensus on the safety prevention and control of nuclear medicine diagnosis and treatment during the outbreak of COVID-19 (1st edition): (translated from Chinese version).},
journal = {European journal of nuclear medicine and molecular imaging},
volume = {48},
number = {4},
pages = {1134-1143},
pmid = {33394078},
issn = {1619-7089},
mesh = {COVID-19/*prevention & control ; China/epidemiology ; Consensus ; Disease Outbreaks/*prevention & control ; Humans ; Nuclear Medicine/*trends ; SARS-CoV-2 ; },
abstract = {In December 2019, an infectious disease caused by a new type of coronavirus infection was prevalent in Wuhan and across the country. On January 20, 2020, the National Health Commission of the People's Republic of China issued No.1 Announcement, which incorporated the novel coronavirus pneumonia into the Class B infectious disease according to the Law on Prevention and Control of Infectious Disease, but the disease should be adopted in the management of Class A infectious disease. In order to effectively control the source of infection, cut off the transmission route, protect the susceptible population, ensure the medical quality and medical safety, perform epidemic prevention and control, and comprehensively guarantee the life safety and physical health of medical staff, patients, and family members, it is very important to organize and carry out nuclear medicine diagnosis and treatment scientifically and safely. According to the national prevention and control policy, Chinese Society of Nuclear Medicine and editorial board of the Chinese Journal of Nuclear Medicine and Molecular Imaging organized professionals to formulate the expert consensus on the safety prevention process of nuclear medicine imaging and nuclide therapy during the period of new coronavirus infection.},
}

COVID-19/*prevention & control
China/epidemiology
Consensus
Disease Outbreaks/*prevention & control
Humans
Nuclear Medicine/*trends
SARS-CoV-2

@article {pmid33378789,
year = {2021},
author = {Klimek, L and Jutel, M and Akdis, CA and Bousquet, J and Akdis, M and Torres, MJ and Agache, I and Canonica, GW and Del Giacco, S and O'Mahony, L and Shamji, MH and Schwarze, J and Untersmayr, E and Ring, J and Bedbrook, A and Worm, M and Zuberbier, T and Knol, E and Hoffmann-Sommergruber, K and Chivato, T},
title = {ARIA-EAACI statement on severe allergic reactions to COVID-19 vaccines - An EAACI-ARIA Position Paper.},
journal = {Allergy},
volume = {76},
number = {6},
pages = {1624-1628},
doi = {10.1111/all.14726},
pmid = {33378789},
issn = {1398-9995},
mesh = {BNT162 Vaccine ; *COVID-19 ; COVID-19 Vaccines ; Humans ; SARS-CoV-2 ; *Vaccines/adverse effects ; },
abstract = {Further to the approval of the Coronavirus disease 2019 (COVID-19) vaccine BNT162b2, several severe anaphylaxis cases occured within the first few days of public vaccination. An investigation is taking place to understand the cases and their triggers. The vaccine will be administered to a large number of individuals worldwide and there are raising concerns that severe adverse events might occur. With the current information, the European Academy of Allergy and Clinical Immunology (EAACI) states its position for the following preliminary recommendations that are to be revised as soon as more data emerge. To minimize the risk of severe allergic reactions in vaccinated individuals, it is urgently required to understand the specific nature of the reported severe allergic reactions, including the background medical history of the individuals affected and the mechanisms involved. To achieve this goal, all clinical and laboratory information should be collected and reported. Mild and moderate allergic patients should not be excluded from the vaccine as this could have a significant impact on reaching the goal of population immunity. Healthcare practitioners vaccinating against COVID-19 are required to be sufficiently prepared to recognize and treat anaphylaxis properly with the ability to administer adrenaline. Further to vaccine administration, a mandatory observation period of at least 15 minutes should be followed for all individuals. The current data have not shown any higher risk for patients suffering from allergic rhinitis or asthma, and this message should be clearly stated by physicians to enable our patients to trust the vaccine. More than 30% of the population suffers from allergic diseases and the benefit of the vaccination clearly outweighs the risk of severe COVID-19 development.},
}

BNT162 Vaccine
*COVID-19
COVID-19 Vaccines
Humans
SARS-CoV-2
*Vaccines/adverse effects

@article {pmid33372938,
year = {2020},
author = {Corona, T and Castañón-González, JA and Clark-Peralta, P and García-Peña, C and Guevara-Guzmán, R and Domínguez-Cherit, G and Halabe-Cherem, J and López-Cervantes, M and Macias-Hernández, A and Rodríguez-Violante, M and Santillán-Doherty, P and Anda, GV and Guinzberg, AL},
title = {Position paper: Impact on medical and health personnel in the SARS-CoV-2 pandemic.},
journal = {Gaceta medica de Mexico},
volume = {156},
number = {5},
pages = {478-480},
doi = {10.24875/GMM.M20000432},
pmid = {33372938},
issn = {0016-3813},
mesh = {COVID-19/*prevention & control/*transmission ; *Health Personnel ; Humans ; Infectious Disease Transmission, Patient-to-Professional/*prevention & control ; Practice Guidelines as Topic ; },
}

COVID-19/*prevention & control/*transmission
*Health Personnel
Humans
Infectious Disease Transmission, Patient-to-Professional/*prevention & control
Practice Guidelines as Topic

@article {pmid33359375,
year = {2021},
author = {Mussini, C and Falcone, M and Nozza, S and Sagnelli, C and Parrella, R and Meschiari, M and Petrosillo, N and Mastroianni, C and Cascio, A and Iaria, C and Galli, M and Chirianni, A and Sagnelli, E and Iacobello, C and Di Perri, G and Mazzotta, F and Carosi, G and Tinelli, M and Grossi, P and Armignacco, O and Portelli, V and Andreoni, M and Tavio, M and , },
title = {Therapeutic strategies for severe COVID-19: a position paper from the Italian Society of Infectious and Tropical Diseases (SIMIT).},
journal = {Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases},
volume = {27},
number = {3},
pages = {389-395},
pmid = {33359375},
issn = {1469-0691},
mesh = {COVID-19/diagnosis/epidemiology/therapy ; Humans ; Italy/epidemiology ; *Practice Guidelines as Topic ; Randomized Controlled Trials as Topic ; SARS-CoV-2/isolation & purification ; Societies, Medical/*standards ; Standard of Care ; *COVID-19 Drug Treatment ; },
abstract = {SCOPE: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection has become pandemic, reaching almost one million death worldwide. At present standard treatment for coronavirus disease 2019 (COVID-19) is not well defined because the evidence, either from randomized or observational studies, with conflicting results, has led to rapid changes in treatment guidelines. Our aim was to narratively summarize the available literature on the management of COVID-19 in order to combine current evidence and interpretation of the data by experts who are treating patients in the frontline setting.

METHODS: The panel conducted a detailed review of the literature and eventual press releases from randomized clinical trials for each possible available treatment. Inductive PubMed search waws performed for publications relevant to the topic, including all clinical trials conducted. The result was a flowchart with treatment indications for patients with COVID-19.

IMPLICATIONS: After 6 months of a pandemic situation and before a possible second coronavirus wave descends on Europe, it is important to evaluate which drugs proved to be effective while also considering that results from many randomized clinical trials are still awaited. Indeed, among treatments for COVID-19, only glucocorticoids have resulted in an association with a significant decrease in mortality in published randomized controlled trials. New therapeutic strategies are urgently needed.},
}

COVID-19/diagnosis/epidemiology/therapy
Humans
Italy/epidemiology
*Practice Guidelines as Topic
Randomized Controlled Trials as Topic
SARS-CoV-2/isolation & purification
Societies, Medical/*standards
Standard of Care
*COVID-19 Drug Treatment

@article {pmid33350389,
year = {2021},
author = {Annweiler, C and Souberbielle, JC},
title = {[Vitamin D supplementation and COVID-19: expert consensus and guidelines].},
journal = {Geriatrie et psychologie neuropsychiatrie du vieillissement},
volume = {19},
number = {1},
pages = {20-29},
doi = {10.1684/pnv.2020.0907},
pmid = {33350389},
issn = {2115-7863},
mesh = {Adult ; COVID-19/mortality ; Dietary Supplements ; France ; Humans ; Randomized Controlled Trials as Topic ; Risk Factors ; Survival Rate ; Vitamin D/*therapeutic use ; Vitamin D Deficiency/complications/drug therapy ; *COVID-19 Drug Treatment ; },
abstract = {After 12 months of viral circulation, the SARS-CoV-2 has infected millions of people around the world, leaving hundreds of thousands dead. With the lack of effective therapy and vaccination against COVID-19, focusing on the immediate repurposing of existing drugs gives hope of curbing the pandemic. Vitamin D is a possible candidate discussed in a high amount of publications. Randomized clinical trials show that vitamin D supplementation significantly reduces the risk of respiratory infections. There are also many evidences that hypovitaminosis D is an independent (and easily modifiable) risk factor for severe forms of COVID-19 and death. Vitamin D supplementation is a simple, safe and inexpensive measure, which is effective in correcting hypovitaminosis D found in 40-50% of the French population and in more than 80% of adults with COVID-19. In this position paper, we propose simple regimens (adapted to the pharmaceutical forms currently available in France) for vitamin D supplementation in adults with or without COVID-19.},
}

Adult
COVID-19/mortality
Dietary Supplements
France
Humans
Randomized Controlled Trials as Topic
Risk Factors
Survival Rate
Vitamin D/*therapeutic use
Vitamin D Deficiency/complications/drug therapy
*COVID-19 Drug Treatment

@article {pmid33323819,
year = {2020},
author = {Sun, TW and Zhang, XJ and Yu, Z and Shang, Y},
title = {Chinese expert consensus on the diagnosis and treatment of severely and critically ill patients with coronavirus disease 2019.},
journal = {Chinese medical journal},
volume = {133},
number = {24},
pages = {2963-2965},
pmid = {33323819},
issn = {2542-5641},
mesh = {COVID-19/diagnosis/*therapy ; Consensus ; Critical Illness ; Humans ; *SARS-CoV-2 ; },
}

COVID-19/diagnosis/*therapy
Consensus
Critical Illness
Humans
*SARS-CoV-2

@article {pmid33313664,
year = {2021},
author = {Diller, GP and Gatzoulis, MA and Broberg, CS and Aboulhosn, J and Brida, M and Schwerzmann, M and Chessa, M and Kovacs, AH and Roos-Hesselink, J},
title = {Coronavirus disease 2019 in adults with congenital heart disease: a position paper from the ESC working group of adult congenital heart disease, and the International Society for Adult Congenital Heart Disease.},
journal = {European heart journal},
volume = {42},
number = {19},
pages = {1858-1865},
pmid = {33313664},
issn = {1522-9645},
mesh = {Adult ; *COVID-19 ; *Cardiovascular Diseases ; *Heart Defects, Congenital/complications/epidemiology/therapy ; Humans ; Pandemics ; SARS-CoV-2 ; },
abstract = {We are witnessing an unparalleled pandemic caused by the novel Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) associated with coronavirus disease 2019 (COVID-19). Current data show that SARS-CoV-2 results in mild flu-like symptoms in the majority of healthy and young patients affected. Nevertheless, the severity of COVID-19 respiratory syndrome and the risk of adverse or catastrophic outcomes are increased in patients with pre-existing cardiovascular disease. Patients with adult congenital heart disease (ACHD)-by definition-have underlying cardiovascular disease. Many patients with ACHD are also afflicted with residual haemodynamic lesions such as valve dysfunction, diminished ventricular function, arrhythmias or cyanosis, have extracardiac comorbidities, and face additional challenges regarding pregnancy. Currently, there are emerging data of the effect of COVID-19 on ACHD patients, but many aspects, especially risk stratification and treatment considerations, remain unclear. In this article, we aim to discuss the broad impact of COVID-19 on ACHD patients, focusing specifically on pathophysiology, risk stratification for work, self-isolation, hospitalization, impact on pregnancy, psychosocial health, and longer-term implications for the provision of ACHD care.},
}

Adult
*COVID-19
*Cardiovascular Diseases
*Heart Defects, Congenital/complications/epidemiology/therapy
Humans
Pandemics
SARS-CoV-2

@article {pmid33307733,
year = {2020},
author = {Nadershah, M and Al-Sebaei, M and AlJabbab, A and AlMajid, E and AlShadwi, A},
title = {Consensus Statement of the Saudi Society of Oral and Maxillofacial Surgery on practice during the COVID-19 pandemic in Saudi Arabia.},
journal = {Annals of Saudi medicine},
volume = {40},
number = {6},
pages = {491-495},
pmid = {33307733},
issn = {0975-4466},
mesh = {*COVID-19/epidemiology/prevention & control ; Consensus ; *Delivery of Health Care/organization & administration/trends ; Humans ; *Infection Control/methods/organization & administration ; Organizational Innovation ; SARS-CoV-2 ; Saudi Arabia/epidemiology ; *Societies, Medical ; *Surgery, Oral/methods/trends ; Triage/methods ; },
abstract = {The coronavirus pandemic (COVID-19) has impacted essentially every country's healthcare system in extraordinary ways, fundamentally changing the way we deliver care. The practice of oral and maxillofacial surgery is no exception. In response to this global health crisis, the Saudi Society of Oral and Maxillofacial Surgery has prepared this consensus statement to inform our clinical and other medical colleagues and the public at large on proper procedures during this time. The statement is based on the best scientific evidence available and follows the guidelines put forth by the Saudi Ministry of Health on the COVID-19 response. It explains how to manage and triage oral and maxillofacial patients based on the level of care needed at the time of clinical presentation.},
}

*COVID-19/epidemiology/prevention & control
Consensus
*Delivery of Health Care/organization & administration/trends
Humans
*Infection Control/methods/organization & administration
Organizational Innovation
SARS-CoV-2
Saudi Arabia/epidemiology
*Societies, Medical
*Surgery, Oral/methods/trends
Triage/methods

@article {pmid33295471,
year = {2020},
author = {Marques-Santos, C and Avila, WS and Carvalho, RCM and Lucena, AJG and Freire, CMV and Alexandre, ERG and Campanharo, FF and Rivera, MAMR and Costa, MENC and Castro, ML},
title = {Position Statement on COVID-19 and Pregnancy in Women with Heart Disease Department of Women Cardiology of the Brazilian Society of Cardiology - 2020.},
journal = {Arquivos brasileiros de cardiologia},
volume = {115},
number = {5},
pages = {975-986},
pmid = {33295471},
issn = {1678-4170},
mesh = {Brazil ; *COVID-19 ; *Cardiology ; Female ; *Heart Diseases ; Humans ; Pandemics ; Practice Guidelines as Topic ; Pregnancy ; *Pregnancy Complications, Neoplastic ; SARS-CoV-2 ; Societies, Medical ; },
}

Brazil
*COVID-19
*Cardiology
Female
*Heart Diseases
Humans
Pandemics
Practice Guidelines as Topic
Pregnancy
*Pregnancy Complications, Neoplastic
SARS-CoV-2
Societies, Medical

@article {pmid33274782,
year = {2021},
author = {Ma, IWY and Hussain, A and Wagner, M and Walker, B and Chee, A and Arishenkoff, S and Buchanan, B and Liu, RB and Mints, G and Wong, T and Noble, V and Tonelli, AC and Dumoulin, E and Miller, DJ and Hergott, CA and Liteplo, AS},
title = {Canadian Internal Medicine Ultrasound (CIMUS) Expert Consensus Statement on the Use of Lung Ultrasound for the Assessment of Medical Inpatients With Known or Suspected Coronavirus Disease 2019.},
journal = {Journal of ultrasound in medicine : official journal of the American Institute of Ultrasound in Medicine},
volume = {40},
number = {9},
pages = {1879-1892},
pmid = {33274782},
issn = {1550-9613},
mesh = {*COVID-19 ; Canada ; Consensus ; Humans ; *Inpatients ; Lung/diagnostic imaging ; SARS-CoV-2 ; },
abstract = {OBJECTIVES: To develop a consensus statement on the use of lung ultrasound (LUS) in the assessment of symptomatic general medical inpatients with known or suspected coronavirus disease 2019 (COVID-19).

METHODS: Our LUS expert panel consisted of 14 multidisciplinary international experts. Experts voted in 3 rounds on the strength of 26 recommendations as "strong," "weak," or "do not recommend." For recommendations that reached consensus for do not recommend, a fourth round was conducted to determine the strength of those recommendations, with 2 additional recommendations considered.

RESULTS: Of the 26 recommendations, experts reached consensus on 6 in the first round, 13 in the second, and 7 in the third. Four recommendations were removed because of redundancy. In the fourth round, experts considered 4 recommendations that reached consensus for do not recommend and 2 additional scenarios; consensus was reached for 4 of these. Our final recommendations consist of 24 consensus statements; for 2 of these, the strength of the recommendations did not reach consensus.

CONCLUSIONS: In symptomatic medical inpatients with known or suspected COVID-19, we recommend the use of LUS to: (1) support the diagnosis of pneumonitis but not diagnose COVID-19, (2) rule out concerning ultrasound features, (3) monitor patients with a change in the clinical status, and (4) avoid unnecessary additional imaging for patients whose pretest probability of an alternative or superimposed diagnosis is low. We do not recommend the use of LUS to guide admission and discharge decisions. We do not recommend routine serial LUS in patients without a change in their clinical condition.},
}

*COVID-19
Canada
Consensus
Humans
*Inpatients
Lung/diagnostic imaging
SARS-CoV-2

@article {pmid33256990,
year = {2021},
author = {Wei, H and Jiang, B and Behringer, EC and Hofmeyr, R and Myatra, SN and Wong, DT and Sullivan, EPO and Hagberg, CA and McGuire, B and Baker, PA and Li, J and Pylypenko, M and Ma, W and Zuo, M and Senturk, NM and Klein, U},
title = {Controversies in airway management of COVID-19 patients: updated information and international expert consensus recommendations.},
journal = {British journal of anaesthesia},
volume = {126},
number = {2},
pages = {361-366},
pmid = {33256990},
issn = {1471-6771},
support = {R01 AG061447/AG/NIA NIH HHS/United States ; },
mesh = {COVID-19/*transmission ; Consensus ; *Exhalation ; Humans ; Infectious Disease Transmission, Patient-to-Professional/*prevention & control ; International Cooperation ; *Personal Protective Equipment ; Practice Guidelines as Topic/*standards ; SARS-CoV-2 ; },
}

COVID-19/*transmission
Consensus
*Exhalation
Humans
Infectious Disease Transmission, Patient-to-Professional/*prevention & control
International Cooperation
*Personal Protective Equipment
Practice Guidelines as Topic/*standards
SARS-CoV-2

@article {pmid33247653,
year = {2020},
author = {Swaminathan, N and Jiandani, M and Surendran, PJ and Jacob, P and Bhise, A and Baxi, G and Devani, P and Agarwal, B and Kumar, VS and Pinto, NM and Damke, U and Prabhudesai, P},
title = {Beyond COVID-19: Evidence-Based Consensus Statement on the Role of Physiotherapy in Pulmonary Rehabilitation in the Indian Context.},
journal = {The Journal of the Association of Physicians of India},
volume = {68},
number = {12},
pages = {82-89},
pmid = {33247653},
issn = {0004-5772},
mesh = {Betacoronavirus ; COVID-19 ; Consensus ; *Coronavirus Infections ; Humans ; India ; *Pandemics ; *Physical Therapy Modalities ; *Pneumonia, Viral ; Practice Guidelines as Topic ; *Quality of Life ; *Respiratory Therapy ; SARS-CoV-2 ; },
abstract = {Post COVID-19 sequelae includes breathlessness, weakness, fatigue, decreased exercise tolerance and impaired quality of life. Physiotherapy based rehabilitation program is an essential component for post COVID-19 patients in facilitating maximum functional recovery. Expert consensus statements are available from the developed countries. There is a need for a guidelines to manage post COVID-19 sequelae in Indian context. The objective of this consensus statement is to provide evidence informed guidelines for post COVID-19 physiotherapy management as a component of pulmonary rehabilitation. This consensus statement was developed by expert panel across India. Published literatures were appraised and used to prepare the recommendations. This is the first of its kind of work providing preliminary guidelines for post COVID-19 physiotherapy.},
}

Betacoronavirus
COVID-19
Consensus
*Coronavirus Infections
Humans
India
*Pandemics
*Physical Therapy Modalities
*Pneumonia, Viral
Practice Guidelines as Topic
*Quality of Life
*Respiratory Therapy
SARS-CoV-2

@article {pmid33236964,
year = {2021},
author = {Galpin, K and Sikka, N and King, SL and Horvath, KA and Shipman, SA and , },
title = {Expert Consensus: Telehealth Skills for Health Care Professionals.},
journal = {Telemedicine journal and e-health : the official journal of the American Telemedicine Association},
volume = {27},
number = {7},
pages = {820-824},
doi = {10.1089/tmj.2020.0420},
pmid = {33236964},
issn = {1556-3669},
mesh = {*COVID-19 ; Health Personnel ; Humans ; Pandemics ; SARS-CoV-2 ; *Telemedicine ; },
abstract = {Background: The COVID-19 pandemic has driven most clinicians, from those practicing in small independent practices to those in large system, to adopt virtual care. However, individuals and organizations may lack the experience and skills that would be considered fundamental prerequisites to adopting telehealth in less urgent times. What are those skills? Before the pandemic, the Association of American Medical Colleges (AAMC) convened national experts to identify and articulate a consensus set of critical telehealth skills for clinicians. Methods: Through a structured review of the literature, followed by several rounds of review and refinement by committee and community members via a modified Delphi process, the committee came to consensus on a set of skills required by clinicians to provide quality care via telehealth. Conclusion: The consensus set of telehealth skills presented in this paper, developed by the AAMC and national experts, can serve providers and health systems seeking to ensure that clinicians are prepared to meet the demand for care delivered via telehealth now and in the future.},
}

*COVID-19
Health Personnel
Humans
Pandemics
SARS-CoV-2
*Telemedicine

@article {pmid33232832,
year = {2021},
author = {Ferreira, CE and Bonvehi, PE and de la Torre, JCG and Sáenz-Flor, KV and Condino-Neto, A},
title = {Algorithms for testing COVID-19 focused on use of RT-PCR and high-affinity serological testing: A consensus statement from a panel of Latin American experts.},
journal = {International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases},
volume = {103},
number = {},
pages = {260-267},
pmid = {33232832},
issn = {1878-3511},
mesh = {Algorithms ; Antibodies, Viral/*blood ; COVID-19/*diagnosis ; COVID-19 Testing/*methods ; Consensus ; Humans ; Reverse Transcriptase Polymerase Chain Reaction/*methods ; *SARS-CoV-2/immunology/isolation & purification ; },
abstract = {UNLABELLED: The COVID-19 pandemic has caused an unprecedented public health, social, and economic crisis. Improving understanding on available tests for detecting COVID-19 is critical for effective management of the pandemic. We proposed that a multidisciplinary expert panel can establish recommendations on ideal use of diagnostic tools, with a focus on RT-PCR and serological high-affinity antibodies (both IgM and IgG) tests for the Latin America region.

STUDY DESIGN: A collaborative multidisciplinary panel of 5 recognized experts in Latin America (an infectious disease specialist, three pathologists, and an immunologist) was convened and supported by Roche Diagnostics to develop standard guidelines and an evidence-based document of best practices on the use of diagnostic tools for COVID-19.

RESULTS: The authors reached consensus on the applicability of diagnostic tools to provide testing algorithms for the use of RT-PCR and serological high-affinity antibodies (both IgM and IgG) tests in three settings: 1) For asymptomatic subjects exposed to a SARS-CoV-2 infected person; 2) For epidemiological purposes and; 3) For symptomatic subjects.

CONCLUSION: The serological high-affinity SARS-CoV-2 antibodies (both IgM and IgG) tests play a key role in COVID-19 diagnosis. These tests can be applied for suspected false-negative RT-PCR results and for individual determination of response. The use of these tests can also contribute greatly to public health strategies, such as population screening and supporting vaccination planning. Serological status for high-affinity antibodies (both IgM and IgG) should be performed ideally 21 days after potential infectious contact, given that the majority of exposed individuals will have seroconverted.},
}

Algorithms
Antibodies, Viral/*blood
COVID-19/*diagnosis
COVID-19 Testing/*methods
Consensus
Humans
Reverse Transcriptase Polymerase Chain Reaction/*methods
*SARS-CoV-2/immunology/isolation & purification

@article {pmid33213540,
year = {2021},
author = {Khan, S and Tsang, KK and Mertz, D and Dolovich, M and Tunks, M and Demers, C and Hassall, K and Maharaj, N and Margallo, K and Cividino, M and Chagla, Z and Duong, M},
title = {A regional Canadian expert consensus on recommendations for restoring exercise and pulmonary function testing in low and moderate-to-high community prevalence coronavirus disease 2019 (COVID-19) settings.},
journal = {Infection control and hospital epidemiology},
volume = {42},
number = {12},
pages = {1535-1537},
pmid = {33213540},
issn = {1559-6834},
mesh = {*COVID-19 ; Canada/epidemiology ; Consensus ; Humans ; Prevalence ; SARS-CoV-2 ; },
}

*COVID-19
Canada/epidemiology
Consensus
Humans
Prevalence
SARS-CoV-2

@article {pmid33187758,
year = {2021},
author = {Luo, Y and Yuan, J and Liu, M and Fang, N and Bai, J and Fei, X and Deng, Y and Yu, T and Mao, J and Zhu, H and Li, C and Peng, Q and Zhang, M and Zeng, S and Xu, G and Niu, C and Dong, T and He, W and Tang, J},
title = {Chinese Expert Consensus on Protection for Ultrasound Healthcare Workers against COVID-19.},
journal = {Ultrasound in medicine & biology},
volume = {47},
number = {2},
pages = {222-229},
pmid = {33187758},
issn = {1879-291X},
mesh = {COVID-19/*prevention & control ; China ; Consensus ; Disinfection ; *Health Personnel ; Humans ; Infectious Disease Transmission, Patient-to-Professional/*prevention & control ; Occupational Exposure/prevention & control ; Personal Protective Equipment ; Quarantine ; Triage ; Ultrasonography/*methods ; },
abstract = {Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection has caused a worldwide pandemic and poses a serious public health risk. It has been proven that lung ultrasound can be extremely valuable in the diagnosis and treatment of the disease, which could also minimize the number of exposed healthcare workers and equipment. Because healthcare workers in ultrasound departments are in close contact with patients who might be infected or virus carriers, it is extremely important that they be provided sufficient protection. Extremely aggressive protection should be avoided because it might lead to a lack of protection equipment for the hospital. Guidance on proper protection management should be provided in detail, for example, how to choose personal protective equipment, how to disinfect the environment. To address these problems, on behalf of the Chinese Ultrasound Doctors Association, Chinese PLA Professional Committee of Ultrasound in Medicine, Beijing Institute of Ultrasound in Medicine and Chinese Research Hospital Association Ultrasound Professional Committee, the authors have summarized the recommendations for effective protection according to existing hygienic standards, their experience and available literature. After the recommendations were completed, two online conferences were held on January 31, 2020 and February 7, 2020, at which the recommendations were discussed in detail. A modified version of the work was circulated and finally approved by all authors, and is the present Chinese Expert Consensus on Protection for Ultrasound Healthcare Workers against COVID-19.},
}

COVID-19/*prevention & control
China
Consensus
Disinfection
*Health Personnel
Humans
Infectious Disease Transmission, Patient-to-Professional/*prevention & control
Occupational Exposure/prevention & control
Personal Protective Equipment
Quarantine
Triage
Ultrasonography/*methods

@article {pmid33185026,
year = {2021},
author = {Tandogdu, Z and Collins, J and Shaw, G and Rohn, J and Koves, B and Sachdeva, A and Ghazi, A and Haese, A and Mottrie, A and Kumar, A and Sivaraman, A and Tewari, A and Challacombe, B and Rocco, B and Giedelman, C and Wagner, C and Rogers, CG and Murphy, DG and Pushkar, D and Ogaya-Pinies, G and Porter, J and Seetharam, KR and Graefen, M and Orvieto, MA and Moschovas, MC and Schatloff, O and Wiklund, P and Coelho, R and Valero, R and de Reijke, TM and Ahlering, T and Rogers, T and van der Poel, HG and Patel, V and Artibani, W and Wagenlehner, F and Maes, K and Rha, KH and Nathan, S and Bjerklund Johansen, TE and Hawkey, P and Kelly, J},
title = {Management of patients who opt for radical prostatectomy during the coronavirus disease 2019 (COVID-19) pandemic: an international accelerated consensus statement.},
journal = {BJU international},
volume = {127},
number = {6},
pages = {729-741},
doi = {10.1111/bju.15299},
pmid = {33185026},
issn = {1464-410X},
mesh = {COVID-19/*epidemiology ; *Critical Pathways ; Delphi Technique ; Health Care Rationing ; Humans ; Infection Control ; Male ; *Pandemics ; *Prostatectomy ; Prostatic Neoplasms/*surgery ; SARS-CoV-2 ; Time-to-Treatment ; },
abstract = {OBJECTIVE: Coronavirus disease-19 (COVID-19) pandemic caused delays in definitive treatment of patients with prostate cancer. Beyond the immediate delay a backlog for future patients is expected. The objective of this work is to develop guidance on criteria for prioritisation of surgery and reconfiguring management pathways for patients with non-metastatic prostate cancer who opt for surgical treatment. A second aim was to identify the infection prevention and control (IPC) measures to achieve a low likelihood of coronavirus disease 2019 (COVID-19) hazard if radical prostatectomy (RP) was to be carried out during the outbreak and whilst the disease is endemic.

METHODS: We conducted an accelerated consensus process and systematic review of the evidence on COVID-19 and reviewed international guidance on prostate cancer. These were presented to an international prostate cancer expert panel (n = 34) through an online meeting. The consensus process underwent three rounds of survey in total. Additions to the second- and third-round surveys were formulated based on the answers and comments from the previous rounds. The Consensus opinion was defined as ≥80% agreement and this was used to reconfigure the prostate cancer pathways.

RESULTS: Evidence on the delayed management of patients with prostate cancer is scarce. There was 100% agreement that prostate cancer pathways should be reconfigured and measures developed to prevent nosocomial COVID-19 for patients treated surgically. Consensus was reached on prioritisation criteria of patients for surgery and management pathways for those who have delayed treatment. IPC measures to achieve a low likelihood of nosocomial COVID-19 were coined as 'COVID-19 cold' sites.

CONCLUSION: Reconfiguring management pathways for patients with prostate cancer is recommended if significant delay (>3-6 months) in surgical management is unavoidable. The mapped pathways provide guidance for such patients. The IPC processes proposed provide a framework for providing RP within an environment with low COVID-19 risk during the outbreak or when the disease remains endemic. The broader concepts could be adapted to other indications beyond prostate cancer surgery.},
}

COVID-19/*epidemiology
*Critical Pathways
Delphi Technique
Health Care Rationing
Humans
Infection Control
Male
*Pandemics
*Prostatectomy
Prostatic Neoplasms/*surgery
SARS-CoV-2
Time-to-Treatment

@article {pmid33179744,
year = {2021},
author = {Baldassarre, LA and Yang, EH and Cheng, RK and DeCara, JM and Dent, S and Liu, JE and Rudski, LG and Strom, JB and Thavendiranathan, P and Barac, A and Zaha, VG and Bucciarelli-Ducci, C and Ellahham, S and Deswal, A and Lenneman, C and Villarraga, HR and Blaes, AH and Ismail-Khan, R and Ky, B and Leja, MJ and Scherrer-Crosbie, M},
title = {Cardiovascular Care of the Oncology Patient During COVID-19: An Expert Consensus Document From the ACC Cardio-Oncology and Imaging Councils.},
journal = {Journal of the National Cancer Institute},
volume = {113},
number = {5},
pages = {513-522},
pmid = {33179744},
issn = {1460-2105},
support = {K23 HL144907/HL/NHLBI NIH HHS/United States ; R01 HL130539/HL/NHLBI NIH HHS/United States ; UL1 TR001863/TR/NCATS NIH HHS/United States ; },
mesh = {COVID-19/*complications/transmission/virology ; Cardiotoxicity/diagnosis/*therapy/virology ; Cardiovascular Diseases/diagnosis/*therapy/virology ; Diagnostic Imaging/*methods ; Expert Testimony ; Humans ; Neoplasms/diagnosis/*therapy/virology ; SARS-CoV-2/*isolation & purification ; },
abstract = {In response to the coronavirus disease 2019 (COVID-19) pandemic, the Cardio-Oncology and Imaging Councils of the American College of Cardiology offers recommendations to clinicians regarding the cardiovascular care of cardio-oncology patients in this expert consensus statement. Cardio-oncology patients-individuals with an active or prior cancer history and with or at risk of cardiovascular disease-are a rapidly growing population who are at increased risk of infection, and experiencing severe and/or lethal complications by COVID-19. Recommendations for optimizing screening and monitoring visits to detect cardiac dysfunction are discussed. In addition, judicious use of multimodality imaging and biomarkers are proposed to identify myocardial, valvular, vascular, and pericardial involvement in cancer patients. The difficulties of diagnosing the etiology of cardiovascular complications in patients with cancer and COVID-19 are outlined, along with weighing the advantages against risks of exposure, with the modification of existing cardiovascular treatments and cardiotoxicity surveillance in patients with cancer during the COVID-19 pandemic.},
}

COVID-19/*complications/transmission/virology
Cardiotoxicity/diagnosis/*therapy/virology
Cardiovascular Diseases/diagnosis/*therapy/virology
Diagnostic Imaging/*methods
Expert Testimony
Humans
Neoplasms/diagnosis/*therapy/virology
SARS-CoV-2/*isolation & purification

@article {pmid33178656,
year = {2020},
author = {Bhaskar, S and Bradley, S and Chattu, VK and Adisesh, A and Nurtazina, A and Kyrykbayeva, S and Sakhamuri, S and Yaya, S and Sunil, T and Thomas, P and Mucci, V and Moguilner, S and Israel-Korn, S and Alacapa, J and Mishra, A and Pandya, S and Schroeder, S and Atreja, A and Banach, M and Ray, D},
title = {Telemedicine Across the Globe-Position Paper From the COVID-19 Pandemic Health System Resilience PROGRAM (REPROGRAM) International Consortium (Part 1).},
journal = {Frontiers in public health},
volume = {8},
number = {},
pages = {556720},
pmid = {33178656},
issn = {2296-2565},
mesh = {*COVID-19 ; Humans ; Pandemics/prevention & control ; Public Health ; SARS-CoV-2 ; *Telemedicine ; },
abstract = {Coronavirus disease 2019 (COVID-19) has accelerated the adoption of telemedicine globally. The current consortium critically examines the telemedicine frameworks, identifies gaps in its implementation and investigates the changes in telemedicine framework/s during COVID-19 across the globe. Streamlining of global public health preparedness framework that is interoperable and allow for collaboration and sharing of resources, in which telemedicine is an integral part of the public health response during outbreaks such as COVID-19, should be pursued. With adequate reinforcement, telemedicine has the potential to act as the "safety-net" of our public health response to an outbreak. Our focus on telemedicine must shift to the developing and under-developing nations, which carry a disproportionate burden of vulnerable communities who are at risk due to COVID-19.},
}

*COVID-19
Humans
Pandemics/prevention & control
Public Health
SARS-CoV-2
*Telemedicine

@article {pmid33166525,
year = {2021},
author = {Freeman-Sanderson, A and Ward, EC and Miles, A and de Pedro Netto, I and Duncan, S and Inamoto, Y and McRae, J and Pillay, N and Skoretz, SA and Walshe, M and Brodsky, MB and , },
title = {A Consensus Statement for the Management and Rehabilitation of Communication and Swallowing Function in the ICU: A Global Response to COVID-19.},
journal = {Archives of physical medicine and rehabilitation},
volume = {102},
number = {5},
pages = {835-842},
pmid = {33166525},
issn = {1532-821X},
mesh = {COVID-19/complications/*rehabilitation ; Communication Disorders/etiology/*rehabilitation ; Consensus ; Critical Care/*standards ; Deglutition Disorders/etiology/*rehabilitation ; Delphi Technique ; Humans ; Intensive Care Units/standards ; Physical Therapy Modalities/*standards ; Respiration, Artificial/adverse effects ; SARS-CoV-2 ; Speech Therapy/methods/*standards ; Speech-Language Pathology/standards ; },
abstract = {OBJECTIVE: To identify core practices for workforce management of communication and swallowing functions in coronavirus disease 2019 (COVID-19) positive patients within the intensive care unit (ICU).

DESIGN: A modified Delphi methodology was used, with 3 electronic voting rounds. AGREE II and an adapted COVID-19 survey framework from physiotherapy were used to develop survey statements. Sixty-six statements pertaining to workforce planning and management of communication and swallowing function in the ICU were included.

SETTING: Electronic modified Delphi process.

PARTICIPANTS: Speech-language pathologists (SLPs) (N=35) from 6 continents representing 12 countries.

INTERVENTIONS: Not applicable.

MAIN OUTCOME MEASURES: The main outcome was consensus agreement, defined a priori as ≥70% of participants with a mean Likert score ≥7.0 (11-point scale: 0=strongly disagree, 10=strongly agree). Prioritization rank order of statements in a fourth round was also conducted.

RESULTS: SLPs with a median of 15 years of ICU experience, working primarily in clinical (54%), academic (29%), or managerial positions (17%), completed all voting rounds. After the third round, 64 statements (97%) met criteria. Rank ordering identified issues of high importance.

CONCLUSIONS: A set of global consensus statements to facilitate planning and delivery of rehabilitative care for patients admitted to the ICU during the COVID-19 pandemic were agreed by an international expert SLP group. Statements focused on considerations for workforce preparation, resourcing and training, and the management of communication and swallowing functions. These statements support and provide direction for all members of the rehabilitation team to use for patients admitted to the ICU during a global pandemic.},
}

COVID-19/complications/*rehabilitation
Communication Disorders/etiology/*rehabilitation
Consensus
Critical Care/*standards
Deglutition Disorders/etiology/*rehabilitation
Delphi Technique
Humans
Intensive Care Units/standards
Physical Therapy Modalities/*standards
Respiration, Artificial/adverse effects
SARS-CoV-2
Speech Therapy/methods/*standards
Speech-Language Pathology/standards

@article {pmid33146360,
year = {2020},
author = {Chagas, AL and Fonseca, LGD and Coelho, FF and Saud, LRDC and Abdala, E and Andraus, W and Fiore, L and Moreira, AM and Menezes, MR and Carnevale, FC and Tani, CM and Alencar, RSSM and D'Albuquerque, LAC and Herman, P and Carrilho, FJ},
title = {Management of Hepatocellular Carcinoma during the COVID-19 Pandemic - São Paulo Clínicas Liver Cancer Group Multidisciplinary Consensus Statement.},
journal = {Clinics (Sao Paulo, Brazil)},
volume = {75},
number = {},
pages = {e2192},
pmid = {33146360},
issn = {1980-5322},
mesh = {Betacoronavirus ; Brazil/epidemiology ; COVID-19 ; *Carcinoma, Hepatocellular/epidemiology/therapy ; Consensus ; *Coronavirus Infections ; Humans ; *Liver Neoplasms/epidemiology/therapy ; *Pandemics ; *Pneumonia, Viral ; SARS-CoV-2 ; },
abstract = {More than 18 million people in 188 countries have been diagnosed as having coronavirus disease (COVID-19), and COVID-19 has been responsible for more than 600,000 deaths worldwide. Brazil is now the second most affected country globally. Faced with this scenario, various public health measures and changes in the daily routines of hospitals were implemented to stop the pandemic. Patients with hepatocellular carcinoma (HCC) are at an increased risk for severe COVID-19 as they present with two major diseases: cancer and concomitant chronic liver disease. The COVID-19 pandemic can significantly impact the management of HCC patients from diagnosis to treatment strategies. These patients need special attention and assistance at this time, especially since treatment for tumors cannot be delayed in most cases. The aim of this guideline was to standardize the management of HCC patients during the COVID-19 pandemic. This document was developed, on the basis of the best evidence available, by a multidisciplinary team from Instituto do Câncer do Estado de São Paulo (ICESP), and Instituto Central of the Hospital das Clínicas da Universidade de São Paulo (HC-FMUSP), which are members of the São Paulo Clínicas Liver Cancer Group.},
}

Betacoronavirus
Brazil/epidemiology
COVID-19
*Carcinoma, Hepatocellular/epidemiology/therapy
Consensus
*Coronavirus Infections
Humans
*Liver Neoplasms/epidemiology/therapy
*Pandemics
*Pneumonia, Viral
SARS-CoV-2

@article {pmid33132066,
year = {2021},
author = {García-Salido, A and Antón, J and Martínez-Pajares, JD and Giralt Garcia, G and Gómez Cortés, B and Tagarro, A and , and , and Belda Hofheinz, S and Calvo Penadés, I and de Carlos Vicente, JC and Grasa Lozano, CD and Hernández Bou, S and Pino Ramírez, RM and Núñez Cuadros, E and Pérez-Lescure Picarzo, J and Saavedra Lozano, J and Salas-Mera, D and Villalobos Pinto, E},
title = {[Spanish consensus document on diagnosis, stabilisation and treatment of pediatric multisystem inflammatory syndrome related to SARS-CoV-2 (SIM-PedS)].},
journal = {Anales de pediatria},
volume = {94},
number = {2},
pages = {116.e1-116.e11},
pmid = {33132066},
issn = {2341-2879},
mesh = {Algorithms ; COVID-19/*diagnosis/*therapy/complications ; Child ; Humans ; Systemic Inflammatory Response Syndrome/*diagnosis/*therapy ; },
abstract = {A new paediatric multisystem inflammatory syndrome, linked to SARS-CoV-2, has been described. The clinical picture is variable and is associated with an active or recent infection due to SARS-CoV-2. A review of the existing literature by a multidisciplinary group of paediatric specialists is presented in this document. Later, they make recommendations on the stabilisation, diagnosis, and treatment of this syndrome.},
}

Algorithms
COVID-19/*diagnosis/*therapy/complications
Child
Humans
Systemic Inflammatory Response Syndrome/*diagnosis/*therapy

@article {pmid33123943,
year = {2021},
author = {Defrancesco, M and Bancher, C and Dal-Bianco, P and Hinterhuber, H and Schmidt, R and Struhal, W and Ransmayr, G and Stögmann, E and Marksteiner, J},
title = {[Position paper of the Austrian Alzheimer Association (Österreichische Alzheimer Gesellschaft, ÖAG) : Effects of the COVID-19 pandemic in Austria on people with dementia and their care environment-problem areas, recommendations, and strategies].},
journal = {Neuropsychiatrie : Klinik, Diagnostik, Therapie und Rehabilitation : Organ der Gesellschaft Osterreichischer Nervenarzte und Psychiater},
volume = {35},
number = {1},
pages = {35-47},
pmid = {33123943},
issn = {2194-1327},
mesh = {Aged ; Aged, 80 and over ; *Alzheimer Disease/therapy ; Austria ; *COVID-19/epidemiology ; Communicable Disease Control ; *Dementia/therapy ; Humans ; *Pandemics ; Practice Guidelines as Topic ; SARS-CoV-2 ; },
abstract = {Older adults are particularly affected by the current COVID-19 (SARS-CoV-2) pandemic. The risk of dying from COVID-19 increases with age and is often associated with pre-existing health conditions. Globally, more than 50 million-in Austria currently approximately 140,000 people-suffer from dementia. The co-occurrence of dementia as a "pandemic of old age" together with the COVID-19 pandemic has a double impact on persons living with dementia and their caregivers. The COVID-19 pandemic poses major challenges for individuals with dementia and their caregivers: (1) People with dementia have limited access to information on COVID-19, may have difficulties with protective measures such as wearing masks and in remembering safety regulations. (2) People with dementia live alone or with their family, or are institutionalized. To reduce the chance of infection among older people in nursing homes, Austrian local authorities have banned visitors to nursing homes and long-term care facilities and implemented strict social-distancing measures. As a result, older people lost face-to-face contact with their family members, became isolated and social activities stopped. Consequently, anxiety, stress and serious concerns about infections among staff in nursing homes increased and they developed signs of exhaustion and burnout during the full lockdown of the facilities. Thus, due to the emerging COVID-19 crisis, the Austrian Alzheimer Association (Österreichische Alzheimer Gesellschaft, ÖAG) and international societies developed recommendations to support people living with dementia and their caregivers on various issues of physical and mental health.},
}

Aged
Aged, 80 and over
*Alzheimer Disease/therapy
Austria
*COVID-19/epidemiology
Communicable Disease Control
*Dementia/therapy
Humans
*Pandemics
Practice Guidelines as Topic
SARS-CoV-2

@article {pmid33089297,
year = {2020},
author = {Zhu, L and Wang, JB and Yu, Q and Huang, ZW and Han, FK and Li, SJ and Sha, Y and Shi, HM and Tao, XF},
title = {[Shanghai municipal expert consensus on standardized prevention and control of COVID-19 during procedures of oral radiology].},
journal = {Shanghai kou qiang yi xue = Shanghai journal of stomatology},
volume = {29},
number = {4},
pages = {431-434},
pmid = {33089297},
issn = {1006-7248},
mesh = {Betacoronavirus ; COVID-19 ; China ; Consensus ; *Coronavirus Infections ; Humans ; *Pandemics ; *Pneumonia, Viral ; *Radiography, Dental ; SARS-CoV-2 ; },
abstract = {The announcement of National Health Commission on January 20, 2020 (No.1 of 2020) has included novel coronavirus pneumonia into the B class infectious diseases according to the law of the People's Republic of China on the prevention and control of infectious diseases, and has been managed as A class infectious diseases. People's governments at all levels and health administration departments have been paying high attention to it. With the alleviation of COVID-19 nationwide, dental clinics gradually resume to work. The main transmission routes of COVID-19 are respiratory droplets and contact transmission, hence oral radiological examination is kind of a high-risk operation. Standardized radiologic process is of great significance to reduce the risk of COVID-19 transmission. In accordance with the national and Shanghai epidemic prevention requirements, and in combination with the actual situation of various medical institutions, Oral and Maxillofacial Radiology Committee of Shanghai Stomatological Association formulated the expert consensus on standardized prevention and control of COVID-19 for clinical reference. This recommendation will be updated according to the situation of epidemic prevention and control in China and the new relevant diagnosis and treatment plans.},
}

Betacoronavirus
COVID-19
China
Consensus
*Coronavirus Infections
Humans
*Pandemics
*Pneumonia, Viral
*Radiography, Dental
SARS-CoV-2

@article {pmid33075144,
year = {2021},
author = {Klimek, L and Jutel, M and Bousquet, J and Agache, I and Akdis, CA and Hox, V and Gevaert, P and Tomazic, PV and Rondon, C and Cingi, C and Toppila-Salmi, S and Karavelia, A and Bozkurt, B and Förster-Ruhrmann, U and Becker, S and Chaker, AM and Wollenberg, B and Mösges, R and Huppertz, T and Hagemann, J and Bachert, C and Fokkens, W},
title = {Management of patients with chronic rhinosinusitis during the COVID-19 pandemic-An EAACI position paper.},
journal = {Allergy},
volume = {76},
number = {3},
pages = {677-688},
doi = {10.1111/all.14629},
pmid = {33075144},
issn = {1398-9995},
mesh = {Adrenal Cortex Hormones/administration & dosage ; Asthma/drug therapy ; Biological Products/therapeutic use ; COVID-19/*epidemiology ; Chronic Disease ; Humans ; Nasal Polyps/drug therapy ; Rhinitis/*drug therapy ; *SARS-CoV-2 ; Sinusitis/*drug therapy ; },
abstract = {BACKGROUND: Chronic rhinosinusitis is regarded as a chronic airway disease. According to WHO recommendations, it may be a risk factor for COVID-19 patients. In most CRSwNP cases, the inflammatory changes affecting the nasal and paranasal mucous membranes are type-2 (T2) inflammation endotypes.

METHODS: The current knowledge on COVID-19 and on treatment options for CRS was analyzed by a literature search in Medline, Pubmed, international guidelines, the Cochrane Library and the Internet.

RESULTS: Based on international literature, on current recommendations by WHO and other international organizations as well as on previous experience, a panel of experts from EAACI and ARIA provided recommendations for the treatment of CRS during the COVID-19 pandemic.

CONCLUSION: Intranasal corticosteroids remain the standard treatment for CRS in patients with SARS-CoV-2 infection. Surgical treatments should be reduced to a minimum and surgery preserved for patients with local complications and for those with no other treatment options. Systemic corticosteroids should be avoided. Treatment with biologics can be continued with careful monitoring in noninfected patients and should be temporarily interrupted during the course of the COVID-19 infection.},
}

Adrenal Cortex Hormones/administration & dosage
Asthma/drug therapy
Biological Products/therapeutic use
COVID-19/*epidemiology
Chronic Disease
Humans
Nasal Polyps/drug therapy
Rhinitis/*drug therapy
*SARS-CoV-2
Sinusitis/*drug therapy

@article {pmid33040381,
year = {2021},
author = {Irons, JF and Pavey, W and Bennetts, JS and Granger, E and Tutungi, E and Almeida, A},
title = {COVID-19 safety: aerosol-generating procedures and cardiothoracic surgery and anaesthesia - Australian and New Zealand consensus statement.},
journal = {The Medical journal of Australia},
volume = {214},
number = {1},
pages = {40-44},
pmid = {33040381},
issn = {1326-5377},
mesh = {*Aerosols ; Anesthesia ; Australia ; COVID-19/epidemiology/*prevention & control/transmission ; Cardiac Surgical Procedures ; Consensus ; Health Personnel/education ; Humans ; Infection Control/*methods ; Infectious Disease Transmission, Patient-to-Professional/*prevention & control ; New Zealand ; *SARS-CoV-2 ; Societies, Medical ; Thoracic Surgical Procedures ; },
abstract = {INTRODUCTION: Coronavirus disease 2019 (COVID-19) is a contagious disease that is caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Health care workers are at risk of infection from aerosolisation of respiratory secretions, droplet and contact spread. There are a number of procedures that represent a high risk of aerosol generation during cardiothoracic surgery. It is important that adequate training, equipment and procedures are in place to reduce that risk.

RECOMMENDATIONS: We provide a number of key recommendations, which reduce the risk of aerosol generation during cardiothoracic surgery and help protect patients and staff. These include general measures such as patient risk stratification, appropriate use of personal protective equipment, consideration to delay surgery in positive patients, and careful attention to theatre planning and preparation. There are also recommended procedural interventions during airway management, transoesophageal echocardiography, cardiopulmonary bypass, chest drain management and specific cardiothoracic surgical procedures. Controversies exist regarding the management of low risk patients undergoing procedures at high risk of aerosol generation, and recommendations for these patients will change depending on the regional prevalence, risk of community transmission and the potential for asymptomatic patients attending for these procedures.

This statement reflects changes in management based on expert opinion, national guidelines and available evidence. Our knowledge with regard to COVID-19 continues to evolve and with this, guidance may change and develop. Our colleagues are urged to follow national guidelines and institutional recommendations regarding best practices to protect their patients and themselves.

ENDORSED BY: Australian and New Zealand Society of Cardiac and Thoracic Surgeons and the Anaesthetic Continuing Education Cardiac Thoracic Vascular and Perfusion Special Interest Group.},
}

*Aerosols
Anesthesia
Australia
COVID-19/epidemiology/*prevention & control/transmission
Cardiac Surgical Procedures
Consensus
Health Personnel/education
Humans
Infection Control/*methods
Infectious Disease Transmission, Patient-to-Professional/*prevention & control
New Zealand
*SARS-CoV-2
Societies, Medical
Thoracic Surgical Procedures

@article {pmid33034302,
year = {2020},
author = {Banothu, KK and Bhat, JI and Das, RR and Dhochak, N and Ghimire, JJ and Goyal, JP and Gulla, KM and Gupta, S and Jat, KR and Kabra, SK and Kalyan, P and Kumar, A and Kumar, P and Kumar, V and Lodha, R and Mathew, JL and Pathania, A and Ratageri, VH and Singh, V and Warankar, S},
title = {Expert Opinion on Restoration of Pediatric Pulmonology Services During the SARS-CoV-2 Pandemic.},
journal = {Indian pediatrics},
volume = {57},
number = {11},
pages = {1055-1059},
pmid = {33034302},
issn = {0974-7559},
mesh = {Airway Management ; COVID-19/*epidemiology/prevention & control/transmission ; COVID-19 Testing ; Chronic Disease/therapy ; Cross Infection/prevention & control ; Diagnostic Techniques, Respiratory System ; Emergency Service, Hospital/organization & administration ; Humans ; India/epidemiology ; Infection Control ; Nebulizers and Vaporizers ; Noninvasive Ventilation ; *Pandemics ; Patient Admission ; *Pediatrics ; Personal Protective Equipment ; Pulmonary Medicine/*organization & administration ; Respiratory Tract Diseases/therapy ; SARS-CoV-2 ; Telemedicine ; Triage ; },
}

Airway Management
COVID-19/*epidemiology/prevention & control/transmission
COVID-19 Testing
Chronic Disease/therapy
Cross Infection/prevention & control
Diagnostic Techniques, Respiratory System
Emergency Service, Hospital/organization & administration
Humans
India/epidemiology
Infection Control
Nebulizers and Vaporizers
Noninvasive Ventilation
*Pandemics
Patient Admission
*Pediatrics
Personal Protective Equipment
Pulmonary Medicine/*organization & administration
Respiratory Tract Diseases/therapy
SARS-CoV-2
Telemedicine
Triage

@article {pmid33034142,
year = {2020},
author = {Haines, J and Esposito, K and Slinger, C and Pargeter, N and Murphy, J and Selby, J and Prior, K and Mansur, A and Vyas, A and Stanton, AE and Sabroe, I and Hull, JH and Fowler, SJ},
title = {UK consensus statement on the diagnosis of inducible laryngeal obstruction in light of the COVID-19 pandemic.},
journal = {Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology},
volume = {50},
number = {12},
pages = {1287-1293},
pmid = {33034142},
issn = {1365-2222},
mesh = {Airway Obstruction/*diagnosis ; *COVID-19 ; Consensus ; *Critical Pathways ; Humans ; Laryngeal Diseases/*diagnosis ; SARS-CoV-2 ; United Kingdom ; },
abstract = {Prior to the COVID-19 pandemic, laryngoscopy was the mandatory gold standard for the accurate assessment and diagnosis of inducible laryngeal obstruction. However, upper airway endoscopy is considered an aerosol-generating procedure in professional guidelines, meaning routine procedures are highly challenging and the availability of laryngoscopy is reduced. In response, we have convened a multidisciplinary panel with broad experience in managing this disease and agreed a recommended strategy for presumptive diagnosis in patients who cannot have laryngoscopy performed due to pandemic restrictions. To maintain clinical standards whilst ensuring patient safety, we discuss the importance of triage, information gathering, symptom assessment and early review of response to treatment. The consensus recommendations will also be potentially relevant to other future situations where access to laryngoscopy is restricted, although we emphasize that this investigation remains the gold standard.},
}

Airway Obstruction/*diagnosis
*COVID-19
Consensus
*Critical Pathways
Humans
Laryngeal Diseases/*diagnosis
SARS-CoV-2
United Kingdom

@article {pmid33027040,
year = {2020},
author = {Bossuyt, X and Damoiseaux, J and Rasmussen, N and van Paassen, P and Hellmich, B and Baslund, B and Blockmans, D and Vermeersch, P and Lopez-Hoyos, M and Vercammen, M and Barret, E and Hammar, F and Leinfelder, U and Mahler, M and Olschowka, N and Roggenbuck, D and Schlumberger, W and Walker, R and Rönnelid, J and Cohen Tervaert, JW and Csernok, E and Fierz, W and , },
title = {Harmonization of antineutrophil cytoplasmic antibodies (ANCA) testing by reporting test result-specific likelihood ratios: position paper.},
journal = {Clinical chemistry and laboratory medicine},
volume = {59},
number = {2},
pages = {e35-e39},
doi = {10.1515/cclm-2020-1178},
pmid = {33027040},
issn = {1437-4331},
mesh = {Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis/blood/*diagnosis/immunology ; Antibodies, Antineutrophil Cytoplasmic/*blood ; Calibration ; Data Interpretation, Statistical ; Diagnosis, Differential ; Humans ; Immunoassay/methods/*standards ; Likelihood Functions ; Myeloblastin/immunology ; Peroxidase/immunology ; Reference Standards ; Sensitivity and Specificity ; },
}

Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis/blood/*diagnosis/immunology
Antibodies, Antineutrophil Cytoplasmic/*blood
Calibration
Data Interpretation, Statistical
Diagnosis, Differential
Humans
Immunoassay/methods/*standards
Likelihood Functions
Myeloblastin/immunology
Peroxidase/immunology
Reference Standards
Sensitivity and Specificity

@article {pmid33014958,
year = {2020},
author = {Bhaskar, S and Bradley, S and Chattu, VK and Adisesh, A and Nurtazina, A and Kyrykbayeva, S and Sakhamuri, S and Moguilner, S and Pandya, S and Schroeder, S and Banach, M and Ray, D},
title = {Telemedicine as the New Outpatient Clinic Gone Digital: Position Paper From the Pandemic Health System REsilience PROGRAM (REPROGRAM) International Consortium (Part 2).},
journal = {Frontiers in public health},
volume = {8},
number = {},
pages = {410},
pmid = {33014958},
issn = {2296-2565},
mesh = {*Ambulatory Care Facilities ; COVID-19/*prevention & control ; Health Personnel ; Humans ; Pandemics ; Physical Distancing ; Telemedicine/*trends ; Videoconferencing ; },
abstract = {Technology has acted as a great enabler of patient continuity through remote consultation, ongoing monitoring, and patient education using telephone and videoconferencing in the coronavirus disease 2019 (COVID-19) era. The devastating impact of COVID-19 is bound to prevail beyond its current reign. The vulnerable sections of our community, including the elderly, those from lower socioeconomic backgrounds, those with multiple comorbidities, and immunocompromised patients, endure a relatively higher burden of a pandemic such as COVID-19. The rapid adoption of different technologies across countries, driven by the need to provide continued medical care in the era of social distancing, has catalyzed the penetration of telemedicine. Limiting the exposure of patients, healthcare workers, and systems is critical in controlling the viral spread. Telemedicine offers an opportunity to improve health systems delivery, access, and efficiency. This article critically examines the current telemedicine landscape and challenges in its adoption, toward remote/tele-delivery of care, across various medical specialties. The current consortium provides a roadmap and/or framework, along with recommendations, for telemedicine uptake and implementation in clinical practice during and beyond COVID-19.},
}